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ABSTRACT 
DETERMINA nON OF IN SILICa RULES FOR PREDICTING SMALL MOLECULE 
BINDING BEHAVIOR TO NUCLEIC ACIDS IN VITRO 
Patrick Andrew Holt 
May 21,2010 
The vast knowledge of nucleic acids is evolving and it is now known that DNA 
can adopt highly complex, heterogeneous structures. Among the most intriguing are the 
G-quadruplex structures, which are thought to playa pivotal role in cancer pathogenesis. 
Efforts to find new small molecules for these and other physiologically relevant nucleic 
acid structures have generally been limited to isolation from natural sources or rationale 
synthesis of promising lead compounds. However, with the rapid growth in 
computational power that is increasingly becoming available, virtual screening and 
computational approaches are quickly becoming a reality in academia and industry as an 
efficient and economical way to discover new lead compounds. These computational 
efforts have historically almost entirely focused on proteins as targets and have neglected 
DNA. We present research here showing that not only can software be utilized for 
targeting DNA, but that selectivity metrics can be developed to predict the binding 
mechanism of a small molecule to a DNA target. The software Surflex and Autodock 
were chosen for evaluation and were demonstrated to be able to accurately reproduce the 
known crystal structures of several small molecules that bind by the most common 
nucleic acid interacting mechanisms of groove binding and intercalation. These software 
IV 
were further used to rationalize known affinity and selectivity data of a 67 compound 
library of compounds for a library of nucleic acid structures including duplex, triplex and 
quadruplexes. Based upon the known binding behavior of these compounds, in silica 
metrics were developed to classify compounds as either groove binders or intercalators. 
These rules were subsequently used to identify new triplex and quadruplex binding small 
molecules by structure and ligand-based virtual screening approaches using a virtual 
library consisting of millions of commercially available small molecules. The binding 
behavior of the newly discovered triplex and quadruplex binding compounds was 
empirically validated using a number of spectroscopic, fluorescent and thermodynamic 
equilibrium techniques. In total, this research predicted the binding behavior of these test 
compounds in silica and subsequently validated these findings in vitro. This research 
presents a novel approach to discover lead compounds that target multiple nucleic acid 
morphologies. 
v 
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CHAPTER I 
INTRODUCTION AND BACKGROUND 
Modem day drug discovery has focused almost exclusively on targeting proteins. 
While these efforts have resulted in many therapeutic successes, other classes of targets 
such as nucleic acids have largely been ignored. In fact, fewer than 2% of currently 
marketed drugs and biologicals target nucleic acids [1]. This is most unfortunate as 
nucleic acids represent promising targets for indications ranging from microbial 
infections to cancer [2-5]. In the past, this lack of focus on nucleic acids as small 
molecule targets may be partly ascribed to limited knowledge of the diversity of nucleic 
acid structure and function. Recently, much scientific progress has been made in the 
understanding of the physiological relevance of duplex, triplex and G-quadruplex 
morphologies of nucleic acids and these structures are becoming increasingly attractive 
small molecule targets [2, 6-8]. Furthermore, various classes of small molecules have 
been shown to bind to unique nucleic acids in a sequence and structurally specific 
manner, as has been elegantly demonstrated by Dervan with the hairpin polyamides and 
Chaires with multiple small molecule families [9-10]. This research has paved the way 
for the approach of discovering novel small molecules that specifically target newly 
discovered nucleic acids that may have particular therapeutic or clinical relevance. 
1 
Nucleic Acid Structures are Promising Small Molecule Targets 
Nucleic acids have long escaped therapeutic targeting because of a lack of 
knowledge and appreciation of the structural and functional diversity of these 
macromolecules. It is now known that DNA can have tremendous diversity with respect 
to structure, conformation and sequence. For example, DNA can exist as a single strand 
or as duplex, triplex and quadruplex structures. DNA can adopt a large number of 
secondary and higher order structures in vivo, including the standard B-form duplex DNA 
as well as other duplex structures such as the Z-form duplex DNA. The sequence 
composition also adds a unique dimension of diversity to DNA. Small molecules have 
been discovered that may bind to particular DNA structures with moderate selectivity and 
modulate biological activity in vivo. One example is the small molecule telomestatin, 
which has been shown to bind to G-quadruplex structures with a greater than 70 fold 
preference compared to duplex DNA and has possible anti-cancer cell activity [11]. This 
suggests that it is possible to identify small molecules with a preference for specific 
nucleic acid structures. The discovery of novel small molecules to date appears to be 
mostly limited to isolation from natural sources and chemical synthesis and sorely 
overlooks the capability of in silico virtual screening and computational approaches. 
Virtual Screening Approaches for Discovering New Drugs 
In silico virtual screening techniques are valuable computational tools for the 
discovery of new small molecules that can bind to a target of interest [12]. Indeed, 
computational methods have been integrated into the discovery process for over 50 
compounds that are in clinical trials as well as marketed drugs [13]. Table 1 shows 
2 
Table 1. A sampling of the various target classes for which ligands have been 
successfully identified by computational approaches. 
3 
Table 1. A sampling of the various target classes for which ligands have been 
successfully identified by computational approaches. Adapted from [14]. 
Target Family Target Name Manuscript 
Reference 
Enzyme Renin [15] 
Drug Metabolizing Enzymes Cytochrome P450s [16] 
Kinases Protein Kinase C [17] 
Transporter Na+/D-glucose co-transporter [18] 
Receptor AMP A receptor [19] 
Channels Potassium and Sodium Channels [20] 
Transcription Factors AP-l transcription Factor [21 ] 
Antibacterial Mycobacterium tuberculosis thymidine [22] 
monophosphosphate kinase 
Antivirual N euroamidase [23] 
4 
compounds that have been discovered using various computational methods against a 
wide array of target classes emphasizing the importance of in silico approaches in 
discovering new compounds in many research areas. 
The benefits of virtual screening are its speed, accuracy, hit rates and 
affordability, which circumvent the often laborious, slow and expensive process of 
synthesis of novel small molecules for testing purposes. These benefits have accelerated 
the adoption of virtual screening in the drug discovery process and it is estimated that up 
to 20% of new drugs will be found by virtual screening methods in the year 2010 [24]. 
There are multiple ways to perform in silico virtual screening experiments as well as 
many small molecule databases that can be used for in silico screening that will be 
described in detail below. 
Virtual screening experiments are typically considered to be either structure-based 
or ligand-based [25]. Structure-based virtual screening methods require the availability 
of an in silico structure of the target. This structure is usually obtained through high-
resolution X-Ray crystallography techniques or by NMR methods. Some of the most 
widespread resources for many in silico solved structures are the RSCB protein data bank 
(PDB) and the Nucleic Acid Database (NDB). These databases are popular as the 
structures can be visualized through a web interface and downloaded directly for virtual 
screening experiments. Structure-based virtual screening uses various software packages 
to screen millions of compounds to determine how well each compound can fit into a site 
on the three dimensional target of interest [26]. This approach involves both "docking" 
the compounds to the target as well as "scoring" the poses and determining which pose is 
"correct" [27]. The "scoring" and ranking of the top poses of each ligand in the binding 
5 
pocket of the target is one of the most challenging aspects of docking [12]. Molecular 
docking using programs such as DOCK, Autodock, Ludi, FlexX and Surflex-Dock have 
been used to find many lead molecules against a variety of targets, of which the vast 
majority are proteins such as thymidylate synthase, retinoic acid receptor, kinases, 
estrogen receptor and thrombin [14, 28-30]. The use of molecular docking appears well 
entrenched in academia and industry and its use will likely increase as virtual databases 
of small molecules and drug targets continue to expand. 
A second type of virtual screening approach is referred to as ligand-based virtual 
screening which requires knowledge of the structure of a biologically active ligand. The 
structure of the active compound is compared to millions of other chemical compounds to 
check for chemical and morphological similarity. The premise is that if the structure of 
the test compound is similar to that of the known active compound, then the test 
compound may possess similar biological activity [27]. If multiple small molecules are 
known to possess similar biological activity, a "pharmacophore" can be constructed 
which describes the ligand chemical properties that are necessary for a ligand to interact 
with its target. This "pharmacophore" modeling can be particularly useful to detect a 
wide number of compounds with diverse chemical features [25]. One consideration with 
ligand-based virtual screening that it does not require knowledge of the structure of the 
target. This can be advantageous because it can be difficult and sometimes controversial 
to actually use the "correct" structure of the target for docking studies. However, it is 
also disadvantageous in that critical interactions of the active compound with the target 
such as hydrogen bonding and steric interactions may not be effectively visualized and 
assessed. Ligand-based virtual screening is a popular approach to look for derivatives of 
6 
known biologically active compounds. This approach has also been used to enrich 
databases for possible selection of lead compounds [27]. Programs such as FlexS, fFlash 
and Surflex-Sim have been previously used with success for ligand-similarity based 
searches [25]. 
A final aspect of virtual screening is the importance of the repository of small 
molecules that are used for screening experiments. The database of compounds for 
virtual screening has increased dramatically in recent years, with tens of millions of 
compounds currently available in multiple databases [27]. In our own experience, one of 
the ZINC databases that we use for virtual screening experiments has increased from 
approximately 2.7 million compounds in 2007 to over 10.6 million compounds in 2009, 
the vast majority of which are purchaseable from vendors world-wide. The value in 
having large databases is the large chemical space that these compounds encompass. 
This vastly increases the number of small molecules considered as possible lead 
candidates which is favorable compared to the relatively few molecules that are evaluated 
by actual chemical synthesis and other drug discovery techniques. Additionally many of 
the in silica libraries have been filtered based on specific criteria (for example, Lipinski's 
Rule of 5) to increase the chance that the molecules are "Drug-Like" in behavior. In the 
case of Lipinski's Rule of 5, a structural analysis was performed on a large library of 
drugs that are either currently marketed or in clinical trials. The following rules were 
developed (coined "Lipinski's Rule of 5") to characterize a small molecule as "Drug-
Like" as the vast majority of compounds that were in the library possessed these 
properties: ~5 hydrogen bond donors, ~1 0 hydrogen bond acceptors, ~500 daltons 
molecular weight and ~5 octanol-water partition coefficient (Log P) [31]. Taken in total, 
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virtual screening against large databases of compounds rationally explores a much larger 
chemical space than using other approaches such as chemical synthesis and represents a 
novel way to discover new lead candidate small molecules against a target of interest. 
Virtual screening targeting DNA forms has been largely ignored 
While the use of virtual screening for the discovery of new ligands that target 
proteins has been well established, very few studies have been performed with nucleic 
acids [2, 32]. This may be partly because almost all virtual screening software has been 
designed for proteins, and may not account for characteristics that are particularly 
important to nucleic acids such as their distinct geometrical symmetry and the 
electrostatic effects of the phosphate backbone. Moreover, there are few published 
reports of the use of these programs to target nucleic acids [33-34]. Perhaps the greatest 
gap in knowledge in this area is the lack of a systematic study to determine whether 
docking software can accurately reproduce known crystal structures of ligands bound to 
nucleic acids and also predict the binding mechanisms of small molecules to nucleic 
acids, which we address here. 
Small molecules typically interact with duplex nucleic acids by binding to the 
minor groove or by intercalation between existing base pairs [4, 10, 35]. The geometry 
of the grooves of triplex and quadruplex structures may have structural features that make 
these nucleic acids unique compared to the major and minor grooves of duplex B-DNA. 
The quadruplex structures in particular have diverse loop regions that may be functional 
targets for small molecule binding. It is of primary interest to develop virtual screening 
metrics that can differentiate small molecules that bind by either minor groove binding or 
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intercalation. This is important because correctly predicting the nucleic acid structural 
selectivity and binding mechanism of small molecules is critical for understanding the 
therapeutic potential and non-specificity of a ligand. It remains of paramount importance 
to first, ascertain whether molecular docking software can be used to target nucleic acids 
and second, if novel rules can be developed to predict nucleic acid structural selectivity 
and the binding mechanism of a given small molecule. This will serve dual roles in 
filling a major basic science knowledge gap in predicting how small molecules bind to 
nucleic acids and also provide potentially enormous opportunities for translating this 
knowledge into the discovery of new therapeutic small molecules. 
Limitations in Previous Virtual Screening Studies 
A limited number of virtual screening studies against nucleic acids suggest that it 
is possible to successfully target these structures for small molecule discovery. The 
DOCK program in particular was used by Grootenhuis and Chen to target duplex DNA 
and RNA, respectively [33, 36-37]. Rohs et al. used a Monte Carlo algorithm to assess 
binding of methylene blue to DNA [38]. Shafer and Kuntz discovered a carbocyanine 
dye (DODC) that binds to G-quadruplexes [39]. Finally, Evans et al. appears to have one 
of the most comprehensive studies assessing minor groove binders to DNA using 
Autodock [34]. However, the Evans study was limited and did not assess ligands that 
bind by intercalation and did not exhaustively explore the Autodock parameters, which 
can significantly affect docking performance and outcome. While all of these studies 
suggest it is possible to use virtual screening to target nucleic acids, none of the studies 
comprehensively compared the ability of the software to reproduce mUltiple minor 
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groove binder and intercalator crystal structures or assessed the software for large scale 
virtual screening feasibility. A major deficiency of the studies is a lack of a knowledge 
base for in silica prediction of the mechanism of action of a ligand. 
Experimental Validation of Predicted In silico "Hits" 
A necessary complementary technique to any virtual screenmg approach is 
empirical testing of the "hits" that are identified from the in silica virtual screen. This is 
important to distinguish the false from true positive hits from the in silica screening data 
[27]. There is much debate about which techniques are appropriate for assessing the 
interaction of a small molecule with an array of nucleic acids. Several methods include 
ESI-MS (Electro spray Ionization Mass Spectroscopy), FRET-melting (Flourescence 
Resonance Energy Transfer), SPR (Surface Plasmon Resonance), Fluorescence 
Intercalation Displacement Assay (FID) and competition dialysis [40]. The method of 
competition dialysis is preferred as it has distinct advantages over the others, although the 
methods of FID has advantages as well and is complementary to competition dialysis. 
For example, ESI-MS requires changing the salt condition of the nucleic acid out of 
sodium and potassium and typically into ammonium acetate, which may dramatically 
impact the structure of nucleic acid morphologies, particularly the therapeutically 
relevant quadruplex structures [40-43]. FRET-melting suffers from having to modify the 
oligonucleotides with a fluorescent probe and possible ligand-probe fluorescence 
interference [40]. Finally, while SPR has the advantage of high sensitivity in assessing 
small molecule-nucleic acid interactions, either the ligand or nucleic acid must typically 
be covalently modified and bound to a chip for analyzing the interaction, as opposed to 
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allowing the interaction to occur free in solution [40]. Additionally, great expertise is 
required in choosing the appropriate chip for assessing the interactions as well as 
significant capital expenditure in purchasing the instrument. For these reasons, ESI-MS, 
FRET -melting and SPR techniques have substantial limitations for assessing the ligand-
nucleic interactions as described here. FID is complementary to competition dialysis and 
may have particular utility if a small molecule lacks a suitable chromophore for 
competition dialysis testing. The assay relies upon the known intercalation of a reporter 
dye such as ethidium bromide or thiazole orange into a DNA of interest. The 
fluorescence of such reporter molecules is markedly increased upon binding to the 
nucleic acid and quenched when free in solution. Thus, the assay can be used for 
competition experiments where small molecule can be added to a solution containing 
DNA and thiazole orange and the fluorescence of thiazole orange can be monitored to 
determine if it is bound or displaced from the DNA. We describe in more detail the use 
of this assay for characterizing the binding mode of some newly discovered compounds 
in Chapter V. 
On the other hand, competition dialysis is a simple, rapid technique that has 
gained world-wide acceptance as a way to quantitatively and rigorously assess the 
binding of small molecules to nucleic acids [10]. The assay can determine the sequence 
and structural selectivity of a single ligand for any nucleic acid of interest. The setup 
involves dialyzing a set of nucleic acids at identical concentration against a common 
dialysate containing the ligand of interest. As the system reaches equilibrium, the ligand 
will accumulate in the dialysis cassette containing the nucleic acid to which the ligand 
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Figure 1. A drawing of the competition dialysis assay setup. 
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Figure 1. A drawing of the competition dialysis assay setup. Adapted from [44]. 
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binds the tightest [10]. The ligand is then dissociated from the nucleic acid usmg 
detergents and quantified by either absorbance or fluorescence. The current version of the 
assay typically consists of 19 nucleic acid species including duplex, triplex and G-
quadruplex morphologies. However, the original 19 structures is but a starting point for 
the assay. The power of this assay is the customizability and freedom of choice of the 
nucleic acid structures; essentially any unique nucleic acid sequence or morphology can 
be added to the array of nucleic acids and tested for ligand binding. Additionally, the 
technique allows for a comparison of the ligand binding properties for many nucleic acids 
that are simultaneously free in solution. This highlights the substantial benefit of this 
technique compared to the previously mentioned methods. Competition dialysis has 
proven valuable in assessing ligand affinity and selectivity for any nucleic acid species 
and has particular utility as described here for testing the binding behavior of a small 
molecule that is predicted from virtual screening metrics. 
In sitico Discovery of Novel Small Molecules with Therapeutic Potential 
The ultimate goal in our research is to combine our in silica research with actual 
testing by competition dialysis and other techniques to provide an integrated platform to 
discover new small molecules that bind to physiologically important nucleic acids. The 
determination of predictive metrics for the purposes of discovering novel small molecules 
that can bind nucleic acids could have substantial therapeutic benefit in many areas of 
disease, most notably cancer. The CDC estimates from 2006 placed cancer as the second 
leading cause of death in the United States, second only to cardiovascular disease. Most 
recently in 2008 in the United States alone, an estimated 565,650 people succumbed to 
cancer [45] which can affect many different organ systems (Figure 2). In fact, the 
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Figure 2. Most Common Anatomical Sites for Cancer Deaths for Males (Top Figure) and 
Females (Bottom Figure). Adapted from [46]. 
15 
Figure 2. Most Common Anatomical Sites for Cancer Deaths for Males (Top Figure) and 
4% 
9% 
9% 
5% 
9% 
15% 
Females (Bottom Figure) . Adapted from [46] . ' 
4% 3% 3% 
3% 
30% 
4% 3% 3% 2% 
2% 
26% 
16 
25% 
25% 
_ Lung & Bronchus 
_ Prostate 
_ Colon & Rectum 
_ Pancreas 
LeukemIa 
_ Liver & bile duct 
c::::::J Esophagus 
_ Urinary Bladder 
_ Non·Hodgkin Lymphoma 
_ Kidney & Renal Pelvis 
_ Other 
_ Lung & Bronchus 
_ Breast 
_ Colon & Rectum 
_ Pancreas 
Ovary 
_ Non-Hodgkin Lymphoma 
c:J Leukemia 
_ Uterine Corpus 
_ Liver & bIle duct 
_ Brain & Nervous System 
_ Other 
lifetime probability of a male developing cancer is 1 in 2 and I in 3 for females [47]. As 
Figure 2 shows, cancer can arise in many anatomical positions and is a major cause of 
morbidity and mortality in the United States. In recent years, the scientific and medical 
community has developed new cancer drugs in response to the demand for new 
treatments. A substantial number of cancer drugs have been approved that are now 
considered essential for treating various forms of cancer. In particular, biologicals such 
as monoclonal antibodies have become attractive treatments for specific cancers because 
of their remarkable specificity and minimal adverse effects [48]. An example is 
Cetuximab, an Epidermal Growth Factor Receptor (EGFR) Inhibitor, which is approved 
for the treatment of locoregionally advanced squamous-cell carcinoma of the head and 
neck (LASCCHN) [49]. While biologicals such as Cetuximab have undoubtedly 
benefited patients, these large molecules are costly and time-consuming to manufacture 
and the cost is prohibitive for many patients. 
Even though the vast majority of new cancer treatments are focused on protein 
targets, there are some existing therapeutics that work by targeting nucleic acids. The 
anthracylines, for example, have been a key class of drugs that target DNA for cancer 
chemotherapy for over 40 years, despite suffering from severe side effects [50-51]. An 
example is cisplatin which is a chemotherapy drug that induces cross linking of DNA and 
is indicated for the treatment of various sarcomas and head and neck cancers. 
Unfortunately, the major limitation of current nucleic-acid based therapies such as 
cisplatin is target non-specificity and toxic side effects, which include in the case of 
cisplatin, severe ototoxicity and neurotoxicity [52]. The development of new anti-cancer 
drugs based on nucleic acid targets has stagnated until recently. 
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A new area of cancer drug development is in the area of G-quadruplex nucleic 
acid structures. These quadruplexes have been observed in the human telomeric region 
of chromosomes and have a novel mechanism of possibly inhibiting cancer cells 
replication [53]. Since over 85% of cancer cells overexpress the reverse transcriptase 
enzyme telomerase, cancer cells are able to maintain the human telomere sequence 
(TTAGGG)n which is responsible for cancer cell immortality [54]. G-quadruplex 
structures have been shown to destabilize telomerase from the telomere, resulting in 
decreasing cancer cell life [55]. Thus, these quadruplexes have become a source of great 
interest for the identification of highly selective, small molecules that may bind and 
stabilize the structures in vivo, and inhibit telomerase activity. In fact, there are several 
G-quadruplex interacting small molecules currently in clinical trials including Quarfloxin 
(Cylene Pharmaceuticals). This area is one of the most promising areas of current anti-
neoplastic small molecule development. As we will describe next in the Dissertation 
Overview, we target tetraplex nucleic acids to test the therapeutic utility of these novel, 
predictive, virtual screening metrics. Additionally, the morphologically distinct triplex 
nucleic acids are targeted because of their ability to potentially modulate gene expression 
[56-58]. Targeting of triplex and tetraplex nucleic acid structures will demonstrate the 
power and utility of this new scientific knowledge for the identification of small 
molecules that can selectively bind to these targets. 
Dissertation Overview 
In silico virtual screening approaches have been under-utilized for small molecule 
discovery because of the inability to predict how small molecules interact with nucleic 
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acids. There is a clear need to detennine if this behavior can be predicted in silica and 
validated in vitro. To meet this need, the goal of this research is to detennine if rules can 
be developed to predict the binding behavior of novel small molecules to therapeutically 
relevant nucleic acids. 
The first goal of this research as detailed in Chapter II is detennining if virtual 
screening methods can be used for targeting nucleic acid structures. Two software 
packages Surflex and Autodock, are selected for the purposes of validating nucleic acids 
as feasible targets. Autodock is selected because it is one of the most widely cited 
molecular docking software [59]. Surflex is chosen since it has the proven advantage of 
rapid docking which may have particular utility for large scale virtual screening 
applications [60]. This is a key initial step in this research, as it must be detennined if the 
currently available software is appropriate for evaluating small molecule interactions with 
nucleic acids. Four nucleic acid-ligand structures were chosen that represent the two 
major mechanisms (minor groove binding and intercalation) that small molecules use to 
bind to nucleic acids. The anti-malarial drug pentamidine and the antiviral drug 
distamycin are two well known drugs that bind to the minor groove of duplex nucleic 
acids [5, 61]. Daunorubicin and ellipticine are anti-neoplastic drugs that were selected as 
prototypical nucleic acid intercalators [62]. We demonstrate that both Autodock and 
Surflex are able to accurately reproduce the in silica structures of these ligand-nucleic 
acid complexes. Interestingly, the docking results change dramatically with the various 
paramaters that can be customized with the software. The "optimal" parameters for 
balancing docking accuracy and ranking were detennined and serve as the basis for the 
software operation for the remaining chapters of this dissertation. The results of the work 
19 
support the use of Surflex in particular for virtual screening applications as the software 
was found to be approximately 10 fold faster than Autodock with comparable docking 
accuracy and ranking. Some considerations and limitations of the software are also 
detailed. The results of this work are published in P.A. Holt et al [63]. 
After demonstrating that molecular docking software can reproduce multiple 
known ligand-nucleic acid crystal structures, the focus of Chapter III is on whether rules 
can be developed to predict the nucleic acid structural specificity and binding mechanism 
of a ligand. This is significant as a major hurdle to current drug development is small 
molecule non-specificity, which can result in drug toxicity and significant adverse 
effects. An in silica nucleic acid library with 10 structures was constructed including 
duplex, triplex and quadruplex morphologies of nucleic acids with appropriate groove 
binding and intercalation sites for docking the ligand. The small molecules from Chapter 
II (daunorubicin, distamycin, ellipticine and pentamidine) were docked to the compounds 
and in silica rules were developed to classify the binding mechanism and sequence 
selectivity of these molecules, based on their known binding behavior. The rules were 
tested on several triplex and quadruplex binding ligands that our lab has recently 
discovered as well as on a set of 67 minor groove binder and intercalator compounds that 
have been previously tested by competition dialysis [10]. The results showed that the 
metrics were able to generally accurately predict whether the compounds were groove 
binders or intercalators, but predicting sequence specificity was more challenging. In 
general, Surflex appeared to outperform Autodock and appears more appropriate for large 
scale virtual screening efforts. 
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The knowledge gained from Chapters II and III is utilized for the discovery of 
new ligands that can bind to a specific nucleic acid and this work is described in Chapter 
IV. In this chapter, both ligand and structure based virtual screening techniques are 
combined as well as utilizing the established in silica selectivity metrics to discover new 
triplex nucleic acid binding small molecules. Chaires et al. have previously identified a 
set of napthylquinoline ligands that were demonstrated by competition dialysis to be 
highly selective triplex poly(dA)-[poly(dT)h intercalators [44]. One of these 
napthlyquinolines in particular, MHQ-12, was used as the parental ligand in a similarity 
search against millions of in silica compounds. For the top similarity hits, additional 
structure-based docking studies were performed and in silica selectivity metrics were 
applied. Two novel compounds were discovered that were tested by competition dialysis, 
UV /Vis thermal melting and circular dichroism and were demonstrated to be highly 
selective intercalators into the targeted triplex DNA. This demonstrated the practical 
application of the in silica metrics that were discovered in the previous chapter and shows 
that novel small molecules can be discovered using an integrated in silica and biophysical 
testing platform. The results of this work are published in P.A. Holt et at [64]. 
Chapter V focuses on the structure-based targeting of G-quadruplex nucleic acids 
for the purposes of discovering new small molecules. The work details the targeting of 
the AGGG(TTAGGG)3 G-quadruplex which is found with increasing frequency in the 
single stranded overhang of the human telomeric region of chromosomes. Using the 
previously optimized software parameters, Surflex and Autodock were used to screen 
over 6.6 million compounds that may interact with the G-quadruplex. Ligands that bind 
by intercalation or at the end of quadruplexes (by "end pasting") are particularly 
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appealing as they may stabilize the quadruplex structure by interactions with the guanine 
quartets. Stabilization of G-quadruplexes can dissociate telomerase and result in 
decreased cancer cell proliferation [55]. A consensus scoring approach was applied 
which combines the top scoring results for Surflex and Autodock and re-ranks the results. 
The top compounds were tested by spectroscopic and fluorescent methods and a 
compound was discovered that interacts with the G-quadruplex DNA by the hypothesized 
binding mechanism. Moreover, the scaffold is unlike any reported to date in the 
literature. The work in this chapter is a practical application of the knowledge 
discovered in previous chapters and demonstrates that the software and approach as 
developed in this work, is capable of discovering new small molecules that bind to a 
nucleic acid by a specific mechanism. 
Summary 
While nucleic acids represent a viable class of drug targets for in silico virtual 
screening, progress has been hampered by the lack of virtual screening rules that can 
predict the binding mechanism of a ligand to a nucleic acid target. The development of 
predictive rules is an essential step to discover novel small molecules to fight disease. It 
is also a critical part in an integrated virtual and actual screening platform that can screen 
millions of compounds in silico and biophysically test the most promising compounds 
identified from the initial computational screen. While there has been much progress in 
the research and understanding of nucleic acids, the therapeutic development of targeting 
nucleic acids lags behind. This appears to be due to a lack of a rapid, efficient and 
economical approach to identify selective small molecules that can bind to nucleic acids. 
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Determination of predictive rules, as described herein, addresses this knowledge gap by 
making it possible to better understand and predict the interaction of small molecules 
with nucleic acids. We believe this new information will ultimately facilitate the 
discovery of novel ligands that target therapeutically relevant nucleic acids. 
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CHAPTER II 
MOLECULAR DOCKING OF INTERCALATORS AND GROOVE BINDERS TO 
NUCLEIC ACIDS USING AUTODOCK AND SURFLEX 
This chapter describes the validation of selected virtual screening software for the 
purposes of targeting nucleic acids. We demonstrate here that the molecular docking 
tools Autodock and Surflex accurately reproduce the crystallographic structures of a 
collection of small molecule ligands that have been shown to bind nucleic acids. Docking 
studies were performed with the intercalators Daunorubicin and Ellipticine and the minor 
groove binders Distamycin and Pentamidine. Autodock and Surflex dock Daunorubicin 
and Distamycin to their nucleic acid targets within a resolution of approximately 2 A, 
which is similar to the limit of the crystal structure resolution. However, for the top 
ranked poses, Autodock and Surflex both dock Ellipticine into the correct site but in a 
different orientation compared to the crystal structure. This appears to be partly related to 
the symmetry of the target nucleic acid, as Ellipticine is able to dock from either side of 
intercalation site but also due to the shape of the ligand and docking accuracy. Surflex 
docks Pentamidine in a symmetrically equivalent orientation relative to the crystal 
structure, while Autodock was able to dock this molecule in the original orientation. In 
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the case of the Surflex docking of Pentamidine, the initial RMSD is misleading, given the 
symmetrical structure of Pentamidine. Importantly, the ranking functions of both of the 
programs are able to return a top pose within approximately 2 A RMSD for 
Daunorubicin, Distamycin and Pentamidine and approximately 3 A RMSD for Ellipticine 
compared to their respective crystal structures. 
Finally, we also discuss some docking challenges and potential pitfalls when 
using these software tools, such as the importance of hydrogen treatment on ligands as 
well as the scoring functions of Autodock and Surflex. Overall for this set of complexes, 
Surflex is preferred over Autodock for virtual screening, as although the results are 
comparable, Surflex has significantly faster performance and ease of use under the 
optimal software conditions tested. These experiments show that the molecular docking 
techniques can be successfully extended to include nucleic acid targets, a finding which 
has important implications for virtual screening applications and in the design of new 
small molecules to target therapeutically relevant morphologies of nucleic acids. The 
results and conclusions of this scientific research were published by P.A. Holt et al [63]. 
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Introduction 
Molecular docking techniques have shown great promise as a new tool in the 
discovery of novel small molecule drugs for targeting proteins [60, 65-67]. Fewer 
molecular docking studies have been performed targeting nucleic acids structures, despite 
advances in the understanding of the functional importance and the unique structural 
features of duplex, triplex and G-quadruplex morphologies [2, 6-8, 32]. This is 
unfortunate since not only are there clinically used drugs that target nucleic acids, but 
many forms of nucleic acids are becoming an increasingly attractive target for anti-
neoplastic and anti-microbial agents [2-5, 10, 44, 61, 68-70]. The few docking studies in 
which nucleic acids are targeted have focused on such sites as the minor groove of DNA, 
a tetraloop structure of RNA and the major groove of an RNA duplex, while rarely 
targeting intercalation sites which also hold therapeutic potential [33-34, 36-37, 71-72]. 
The use of molecular docking has important implications for the synthesis and 
development of small molecule drugs that selectively target nucleic acids since these 
techniques have the potential to shed light on the interaction and mechanism of action of 
these ligands with targets that may have medicinal value. 
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Small molecules can interact with nucleic acids at multiple sites to alter nucleic acid 
function [71, 73-74]. In the case of duplex DNA, one drug class binds within the minor 
groove and a second class intercalates between existing base pairs of the nucleic acid 
structure [4, 10, 35]. Intercalators and groove binders have distinct thermodynamic 
signatures that indicate different driving forces for binding [75]. The minor groove is an 
attractive target for small molecules since this site has less competition from proteins and 
polymerases, which typically interact with the major groove [5]. An exeption are histone 
tails which can bind in the minor groove of DNA. The closer proximity of the strands in 
the minor groove compared to the major groove allows more contact surface area for a 
small molecule to bind tightly [76]. The unfavorable geometry of the major groove is 
another reason why few drugs target this groove [71]. Two well-known minor groove 
binders are the anti-malarial drug Pentamidine and the antiviral drug Distamycin, which 
we selected for our studies [5, 61, 77-78]. While only limited docking studies have been 
performed with minor groove binders, even fewer studies have tested whether drugs that 
act through intercalation can be modeled successfully using docking methods [4, 66]. We 
selected two prototypical intercalators, Daunorubicin, a drug commonly used to treat 
certain forms of leukemia, and Ellipticine, another anti-neoplastic drug, for docking 
experiments using Autodock (4) [79] and Surflex (2.11) (Figure 3) [80]. 
Autodock 4 and Surflex 2.11 have been used previously for protein-ligand 
docking, but very few studies have been performed using nucleic acids as targets [2]. 
Autodock is a logical selection for further exploration as it has been shown in some cases 
to be superior to DOCK, FlexX and GOLD at reproducing the crystallographic pose of 
ligand-protein complexes [81]. Surflex was chosen because it has rapid computational 
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Figure 3. Chemical structures of the four test ligands used in the Autodock and Surflex 
docking studies. (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and (D) Pentamidine. 
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speed with protein-ligand docking which could prove useful for virtual screening [60]. 
Autodock and Surflex have important differences in search algorithms and scoring 
functions. A search algorithm is initially used for conformationally sampling the ligand 
and target interactions, and scoring functions are used for evaluating and ranking the final 
poses of the ligand to determine the "correct" pose [82]. 
Autodock performs molecular dockings by pre-calculating energy grids around a 
site of interest on the target [83]. A stochastic search algorithm utilizing the Lamarkian 
Genetic Algorithm (LGA) for exploring the grid space is used to perform energy 
evaluations of the position of the ligand with respect to the target energy grids [83]. This 
algorithm explores the various orientations and conformations of the whole ligand 
relative to the energy grids for the defined number of energy evaluations and returns the 
lowest energy conformation in the target site [83]. The LGA has found particular utility 
in modeling systems with large numbers of rotatable bonds and possible numbers of 
conformations [83]. Surflex uses a so-called "whole" molecule alignment algorithm 
based on morphological similarity between the ligand and target [60]. This docking 
approach aligns the ligand to a "protomol" or idealized ligand in the active site of the 
target [60]. The protomol is composed of a collection of fragments or probe molecules 
that characterize the surface morphology of the binding site [84]. These probe molecules 
consist of CH4, c=o and N-H fragments that model steric effects in the binding pocket, 
hydrogen bond acceptor groups and hydrogen bond donor groups, respectively [60, 84]. 
The docking ligand fragments are checked for alignment and similarity against the 
protomol probes [60]. This is referred to as a "whole" molecule approach because after 
the initial ligand fragmentation, both the small fragment and the rest of the "whole" 
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ligand are carried into the protomol binding site [60]. However, only the small fragment 
is checked for similarity and alignment against the protomol, while the rest of the 
"whole" ligand is assessed for steric interactions in the target site after optimal alignment 
of the fragment [60). This "whole" molecule approach is powerful because it considers 
the subsequent position of the rest of the "whole" molecule with respect to the target after 
the small fragment is optimally aligned with the protomol [60]. This is an important 
difference between Autodock and Surflex, since Autodock involves evaluation of the 
conformations of the whole ligand without ligand fragmentation [83). 
The scoring functions for Autodock and Surflex are partially empirically based, 
with Autodock incorporating an Amber type force field and Surflex calculating atom to 
atom pairwise interactions between the ligand and target [60, 83, 85]. Autodock evaluates 
pairwise interactions based on van der Waals radii of the atoms to determine the free 
energy of binding and returns the optimal lowest energy docked conformation as the best 
docked pose [82). The Surflex scoring function is parameterized by calculating van der 
Waals distances between protein and ligand and parameterization of the scoring function 
was based on 34 protein-ligand complexes [86). Surflex assigns the atoms as either polar 
or non-polar and then calculates a score based on hydrophobic and polar contacts 
between the two atoms [67). The docked poses are then ranked according to the maximal 
Surflex Overall score. 
Aside from the algorithmic differences in Surflex and Autodock, there are several 
other aspects of molecular docking in general and these programs specifically that present 
challenges to successful docking of ligands to nucleic acids. First, because proteins have 
attracted the most interest as drug targets, proteins have also been the focus of most 
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docking efforts compared to nucleic acids [82]. This leads to the question of whether 
these protein-configured docking programs will work for nucleic acids because of the 
unique structural features of nucleic acids including their high charge density, exposed 
binding sites, and distinct geometrical symmetry [82, 87]. Another challenge is the 
dependence on crystal structures for visualizing how ligands interact with their targets 
and for assessing the accuracy of docking software. This approach relies on both the 
availability and resolution of the crystal structure. For nucleic acids, there are few crystal 
structures of ligand-nucleic acid complexes available and even small variations in the 
resolution of the atomic positions of the crystals can significantly affect the modeling of 
important forces between the ligand and target such as hydrogen bonding [88]. 
Differences in scoring functions also present a challenge for docking, as ranking of the 
poses is typically the most difficult aspect of docking [24, 89]. The coefficients and 
weighting for the scoring function terms are calibrated based on ligand-protein 
complexes, and it is unknown how well Autodock and Surflex would perform with 
ligand-nucleic acid complexes [85]. Autodock and Surflex include entropic contributions 
by accounting for conformational and tortional changes as well as a term for solvation 
[60, 85]. However, the entropic contribution of solvation terms for most docking 
programs has been difficult to incorporate accurately in scoring functions and could 
contribute to erroneous pose ranking [82]. Another traditionally challenging area for 
docking programs is accounting for target flexibility, since even small conformational 
changes of the ligand in the binding pocket can cause dramatic changes in the scoring 
function [67]. While Autodock has the option to explore side chain flexibility for protein 
receptors, this function has not been extensively explored in the published literature for 
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nucleic acids. Moreover, Surflex does not take target flexibility into account during 
molecular docking [60]. To fairly compare the performance of these two programs, target 
flexibility was not considered in these experiments. These are important considerations 
when performing docking of ligands to nucleic acids using Autodock and Surflex, and 
could significantly impact docking performance. 
In spite of these challenges, however, we demonstrate that Autodock and Surflex 
can accurately dock small molecules with different binding modes to nucleic acid targets. 
More importantly, the ranking of the poses is also evaluated, which has been the more 
challenging aspect for many docking programs [24, 89]. The minor groove binders 
Distamycin and Pentamidine, and the intercalators, Daunorubicin and Ellipticine were 
selected for docking studies since these small molecules have crystal structures that are 
available in the Protein Data Bank (PDB). Autodock and Surflex software operating 
parameters were evaluated to determine which parameters increase docking accuracy and 
the successful ranking of the poses. Given the challenge of docking to nucleic acids, 
some reasons for suboptimal docking are detailed, including the importance of hydrogens 
on ligands, the scoring functions of the programs, and the quality of the crystal structure. 
This collection of experiments demonstrate the utility of these programs for molecular 
docking of ligands to target nucleic acids. 
Experimental and Computational Methods 
Virtual Library Preparation. Ligand-nucleic acid complex crystal structures for 
Daunorubicin, Distamycin, Ellipticine and Pentamidine were obtained from the Protein 
Data Bank with identification numbers of 152d, 2dnd, lz3f and Id64, respectively. The 
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resolutions of these structures are 1.4 A, 2.2 A, 1.5 A and 2.1 A, respectively. 
Distamycin and Pentamidine are bound to the minor groove of DNA duplex dodecamers 
d(CGCAAATTTGCG)z and d(CGCGAATTCGCG)z, respectively. Daunorubicin and 
Ellipticine intercalate between the Cytosine and Guanine nucleotides in the sequence 
d(CGATCG)2. For the Ellipticine intercalation PDB structure, Maestro (8.0) [90] was 
used to construct the symmetrical strand to form a complete, complementary, double 
stranded DNA. For the intercalator nucleic acid targets, there were two intercalation sites 
on the target. Thus, the 3' terminal Guanine residue was removed from the 6 base pair 
sequence so that there would only be a single intercalation site in the target nucleic acid 
structure. The ligand and nucleic acid targets were saved as separate files for docking 
purposes. 
The PDB files were visually inspected using Macromodel (7.0) [91] and all water 
molecules were removed. Amber ligand atom types were assigned using Sybyl (7.3) [92] 
and hydrogen atoms were added as appropriate. The program Antechamber in the 
software suite Amber (8) [93] was used to assign AMI-BCC charges to the atoms in each 
of the ligands and to also convert the files from PDB format to MOL2. Python scripts 
were used to prepare the nucleic acid structures in PDBQT format with Gasteiger charges 
for use in Autodock experiments while MOL2 files were used for Surflex experiments. 
Autodock 4 Methods. Autodock 4 and the graphical user interface Autodock Tools 
(1.4.6) [94] were compiled for a Macintosh OS X PowerMac G5 and Linux workstations. 
Autodock Tools 1.4.6 was used for establishing the Autogrid points as well as 
visualization of docked ligand-nucleic acid structures. The target site on the nucleic acid 
was specified to encompass either the entire minor groove or the intercalation target site. 
34 
----------------------------------------------------------------------------------_.--.-----
Table 2. Autodock Grid Map Coordinate Dimensions and Grid Center Information 
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Table 2. Autodock Grid Map Coordinate Dimensions and Grid Center Information 
Test Ligand Grid Point Characteristics Grid Center Characteristics 
(Dimensions) (Dimensions) 
X y Z Total X Y Z 
Number of 
Points 
Daunorubicin 52 42 28 66091 14.332 13.212 5.489 
Distamycin 34 50 64 98175 9.776 21.55 76.162 
Ellipticine 58 32 40 79827 0.992 19.28 46.762 
Pentamidine 34 54 52 102025 10.298 20.854 8.457 
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The grid center was also established by centering the grid box on either the minor groove 
or the intercalation site. The grid maps had a spacing of 0.375 A (Table 2). 
Several available docking parameter options in Autodock 4 were systematically 
varied to determine the optimal conditions for ligand-nucleic acid docking. These factors 
include the number of total energy evaluations per docking run and also the total number 
of docking runs performed. The total number of energy evaluations is the total number of 
ligand-target energy interaction evaluations before the lowest energy conformation is 
selected. These factors are suggested as logical starting areas of optimization as they 
have previously been shown to impact ligand-protein docking studies [95]. The number 
of energy evaluations per docking run was varied as 200,000 (2E5), 2,000,000 (2E6) or 
20,000,000 (2E7). Docking runs were varied as 5, 10 or 20 runs. Thus, a total of nine 
experiments were performed with varying numbers of energy evaluations and dockings to 
determine if these factors would impact docking accuracy and ranking. All other docking 
parameters were left at the default values. For the Autodock parameterization testing 
experiment with 50 docks and 5E7 energy evaluations, the "ga_num_generations" was set 
at 100,000. Normally, the docking run will terminate when either the 
"ga_num_generations" or the number of energy evaluations is reached, so the 
ga_num_generations was increased to from 27,000 to 100,000 to ensure that 5E7 energy 
evaluations was reached for these docking experiments [59]. 
SurJlex 2.11 Methods. Surflex 2.11 was compiled for a Macintosh OS X PowerMac 
G5 and Linux workstations. The protomol was generated using a ligand-based approach, 
where a small molecule is selected that fits into the site of interest. The structure of the 
molecule in the site is then used for protomol generation. The protomol represents a set of 
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Figure 4. Chemical structure of Furamidine, the ligand used to generate Surflex 2.11 
protomols. 
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Figure 4. Chemical structure of Furamidine, the ligand used to generate Surflex 2.11 
protomols. 
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molecular fragments that characterizes the active site and to which the ligand of interest 
is fragmented and checked for both similarity and alignment [67]. Furamidine was 
chosen as the ligand for protomol generation, as it has been previously shown to be a 
minor groove binder and is small enough to fit into the intercalation site to ensure 
adequate protomol generation (Figure 4) [4, 61, 96]. Importantly, this also reduces the 
bias of the evaluation by not using the actual ligands to be docked and is a more realistic, 
generalized docking approach. Two important factors that can significantly effect the size 
and extent of the proto mol generated are "proto_thresh" and "proto_bloat" options. 
"Proto_thresh" determines how far the protomol extends into the concavity of the target 
site while "proto_bloat" impacts how far the protomol extends outside of the concavity 
[97]. For the purposes of these experiments, "proto_thresh" was set to 0.2 and 
"proto bloat" was left at the default (0) for all protomols generated except for 
Daunorubicin, where a "proto_bloat" of 0.5 was used. Protomols were visualized with 
Sybyl 7.3 to ensure proper coverage of the desired target area. 
Surflex 2.11 offers many parameters that can be customized to help optimize 
ligand targeted docking. An investigation of all of the combinations of these factors is 
beyond the scope of this paper. Instead, two factors, the "Multistart 5" and "Random 5" 
options, were selected as these are thought to have the potential to most significantly 
impact the accuracy of the docked poses. The "Multi start 5" designation enables docking 
to begin from 5 different initial starting positions around the designated target. 
Previously, Jain et al. had observed little increase in successful docks with protein targets 
beginning at a value of 5 ("Multi start 5"), relative to the additional computational 
resources required for docking these extra conformations [97]. A "Random 5" option 
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ensures that the ligand adopts 5 random X,Y,Z coordinate conformations prior to 
initiating docking calculations. These options are both thought to be important since it 
minimizes the chance that the ligand may be randomly assigned to an energetically or 
conformationally unfavorable position from which it cannot recover during the docking. 
A total of three experiments were subsequently performed, with the first having default 
Surflex 2.11 options ("No Multistart", "No Random"), the second with implementation of 
"Multi start 5" and the last experiment with implementation of both "Multi start 5" and 
"Random 5" to test for a potential synergistic effect between these two options. All other 
parameters were left at the default values. 
RMSD Calculations. One metric for evaluation of the quality of docking results is the 
difference in the X, Y ,Z coordinates between the docked pose and the known crystal 
structure which can be used to calculate the Root Mean Square Deviation (RMSD) 
between the two poses. For consistency in evaluation of docked poses, the Surflex 2.11 
software RMSD method was used for calculation of the RMSD differences for both 
Autodock and Surflex results based on only the heavy atoms. This method determines 
the RMSD between the docked pose and the crystallographic structure using a direct 
atom to atom comparison of the two structures. An additional Surflex RMSD function 
(Actual RMSD ISO) was used to account for internal ligand symmetry. This function is 
independent of atom numbering and computes isomorphisms between the crystal and 
docked poses, returning the lowest symmetrical RMSD value [98]. The practice of 
accounting for ligand symmetry is fairly universal and has been documented in previous 
papers [99]. To address nucleic acid target symmetry, Macromodel 7.0 was used to flip 
and superimpose the docked pose on the crystallographic pose. This involves copying 
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the complex consisting of the ligand docked to the target nucleic acid and then selecting 
to superimpose DNA bases from the copied structure onto the opposite DNA base of the 
original structure. Molecular superposition was performed using the "Superimpose 
Atoms" (SuprA) function followed by the "Rigid Superposition" (RigSA) function. In all 
cases, the resolution of the superposition was less than 0.15 A. The superimposed 
structures were saved and the coordinates were used for RMSD calculations. Surflex 
docked poses are in a MOL2 file format which can be used directly by the Surflex 
program for RMSD calculations. Autodock docked poses are in a PDB file format and 
were converted to a MOL2 file format using Open Babel (2.1.1) [100] or iBabel [101] 
(2.0) prior to RMSD calculations. Docked poses of Autodock and Surflex in the target 
binding site were visualized using Autodock Tools. 
Autodock and Surflex Scoring Function Methods. Rescoring of all top ranked 
Autodock and Surflex poses and the crystal structure poses was performed using the 
Autodock and Surflex scoring functions. To rescore all of the poses using the Autodock 
scoring function, the files were converted to Autodock PDBQT file format by merging all 
of the non-polar hydrogens. The Autodock epdb command was used to calculate a free 
energy of binding (kcallmol) for each of the poses. The Surflex "score list" command 
was used to rescore the top ranked poses using the Surflex scoring function. Macromodel 
was used to add hydrogens to the crystal structures and to the top ranked Autodock poses 
which normally only has polar hydrogens added for docking purposes. The Surflex 
scoring function ranks poses by an affinity score, pKd [97]. To fairly compare the 
docking poses for these two programs, the Surflex pKd results were converted to free 
energy of binding (kcallmol), as previously described, where RT = 0.59 kcallmol [102]: 
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Free Energy of Binding = RT loge(10-pKd) (1) 
Macromodel Energy of Binding Methods. Macromodel was used as a third, 
independent software to calculate the energy of binding of the poses using different force 
fields and solvation. All hydrogens were added, as previously described. The energy of 
binding was determined in structures with and without energy minimization of the 
hydrogens, as follows: 
Energy of Binding = Ecomplex - Eligand - Enuc1eic acid (2) 
Where: Ecomplex is the energy of the docked ligand in the target and the Eligand and Enuc1eic 
acid represent the individually calculated energies. Energy minimization was performed 
by the Polak-Ribier Conjugate Gradient (PRCG) method for 1000 iterations with a 
convergence threshold of 0.05. The force fields were set at either Amber* or OPLS2005, 
with and without implicit water solvation to show the effects of these factors on the 
energy of binding. The experiments with no implicit water solvation were performed 
with distant dependent electrostatic treatment with a dielectric constant of 4.0 and an 
extended cutoff. The experiments with water solvation were performed with a constant 
dielectric electrostatic treatment with a dielectric constant of 1.0 and a normal cutoff. 
Results and Discussion 
Few studies have been performed to determine if molecular docking techniques 
such as Autodock and Surflex can dock ligands accurately to nucleic acids. We compare 
two poses derived from the docking calculations, the lowest RMSD pose for accuracy 
comparisons, and the top ranked pose for ranking comparison. A common metric for 
evaluation of accurate doc kings is to calculate the RMSD between the crystallographic 
pose and the docked conformation. A level of significance of 2 A will be evaluated to 
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facilitate a comparison of these data to docking data in other reports [2, 86, 89, 99, 103]. 
When evaluating the ranking functions of the programs under different software 
conditions, only the single top ranking pose was used for comparing software conditions, 
as this is typically the mostly likely and facilitating pose that would be evaluated across 
large libraries of ligands that are used for virtual screening. The top pose was also 
inspected visually to determine the goodness of the ligand fit within the expected target 
site. Using these metrics, the optimal software conditions to maximize docking accuracy 
and ranking were "S docks" and "2E7 energy evaluations" for Autodock and either the 
"Multi start S" and "No Random" or the "Multi start S" and "Random S" for Surflex. 
Autodock 4 Docking Accuracy. Close examination of the dock with the lowest RMSD 
for each software parameterization shows that Autodock is able to accurately reproduce 
the crystal structure of several ligand-nucleic acid complexes to a resolution of less than 2 
A (Figure SA). Taking ligand and nucleic acid target symmetry into account results in 
even lower RMSD poses for Pentamidine (ligand symmetry) and Ellipticine (nucleic acid 
target symmetry). Of the four ligands tested, Pentamidine is the only chemically 
symmetrical ligand. Accounting for this symmetry results in lower RMSD results since 
several of the poses that are docked in a flipped orientation relative to the crystal 
structure can be recalculated (Figure SB). At first glance, the higher overall RMSD 
results for the optimal Ellipticine pose can be misleading as this appears to be a relatively 
poor docking. Visualization of the dockings reveals that the ligand is actually docked 
successfully into the intercalation site but lies in a flipped orientation rotated 180 degrees 
relative to the crystal pose. This flipped orientation of Ellipticine occurs for all of the 
lowest RMSD poses (Figure SA) as well as the top ranked poses (Figure 6A). The 
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Figure 5. Autodock and Surflex accuracy: The dock with the lowest RMSD is presented, 
regardless of ranking. Figures A and C present the RMSD calculated without taking into 
account ligand or nucleic acid symmetry, for Autodock and Surflex, respectively. Figures 
Band D includes ligand and nucleic acid symmetry, for Autodock and Surflex, 
respectively. Black = Daunorubicin, Blue = Distamycin, Red = Ellipticine, Green = 
Pentamidine. 
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Figure 5. Autodock and Surflex accuracy: The dock with the lowest RMSD is presented, 
regardless of ranking. 
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Figure 6. The top ranked pose by Autodock and Surflex. Figures A and C present the 
RMSD calculated without taking into account ligand or nucleic acid symmetry, for 
Autodock and Surflex, respectively. Figures Band 0 include ligand and nucleic acid 
symmetry, for Autodock and Surflex, respectively. Black = Daunorubicin, Blue = 
Distamycin, Red = Ellipticine, Green = Pentamidine. 
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Figure 6. The top ranked pose by Autodock and Surflex. 
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orientation and quality of the docked Ellipticine pose is partially explained by the 
symmetrical nature of the nucleic acid target, Slllce Ellipticine can dock into the 
intercalation site not only from the orientation observed in the crystal structure but also 
from a flipped orientation with intercalation from the opposite side of the nucleic acid. 
Given that the Surflex RMSD calculator is based solely on the ligand poses and is 
irrespective of the nucleic acid target structure symmetry, the RMSD for Ellipticine is 
unusually high, even though Ellipticine is positioned well inside the intercalation site 
compared to the crystal structure. Thus, flipping and superposition of the docked pose on 
the crystallographic pose using Macromodel was necessary for an accurate comparison to 
the crystal structure. The fact that Ellipticine is docked in the intercalation site is 
encouraging, especially given the steric hindrance and tight fit typically associated with 
intercalation sites. Note that the Autodock grid is also large enough to allow for potential 
docking into the groove sites located near the intercalation site, so the intercalation dock 
is the preferred site. This emphasizes that RMSD values are only one metric for 
evaluating quality of docking poses and that the top poses should be visually inspected to 
check for ligand-target symmetry. 
The lowest RMSD docking pose for Daunorubicin and Pentamidine are close to 
the resolution of the crystal structures, especially at the software conditions of "5 docks" 
and "2E7 energy evaluations". In particular, the RMSD for Daunorubicin is almost 
always lower than 1 A. The RMSD values for Distamycin appear to be the most variable 
over the different software conditions, which is not surprising given that Distamycin has 
the highest number of rotatable bonds (14) compared to Daunorubicin (9), Pentamidine 
(12) and Ellipticine (0). The number of rotatable bonds for each molecule was defined by 
49 
AutoDockTools usmg a united-atom representation that merges non-polar hydrogens 
[94]. AutoDockTools is used to automatically select the rigid "root" section of the ligand 
and the "branches" off of the "root" are subsequently defined as rotatable bonds [59]. 
Molecules with larger numbers of rotatable bonds are expected to take a larger number of 
energy evaluations to converge to an energy minimum due to a larger number of degrees 
of freedom and conformational states [59, 99]. The docking results for Distamycin are 
especially encouraging considering that most small molecules that are tested for 
therapeutic utility typically have less than 12 rotatable bonds [103]. The number of 
energy evaluations appears to be most important when the fewest number of docks (5) is 
used, and the accuracy of the Distamycin docking increases significantly with increasing 
number of energy evaluations. Moreover, once the number of energy evaluations used 
reaches 2E7, there appears to be no increase in docking accuracy when the number of 
docks is increased from 5 to 10 or 20. This finding is consistent with previous 
observations from ligand-protein studies that tested the effects of varying energy 
evaluations and number of dockings on docking accuracy [95]. Visualization of the 
Distamycin docking poses that have a resolution of greater than 2 A show that even 
though the RMSD is higher than the cutoff, the ligand still occupies a similar space in the 
minor groove relative to the crystal structure. These results suggest that a software 
parameterization of "5 docks" combined with "2E7 energy evaluations" is acceptable, as 
the resolution of all of these docks with the exception of Ellipticine is less than 2 A. 
Autodock 4 Pose Ranking. The ability of Autodock to correctly rank the lowest 
RMSD docks must also be assessed as a particularly challenging aspect of molecular 
docking is scoring the docked poses correctly. The rank of the lowest RMSD pose out of 
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all dockings for either Autodock and Surflex is shown in Figure 7. Autodock ranks the 
docked conformation by calculating a binding energy and sorting the results from lowest 
to highest energy. Ideally, the docked pose with the lowest binding energy would 
correspond to the docked pose with the lowest RMSD. In all software conditions, the top 
ranked dock for Daunorubicin achieves the RMSD cutoff of 2 A. (Figure 6). 
A number of poses with RMSD values less than 2 A are produced for Distamycin and 
Pentamidine using several different software conditions. However, there are a number of 
top ranked poses for Distamycin, Ellipticine and Pentamidine in several software 
conditions that merit further discussion as these had higher RMSD values. It is critical to 
ascertain whether the high RMSD values associated with these poses is due to lack of 
consideration of either ligand or target symmetry or if the pose itself is of marginal 
quality. Visual inspection of the four top ranked poses for Distamycin with a resolution 
of greater than 12 A RMSD suggests that the flipped orientation of the ligand relative to 
the crystal structure is the main cause of the high RMSD. However, the high RMSD 
cannot be ascribed solely to nucleic acid target symmetry, as the crystal structure shows 
that Distamycin is not centered around the minor groove and superposition of the docked 
pose results in poor visual overlap with the crystal structure. Instead there appears to be 
poor docking that is localized to the multiple terminal nitrogen groups, which float freely 
outside of the minor groove instead of the expected tight binding within the minor groove 
that is observed with the crystallographic structure. The marginal accuracy of these 
dockings may be influenced by the large number of rotatable bonds observed with 
Distamycin. This significantly increases the degrees of freedom and number of possible 
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Figure 7. The rank of the lowest RMSD pose out of all dockings. Figures A and C present 
the rank without taking into account ligand or nucleic acid symmetry, for Autodock and 
Surflex, respectively. Figures Band D includes ligand and nucleic acid symmetry, for 
Autodock and Surflex, respectively. Black = Daunorubicin, Blue = Distamycin, Red = 
Ellipticine, Green = Pentamidine. 
52 
Figure 7. The rank of the lowest RMSD pose out of all dockings. 
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conformations of the ligand, making it challenging to dock to the target [59, 99]. With 
respect to Ellipticine, the high RMSD values appear to be due to a combination of the 
flipped orientation of the ligand which can be reassessed by accounting for nucleic acid 
target symmetry, and also by marginal overall alignment of the docked pose relative to 
the crystal structure. Pentamidine is a unique case where consideration of ligand 
symmetry into the RMSD calculations dramatically reduces the RMSD values for several 
top ranking poses (Figures 6B). This shows that the high RMSD is ascribed to ligand 
symmetry rather than to marginal docking quality and atom overlap. 
In summary, there are several software conditions that appear promising with 
respect to ranking of the poses including "5 docks" with "2E7 energy evaluations" and 
"10 docks" with "2E5 energy evaluations". However, the real value in assessing 
Autodock performance lies in combining both docking accuracy and ranking of the 
docked results. A software parameterization of "5 docks" and "2E7 energy evaluations" 
appears best able to balance docking accuracy and ranking. By using this 
parameterization, docking of Daunorubicin, Distamycin and Pentamidine was achieved to 
a resolution of approximately 2 A, while the intercalator Ellipticine was the most 
challenging dock, with a top pose resolution of approximately 3 A. These docked 
conformations are also visually in close agreement with the observed crystal structure 
(Figure 8). 
Surflex 2.11 Docking Accuracy. The Surflex docking results generally show that 
crystal structures are accurately reproduced (Figure 5). In all experiments, Daunorubicin 
and Distamycin are docked accurately to a resolution of less than 2 A. Visualization of 
the lowest RMSD Ellipticine pose demonstrates that Ellipticine is docked in the correct 
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Figure 8. Comparison of the top ranked Autodock pose (magenta) to the PDB 
crystallographic pose (yellow) for the experiment with a software conditions of "5 docks" 
and "2E7 energy evaluations." (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and 
(D) Pentamidine. 
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Figure 8. Comparison of the top ranked Autodock pose to the PDB crystallographic pose 
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orientation relative to the crystal structure. The higher RMSD for the top Ellipticine pose 
relative to the other compounds appears to be due to the marginal alignment of the ligand 
structure with the crystal structure. A similar marginal overlap was observed for the 
Autodock Ellipticine poses, as described previously. Importantly, Ellipticine is located 
well inside the intercalation site. For Pentamidine, incorporation ofligand symmetry into 
the RMSD calculation results in significant increases in the docking accuracy for all 
software conditions, with the lowest RMSD structures occurring with the "Multi start 5" 
only experiment, and the "Multistart 5" and "Random 5" combination experiment. This 
is attributed to inclusion of poses that were docked in a flipped orientation that initially 
had RMSD values greater than 12 A, but subsequently have significantly lower RMSD 
values after taking into account ligand symmetry. With respect to docking accuracy, 
addition of the "Multi start 5" option produces a better docked pose for Pentamidine. This 
supports the hypothesis that initiating the docking of the ligand from multiple points 
surrounding the nucleic acid target increases the accuracy of the dockings. Interestingly, 
the addition of the "Random 5" option in combination with the "Multi start 5" option did 
not significantly impact the lowest RMSD dock produced for these test ligands. The 
"Random 5" option generates 5 randomized X,Y,Z coordinate positions of the atoms at 
the initial starting position of the ligand [97]. Most importantly, Surflex is able to dock 
the ligands to the nucleic acid targets and produce docking results with RMSD values 
close to the resolution of the observed crystal structure. 
Surflex 2.11 Pose Ranking. Ranking of Surflex results is performed by maximizing 
the Surflex Overall Score, which consists of an affinity score of the ligand for the target. 
Ideally, a maximal Surflex Overall Score would correspond with the lowest RMSD pose. 
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Figure 9. Comparison of the top ranked Surflex pose (magenta) to the PDB 
crystallographic pose (yellow) for the experiment with a software parameterization of 
"Multistart 5" and "Random 5." (A) Daunorubicin, (B) Distamycin, (C) Ellipticine and 
(D) Pentamidine. 
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Figure 9. Comparison of the top ranked Surflex pose (magenta) to the PDB 
crystallographic pose (yellow) for the experiment with a software parameterization of 
"Multi start 5" and "Random 5." 
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Inspection of the RMSD values for the top Surflex docks ranked by maximal Surflex 
Overall Score are at first glance misleading (Figure 7). In particular, the experiment that 
included the "Multi start 5" and "No Random" options and the experiment with the 
"Multi start 5" and "Random 5" options initially appear to have a poor docking pose for 
Pentamidine. However, closer visual inspection of the docked conformation relative to 
the crystal structure pose again emphasizes the use of symmetry for RMSD calculations 
where appropriate (Figure 9), which reduces the RMSD to under 2 A. 
For all of the experiments, Ellipticine is docked in a flipped orientation in the 
intercalation site, which was initially thought to be the major factor influencing the high 
calculated RMSD value. However, even after accounting for nucleic acid target 
symmetry, Ellipticine has still only minimal overlap with the crystal structure. 
Inspection of the top ranked dock for Daunorubicin for the software parameterization 
with "No Multistart" and "No Random" and the software parameterization with 
"Multistart 5" and "No Random" options appears to show Daunorubicin in a flipped 
orientation relative to the crystal structure. The Daunosamine ring occupies the minor 
groove, which is similar to the ring location in the crystal structure. After taking into 
account the nucleic acid target symmetry, the docking pose RMSD values for both the 
"Multi start 5" and "No Random" experiment and the "Multi start 5" and "Random 5" 
experiment are dramatically improved, to a resolution of 3.4 A and 2.3 A, respectively. 
Finally, all Surflex software conditions docked Distamycin to the target at a resolution of 
less than 2 A. These results emphasize the importance of not only calculating RMSD 
values for docked poses, but also visualizing results to check for reasonable docking 
conformations. 
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The software parameterization with "Multi start 5" alone and the software 
parameterization with both "Multi start 5" and "Random 5" appear to produce the top 
ranked results with the lowest RMSD structures, compared to the software 
parameterization of "No Multistart" and "No Random" options. The top ranked pose for 
Daunorubicin using the "Multi start 5" and "Random 5" software parameterization has an 
RMSD of 1.3 A and is superior to the top ranked dock for the other Surflex experiments. 
Both software conditions dock Distamycin and Ellipticine comparably with respect to the 
RMSD of the top ranked Surflex pose. For Pentamidine, the top ranked pose for the 
"Multi start 5" and "No Random" option experiment has a marginally better RMSD for 
the top pose compared to the top pose from the "Multistart 5" and "Random 5" 
experiment. Overall, the performance of the "Multi start 5" and "No Random" experiment 
and the "Multistart 5" and "Random 5" experiments are comparable. 
Extended Parameter Optimization for Autodock and Surflex. While the overall 
docking results for Surflex and Autodock generally show the ability to accurately 
reproduce the crystal structure and rank the results, it is important to determine the reason 
for some of the more challenging dockings such as Ellipticine and Distamycin. One 
possibility for the marginal docking accuracy could be an inadequate number of iterations 
(number of docks and energy evaluations for Autodock, and multistart number and 
random parameters for Surflex) of the software. If this is the case, it would be expected 
that increased docking accuracy and ranking could be obtained by increasing the 
exploration of the Autodock and Surflex parameters. 
To investigate this possibility for Autodock, the docking experiments with the 
four ligands were repeated after increasing the number of dockings from 5 to 50 and the 
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number of energy evaluations from 2E7 to 5E7. The number of dockings were selected 
based on previous applications of the software [59]. The number of energy evaluations 
was increased to 5E7, which is consistent with the number of energy evaluations used in 
previous protein docking experiments [95]. A similar approach was taken with Surflex by 
increasing the Multistart parameter from 5 to 10 and the Random parameter from 5 to 10. 
However, Jain et al. had previously seen only marginal improvement in increasing the 
Multistart parameter greater than 5 with protein docking [97]. 
Evaluation of the docking accuracy (Figure 10) and ranking (Figure 11) results 
show that there is no benefit in docking accuracy or ranking for either Autodock or 
Surflex by extending dockings and evaluations of software parameters. Moreover, the 
Autodock experiments took approximately 25 fold longer under conditions of 50 docks 
and 5E7 energy evaluations compared to conditions of 5 docks and 2E7 energy 
evaluations. Surflex took approximately 5 times longer under conditions of Multistart 10 
and Random 10 compared to Multistart 5 and Random 5. Even if the extended 
experiments showed improved docking accuracy and ranking, the increase III 
computational time could be a limiting factor for use in virtual screening applications. In 
summary, the results suggest that the originally optimized Autodock conditions of 5 
docks and 2E7 energy evaluations and Surflex conditions of Multistart 5 and Random 5 
are optimized for molecular docking to nucleic acids. 
Evaluation of the Autodock and Surflex Scoring Functions. As the docking 
accuracy and ranking does not appear to be related to suboptimal software 
parameterization, another possible contribution to marginal docking may be from the 
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Figure 10. Autodock and Surflex Parameterization Accuracy. The dock with the lowest 
RMSD is presented, regardless of ranking. Figures A and C present the RMSD 
calculated without taking into account ligand or nucleic acid symmetry, for Autodock and 
Surflex, respectively. Figures Band D includes ligand and nucleic acid symmetry, for 
Autodock and Surflex, respectively. Black = Daunorubicin, Blue = Distamycin, Red = 
Ellipticine, Green = Pentamidine. 
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Figure 10. Autodock and Surflex Parameterization Accuracy. 
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Figure 11. Autodock and Surflex Parameterization Ranking. Figures A and C present 
the RMSD calculated without taking into account ligand or nucleic acid symmetry, for 
Autodock and Surflex, respectively. Figures Band D include ligand and nucleic acid 
symmetry, for Autodock and Surflex, respectively. Black = Daunorubicin, Blue = 
Distamycin, Red = Ellipticine, Green = Pentamidine. 
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Figure 11. Autodock and Surflex Parameterization Ranking. 
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scoring functions of these programs. This is possible given that scoring functions are one 
of the major challenges of current docking programs [104]. To investigate this possibility, 
the crystal structure and the top ranked poses for each method were rescored using both 
the Surflex and Autodock scoring functions. The poses were scored and ranked 
according to the lowest free energy of binding. An additional molecular mechanics 
method was selected to calculate the energy of binding of the crystal pose, Autodock, and 
Surflex poses. This was useful as the added hydrogens could also be selectively 
energetically minimized, which highlighted the hydrogen atom treatment as a potential 
pitfall. Macromodel 9.S was used to determine the effects on the energy of binding of 
using either the OPLS200S or Amber* force field with and without water as an implicit 
solvent. These experiments investigated if the limitations in the ranking of the software 
were related to the scoring functions for these programs. 
Scoring of Poses by Autodock and Surjlex. The direct comparison of the Surflex and 
Autodock Scoring Functions is shown in Figure 12. Unsurprisingly, the Surflex scoring 
function tends to score the Surflex poses the best while the Autodock scoring function 
tends to score the Autodock poses the best. The Surflex scoring function scores the 
Autodock poses reasonably well, with a low free energy of binding. In general, the 
Autodock scoring function produces results with the lowest free energy of binding. Both 
Autodock and Surflex appear to typically score either the Autodock or Surflex poses as 
having lower free energy of binding compared to the crystal pose. The Surflex scoring 
function produces a "Static" score (red, Figure 12) and an "Optimized" score (green 
Figure 12) when scoring an individual pose. The "Static" score applies the Surflex 
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Figure 12. Comparison of the Free Energy of Binding for the Crystal pose, Autodock top 
ranked pose and Surflex top ranked pose for various ligands using the Autodock and 
Surflex Scoring Functions. Blue = Autodock Scoring Function. Red = Surflex Static 
Scoring Function. Green = Surflex Optimized Scoring Function. (A) Daunorubicin, (B) 
Distamycin, (C) Ellipticine and (D) Pentamidine. 
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Figure 12. Comparison of the Free Energy of Binding for various ligands. 
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SCOrIng function directly to the input pose, with no energy minimization. The 
"Optimized" score performs a gradient energy minimization and subsequently scores the 
pose. Scoring of the Surflex poses using the Surflex scoring function reveals little 
difference between the Static score and Optimized score. On the other hand, Autodock 
and the crystal structure scores are significantly improved when comparing the "Static" 
score to the "Optimized" score. One possible explanation for this difference is how the 
hydrogens are accounted for by these docking programs. 
Hydrogen Atom Treatment of Poses Can Significantly Effect Free Energy of Binding. 
It appears from Figure 12 that the significant difference in the "Static" and "Optimized" 
Surflex scoring function scores for Autodock and the crystal poses could be influenced 
by the way hydrogen atoms are added to these structures. In order to determine if this is 
the case, it is important to first address the way hydrogens are normally accounted for by 
these programs. Surflex adds all hydrogens on the ligand prior to docking so all of the 
hydrogens are present during scoring. The crystal structure does not have any hydrogens 
added. Autodock uses a United Atom force field which takes into account "polar" 
hydrogens that are attached to electronegative atoms [59]. "Non-polar" hydrogens 
attached to carbon atoms are merged and the charge is added to the nearby carbon atom 
[85]. To evaluate whether the trends in Figure 12 could be influenced by the way 
hydrogens are handled by the docking programs, Macromodel was used to add all 
hydrogens to the ligands and their binding energies were recalculated both before and 
after energy minimization of the hydrogens (Figure 13). Comparing the binding energy 
of the poses before and after minimization of the hydrogens shows that the most 
significant decrease in energy after minimization is seen with the crystal structure. 
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Figure 13. Calculated Energy of Binding by Macromodel for the Crystal pose, Autodock 
top ranked pose and Surflex top ranked pose for various ligands using the Amber* and 
OPLS2005 Force Fields with and without implicit water solvation. Solid Blue 
=OPLS2005, no implicit water solvation. Blue with Hatches = OPLS2005, with implicit 
water solvation. Solid Gray = Amber*, no implicit water solvation. Gray with Hatches = 
Amber*, with implicit water solvation. (A) and (B): Daunorubicin, before and after 
hydrogen minimization, respectively. (C) and (D): Distamycin, before and after 
hydrogen minimization, respectively. (E) and (F): Ellipticine, before and after hydrogen 
minimization, respectively. (G) and (H): Pentamidine, before and after hydrogen 
minimization, respectively. 
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Figure 13. Calculated Energy of Binding by Macromodel for the various ligands. 
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However, there is also a substantial reduction in the energy of binding for Autodock. The 
Surflex binding energies appear to be the least affected presumably because all hydrogens 
were accounted for during docking and scoring. The results in Figure 13 are important 
because a molecular mechanics approach was used to assess each of the poses for the 
docking programs with two force fields and two solvation approaches. These results 
show that Surflex appears to consistently produce the docked poses with the lowest 
energy of binding. This suggests the hydrogen atom treatment is an important 
consideration when scoring docked poses and can substantially influence scoring and 
energy calculations. It is interesting to note that Ellipticine, which has the fewest number 
of rotatable bonds and hydrogen atoms is least effected by hydrogen atom treatment. 
Effects of Force Field Choice and Solvation on Energy of Binding. A series of 
experiments was performed to test the effects of using either the Amber* and OPLS2005 
force fields, with and without implicit water solvation, on the energy minimization and 
the calculated energy of binding of the ligands to the targets. The Amber* force field 
was selected because the Autodock force field is parameterized based on the Amber force 
field [59, 85]. OPLS2005 was chosen because it is an updated general force field from 
the original OPLSAA force field that has demonstrated utility in evaluating protein 
structures [105]. The calculated energy of binding of the top ranked ligand poses, before 
and after energy minimization of the added hydrogens are shown in Figure 13. The 
force field choice and solvation effects can substantially influence the calculated energy 
of binding. For the structures where the hydrogens were energetically minimized, the use 
of the Amber* force field with inclusion of water solvation appears to produce energy of 
binding results that are most consistent with the results in Figure 12 that were obtained 
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usmg the Autodock and Surflex SCOrIng functions. The energy of binding of the 
Autodock and Surflex poses appears substantially lower than the crystal structures, with 
the exception of Ellipticine. It appears in these cases that for the Autodock and Surflex 
poses, the addition of implicit solvation in just the energy minimization is not 
advantageous and not indicative of a favorable binding event. In total, this shows that 
force field selection and solvation factors can contribute substantially to scoring and 
ranking docked poses and this could be one of the main challenge of docking ligands to 
nucleic acids. 
Crystal Structure Energies are not necessarily the "Minima". The free energy of 
binding for the crystal structure and top ranked Autodock and Surflex poses, determined 
by either the Autodock or Surflex scoring function is shown in Figure 12. The top ranked 
Autodock or Surflex pose almost universally has a comparable or lower free energy of 
binding compared to the reference crystal structure. This is true irrespective of the 
scoring function. These results are supported by the molecular mechanics results in 
Figure 13, where the calculated energy of binding for all ligands, apart from Ellipticine, 
is comparable to or lower than the crystal structure. These results are important for 
several reasons. First, the crystal structures should not be assumed to be the energetically 
minimized conformation in the nucleic acid target, as the structure is a product of 
experimental data and the original force field it is fitted to. Interestingly, the energy of 
the lower resolution crystals, Distamycin (2.2 A) (Figure 13D) and Pentamidine (2.1 A) 
(Figure 13H), appear to have more variability between the energy of the top ranked poses 
and the crystal structure compared to the higher resolution crystal structures 
Daunorubicin (1.4 A) (Figure 13B) and Ellipticine (1.5 A) (Figure 13F). This suggests 
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that the quality and resolution of the crystal structure may be a consideration when 
performing docking studies and evaluating poses. However, it is also a function of 
flexibility of the ligand as Distamycin and Pentamidine are the most flexible. Another 
reason these results are important is that the docked poses such as Distamycin that 
initially appeared to be of only marginal accuracy by RMSD compared to the crystal 
structure are better than initially thought with respect to the energy of binding, which 
implies that the crystal structure ligand pose may not be optimal to start with. 
Overall Comparison of Autodock and Surflex Performance. In assessing the overall 
performance of Autodock and Surflex, several facets of docking must be compared 
including docking accuracy, docking ranking, computational speed, and even ease of use. 
Both Autodock and Surflex have comparable performance in accurately reproducing the 
crystal structure and ranking the poses, particularly with software conditions of "5 docks" 
with "2E7 energy evaluations" and "Multi start 5" and "Random 5" respectively. 
However, one important factor where performance differs substantially are the 
computational resources required for docking. Using 2.0 GHz AMD Opteron 246 
processors, Surflex performed the dockings significantly faster than Autodock for all 
ligands tested. The average time to complete each Surflex docking with a software 
parameterization of "Multi start 5" and "Random 5" was just under 8 minutes while 
Autodock with a software parameterization of "5 docks" with "2E7 energy evaluations" 
took approximately 76 minutes. Given that the docking accuracy and ranking results 
were comparable, the significantly faster docking speed of Surflex makes it particularly 
well suited for virtual screening applications where large numbers of ligands are 
screened. Surflex is also superior with ease of use, as it is a single executable application 
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with direct input from a MOL2 file format. Autodock requires file conversion from a 
MOL2 into a PDBQT file format prior to performing molecular dockings. For these 
reasons, under the tested software conditions, we show Surflex is a superior software 
package for virtual screening of nucleic acids in the system reported here. 
Comparison of Results to Previous Studies. Relatively few molecular docking studies 
have been performed with nucleic acids. In comparing the data presented in this paper to 
other docking papers, we placed particular emphasis on the evaluation of the accuracy of 
the top ranked pose returned by either Surflex or Autodock. This is a logical approach 
for assessing docking software performance for virtual screening applications, since 
when screening a large ligand database, only the evaluation of the top ranked pose may 
be computationally feasible. Several previous studies have focused on utilization of the 
DOCK program for molecular docking of ligands to nucleic acids. Grootenhuis et al. 
used DOCK to target the minor groove, major groove and an intercalation site on duplex 
DNA while more recently, Chen et al. successfully targeted the major groove of RNA 
[33,36-37]. Van et al. targeted an RNA tetraloop structure and demonstrated docking at a 
similar resolution to what was observed in our study of docking ligands to DNA targets 
[72]. Rohs et al. recently developed a molecular docking approach utilizing a Monte 
Carlo algorithm that successfully demonstrated the binding of methylene blue to DNA by 
minor groove and intercalation binding modes [38]. However, methylene blue has only 
four rotatable methyl groups with fewer degrees of freedom than several of the more 
conformationally complex ligands tested in this study [38]. 
One report of docking studies to nucleic acids using Autodock was performed by 
Evans et al., who demonstrated the ability of a previous version of Autodock to 
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accurately predict binding of minor groove binders to their respective nucleic acid targets 
[34]. A direct comparison of all of the results from the Evans paper and this study is 
difficult due to different operating conditions and software versions for Autodock; 
however, some differences are noteworthy. One limitation of the previous study is that 
while the number of energy evaluations was varied, the maximum number of evaluations 
performed was only 2.5E6. Based on our studies, we found that 2E7 energy evaluations 
was optimal for docking accuracy and pose ranking. Another consideration is that in this 
previous study the number of dockings was kept constant. We evaluated the parameters 
by varying both the number of docks and energy evaluations to determine which 
combination of software parameters is best for virtual screening applications. Similar to 
the results in this paper, Evans did find that in general, increasing the number of energy 
evaluations increased the accuracy of the predicted pose, with respect to the crystal 
structure [34]. However, we also found that using fewer numbers of dockings while 
concurrently increasing the number of energy evaluations increases both pose accuracy 
and ranking. This is presumably due to a more complete exploration of the energetic 
landscape surrounding the ligand-target interaction. This has important implications for 
virtual screening where of crucial importance is the accuracy of the top ranked pose. 
Generally, the results of Evans et at. are consistent with results in this paper, and show 
that Autodock is able to successfully predict the binding of multiple minor groove 
binders to their targets at a resolution of approximately 2 A [34]. However, based on the 
data herein, we recommend using more energy evaluations and fewer numbers of docks 
for virtual screening applications to produce the best top ranked dock. While the results 
in this paper expand and add value to previous Autodock work targeting nucleic acids, 
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importantly, we show that the results with Surflex in particular are very useful, 
applicable, and the first published study to demonstrate successful molecular docking of 
intercalators or minor groove binders to nucleic acid targets using this software. 
Conclusions 
The results reported here support the primary objective of this work, which is to 
test Autodock 4 and Surflex 2.11 for accurately reproducing ligand-bound nucleic acid 
structures. This is a critical first step in validating these software for future use in 
targeting specific nucleic acid structures. Even given the aforementioned limitations and 
uncertainties of using Autodock 4 and Surflex 2.11 with nucleic acids, these results show 
that these software can accurately reproduce the crystal structures of both groove binders 
and intercalators. Ours is one of only a few studies to date to have shown that nucleic 
acids can be successfully targeted using these docking methods. Our results show that an 
Autodock 4 software condition of "5 docks" and "2E7 energy evaluations" is the best for 
combined docking accuracy and ranking. The Surflex 2.11 software conditions of 
"Multistart 5" and "No Random" and "Multi start 5" and "Random 5" appear equally good 
at producing top ranked structures with low RMSD values relative to the crystal structure. 
Extended experiments testing further increases in Autodock and Surflex parameterization 
did not improve docking accuracy or ranking. The most challenging ligand to dock 
accurately was Ellipticine, which was no surprise given the small pocket in the nucleic 
acid and tight fit associated with the binding of ligands into the intercalation site. Given 
that the Autodock and Surflex scoring functions for ranking the docked poses were 
parameterized based on protein-ligand structures, the ranking results are particularly 
encouraging [2, 86]. Both programs are able to return a top ranked pose with 
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approximately 2 A RMSD for Daunorubicin, Distamycin and Pentamidine and a pose 
with approximately 3 A RMSD for Ellipticine. It is important to consider that while the 
docking accuracy and pose ranking of these programs is comparable, Surflex performs 
docking much faster than Autodock under the optimized software conditions in this 
paper. Surflex also requires less manipulation of input files, suggesting that Surflex is 
preferred for virtual screening applications for systems similar to presented here. 
Based on these docking studies, several points should be strongly considered when 
performing molecular docking with nucleic acids and evaluating docked poses. Docking 
parameters should be explored in detail since suboptimal software conditions can 
significantly impact the accuracy and ranking of the docked poses. When evaluating 
docked poses, visualization of the most promising docking poses should be performed as 
well as calculation of RMSD values. It is crucial to also account for both ligand and 
target symmetry by either including ligand symmetry in RMSD calculations or 
performing molecular superposition to account for nucleic acid target symmetry. Given 
the conformation and structural heterogeneity of proteins, target symmetry is less likely 
with respect to docking. However, nucleic acid targets are much more likely to exhibit 
symmetry due to the simple base pair composition and the nature and geometry of the 
nucleic acid strand associations. Another consideration when performing docking is the 
hydrogen atom treatment of the software, as this can significantly impact the free energy 
of binding. These studies also demonstrated that force field and solvation selection can 
dramatically effect the binding energy. Finally, selection of high quality and high 
resolution crystal structures is especially important when using these structures as 
reference conformations to evaluate docking poses. Based on the results in this paper, it 
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is important to consider that the crystal structure does not necessarily represent the 
energetically minimized pose with respect to the poses generated by docking software. 
These findings have important implications not only in the field of chemistry and 
computational biology, but also in the area of organic small molecule synthesis using 
structure-based drug design. Many previous efforts at rational drug design have focused 
on time-consuming and expensive small molecule synthesis methods. If reliable, 
molecular docking allows for the construction of virtual libraries of molecules that can be 
docked against any nucleic acid target of interest. One of the logical next steps in 
molecular docking to nucleic acids is the development of rules to select ligands that may 
bind nucleic acid targets with affinity and specificity. These experiments suggest that 
molecular docking techniques may have particular value as a virtual screening precursor 
step to full chemical synthesis of drug candidates. 
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CHAPTER III 
DEVELOPMENT OF IN SILICO PREDICTIVE METRICS THAT GOVERN 
SMALL MOLECULE - NUCLEIC ACID INTERACTIONS 
Work in our previous chapter described the validation of the molecular docking 
software Surflex and Autodock for the purposes of reproducing the crystal structure of 
the minor groove binder and intercalator small molecules bound to nucleic acid targets. 
The results were significant as they demonstrated that these software can be used for 
molecular docking to nucleic acids. However, this work involved rationalization of 
known crystal structure data by docking the small molecules to a single nucleic acid 
target. The question remains whether a compound can be screened against multiple 
nucleic acids in silico for the purposes of predicting binding mechanism and sequence 
and structural selectivity. Determining if predictive in silico metrics can be developed to 
answer this question is the focus of this chapter. 
This chapter details a novel approach to predict the binding mechanism and 
sequence and structural selectivity of small molecules for nucleic acids. We describe the 
construction of an in silico nucleic acid library and the docking of the small molecules 
from Chapter II (daunorubicin, distamycin, ellipticine and pentamidine) to the array of 
nucleic acids. Metrics were developed that successfully classify these compounds as 
either groove binders and intercalators, with moderate success at predicting sequence and 
structural selectivity. The metrics were further tested on several new triplex and 
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quadruplex binding small molecules that our lab has recently discovered. Finally, using 
the in silica metrics, an extensive 67 member small molecule library for which in vitra 
nucleic acid sequence and structural binding data exists, was classified on the basis of 
binding mechanism and sequence selectivity. This was the most robust test of the metrics 
as the compound library was highly heterogeneous with respect to binding mechanism of 
action and sequence preference. In total, we demonstrate that the metrics as described 
here can generally successfully predict the mechanism of binding of a ligand to a nucleic 
acid in silica although it was generally more challenging to predict sequence and 
structural selectivity. A summary comparison of the performance and limitations of 
Surflex and Autodock is also detailed. The new information described here can facilitate 
large scale virtual screening efforts that can be used to discover new small molecules in 
silica that bind to a specific site on a nucleic acid structure and with a desired binding 
mechanism. 
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DEVELOPMENT OF IN SILleD PREDICTIVE METRICS THAT GOVERN 
SMALL MOLECULE - NUCLEIC ACID INTERACTIONS 
Patrick A. Holt, Jonathan B. Chaires, John O. Trent. 
Introduction 
Knowledge about the structure and function of nucleic acids has increased 
dramatically in recent years. It is now known that nucleic acids are highly polymorphic 
and can adopt physiologically relevant structures in vivo that are promising targets for 
drug development. There is increasing evidence suggesting that DNA is altered in many 
neoplastic conditions and there are many nucleic acid structures that are intriguing targets 
for small molecule drug discovery [106]. G-quadruplex structures are but one example. 
These structures are found in increased prevalence in the single stranded telomeric ends 
of chromosomes. Stabilization of G-quadruplexes through small molecule targeting has 
been shown to inhibit cancer cell life by inhibiting telomerase association with the 
chromosome. As telomerase is overexpressed by cancer cells and not normal cells, this is 
a potentially effective strategy for selectively targeting tumor cells [53-55]. 
There are multiple known small molecules that bind to G-quadruplexes. One 
example is the porphyrin TmPyP4 which has potential anti-cancer properties in vivo 
[107-108]. Unfortunately, many of these molecules, TmPyP4 included, suffer from poor 
selectivity and are known to bind to many other nucleic acid structures and sequences in 
vitro, which is a major concern for further clinical development [10, 109]. This poor 
selectivity may be in large part because many small molecules are designed or 
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synthesized only considering the binding to a single target of interest and may not take 
into account binding and interactions with other potential targets in vitro and in vivo. 
There is a critical need to determine if the mechanism of action and sequence and 
structural selectivity of small molecules for nucleic acids can be predicted in silica. This 
would allow for the virtual screening of millions of molecules in silica for the best "hit." 
We describe here a novel computational strategy here to address this unmet need. 
Before detailing our in silica approach for predicting small molecule-nucleic acid 
interactions, we briefly review the important binding mechanisms of compounds to 
nucleic acids. Small molecules can interact with nucleic acids by two main modes of 
binding; groove binding and intercalation [110]. The minor groove of DNA provides a 
site for many small molecules to bind because of the favorable geometry of the groove 
and because there is less competition from polymerases and proteins that typically target 
the major groove of duplex DNA [5]. Small molecules that bind to the minor groove 
typically have intrinsic curvature present or have the capability of existing as a stable, 
low energy conformation that is compatible with the geometry of the minor groove [111]. 
This compound curvature or "crescent shape" is an important property of many minor 
groove binding small molecules as this allows the compound to bind between the walls of 
the minor groove [111-112]. However, compound curvature is not an absolute 
requirement for compounds that bind to the minor groove, as some linear diamidine 
compounds have been identified that possess minor groove binding activity [113]. A few 
examples of small molecules that bind to the minor groove are DAPI, pentamidine and 
distamycin. 
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The second mam binding mechanism of small molecules to nucleic acids is 
intercalation which occurs by insertion of the molecule between adjacent base pairs in the 
nucleic acid. Intercalation of a small molecule into DNA exerts a profound change on the 
structure of DNA. In order for the intercalator to stack between the adjacent bases, the 
nucleic acid must unwind partially and increase in length [110]. "Classical" intercalators 
typically possess a fused, planar aromatic ring system which allows a small molecule to 
insert between adjacent base pairs. In almost all cases, the small molecules also possess a 
cationic external charge and many times bind cooperatively to DNA [110]. Molecules 
that intercalate into DNA include ethidium bromide and acridine based molecules. 
Compounds can also interact by hybrid methods where contributions of both 
intercalation and groove binding are involved. Additionally, in some cases, molecules 
can stack onto the ends of specific DNA structures ("end-stacking") such as G-
quadruplexes, which involves interaction of the ligand with the guanine quartet on the 
one side and the flanking DNA loops on the other side. This is in contrast to intercalation 
into G-quadruplexes which occurs when a compound inserts between two adjacent 
guanine tetrads. Finally, molecules can have chemical properties that allow intercalation 
of part of the molecule with concomitant groove binding of substituents which is referred 
to as "threading" intercalation. Generally, however, small molecules are divided along 
the main categories of minor groove binding and intercalation. 
We focus here on determining if predictive in silico rules can be developed to 
predict the nucleic acid binding mechanism and sequence specificity of a small molecule 
in silico. This would provide valuable information as the rules could be applied to 
virtually screen large numbers of small molecules to identify ones that bind with a known 
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mechanism of action to a specific nucleic acid target. Large scale in silica molecular 
docking of small molecules to a target of interest is becoming an accepted approach for 
discovering novel small molecules for drug development. This field has largely focused 
on proteins until recently as many of the software have been designed with proteins in 
mind. However, validation of various software with nucleic acids has been successful 
and recent evidence suggests that the molecular docking software, Surflex and Autodock 
has particular utility for the virtual screening of large numbers of compounds to 
promising nucleic acid targets [34, 63]. We previously reported (as described in 
Chapter II) the use of Surflex and Autodock to successfully reproduce the known crystal 
structure pose of a collection of small molecules that bind by groove binding and 
intercalation to nucleic acid targets [63]. While these studies were successful, they relied 
on the presence of a single in silica structure of a small molecule with nucleic acid and 
did not determine if the docking software can predict sequence or structural selectivity. 
The question remains whether rules can be developed for Surflex and Autodock that can 
predict whether small molecules will groove bind or intercalate and to which sequences 
and DNA morphologies that the small molecules prefer. 
We report here the development of in silica rules that can be used to predict the 
mechanism of action and the sequence specificity of an array of small molecules. An 
initial set of four small molecules (daunorubicin, distamycin, ellipticine and pentamidine-
-the so-called "Positive Control" set of ligands) were selected because Surflex and 
Autodock can successfully reproduce the known crystal structures of these groove 
binders and intercalators [63]. These compounds were docked to an array of 10 nucleic 
acids that were constructed in silica. The array of nucleic acids are highly diverse and 
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consist of duplex, triplex, and quadruplex DNA and RNA as well as groove and 
intercalation sites and sequence heterogeneity. Based on the docking results, in silica 
rules were developed to classify the compounds on the basis of their binding mechanism 
and to assess the sequence and structural selectivity of the compounds. The rules were 
further tested on several novel triplex and quadruplex binding small molecules (the 
"Validation" set) that our laboratory has discovered. Finally, the rules were also tested 
on a 67 set of compounds (the "67 Compound Library" set) for which nucleic acid 
sequence and structural data for the 10 array of nucleic acid structures was previously 
acquired by competition dialysis. In summary, we present the development of in silica 
metrics that rationalizes existing data and can predict critical binding information about 
small molecules in silica. 
The development of in silica rules for predicting small molecule-nucleic acid 
binding behavior has significant implications for the field of drug discovery. This is a 
vastly unexplored area of research and there have been almost no efforts to predict the 
binding mechanisms of small molecules by in silica approaches [114]. The development 
of predictive rules to govern small molecule-nucleic acid interactions will facilitate 
screening of many small molecules to the in silica array of targets to determine binding 
mode and sequence specificity. This will be a valuable tool to discover new small 
molecules by virtual screening or alternatively, preempt chemical synthesis of derivatives 
of known small molecules which is an often expensive and laborious undertaking. 
Another consideration is that the in silica array of 10 nucleic acids is but an initial point 
for testing. The power of this approach is that the in silica screen and library can be 
expanded or customized as more structures become available in silica. In total, we 
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believe this information will allow for the virtual screenmg of millions of small 
molecules in silico to discover compounds that can bind to a nucleic acid target of 
interest by a known binding mechanism and sequence specificity. This will provide an 
essential tool for novel lead compound discovery. 
Experimental and Computational Methods 
Construction of the In silico Nucleic Acid Library. The first challenge was to build a 
structurally equivalent in silico nucleic acid library compared to the library that was used 
for competition dialysis for the 67 Compound Set. This array could also be used for the 
Positive Control and Validation sets as nucleic acids were included in the array that were 
known to interact with these small molecules. A representative 10 nucleic acid in silico 
library was built and serves as the basis for the docking experiments described here 
(Table 3). The nucleic acids exhibit a wide variety of structural and sequence diversity. 
Duplex, triplex and quadruplex nucleic acids are represented as well as an array of 
binding sites including grooves, intercalation and end-pasting sites (Figure 14). 
All of the nucleic acids were either built using Sybyl 8.1 or by direct download 
from the Protein Data Bank (PDB) database [115]. Unless otherwise noted, all nucleic 
acids were 12 nucleotides in length. Additionally, the nomenclature used herein for 
nucleic acids is the following: polydA: polydT consists of one strand Adenine and one 
strand Thymine while poly( dAdT) consists of alternating Adenine and Thymine 
nucleotides on each strand. Pure duplex DNAs (poly(dAdT), polydA : polydT, polydG : 
polydC and poly(dGC» were built in the B-Form while the RNA-DNA hybrid (polyrA : 
polydT) and pure RNA (polyrA : polyrU) were built in the A-Form as these are the 
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Table 3. The following table describes the nucleic acid morphologies, sequences and 
sites targeted for molecular docking and are identical to those used in competition 
dialysis. The nomenclature for each nucleic acid will be the nucleic acid identifier in 
remaining figures and tables in this chapter. 
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Table 3. The following table describes the nucleic acid morphologies, sequences and 
sites targeted for molecular docking and are identical to those used in competition 
dialysis. The nomenclature for each nucleic acid will be the nucleic acid identifier in 
remaining figures and tables in this chapter. 
Nucleic Acid Sequence Targeted Site Nomenclature 
Morphology 
Duplex A form polyrA : polydT Major groove ar2 
Duplex A form po lyrA : polyrU Major groove au2 
DUl!lex B form jJolydA : po!ydT Minor groove tal 
Duplex B form poly(dAdT) Minor groove at2 
Duplex B form polydG : polydC Minor groove cg2 
Duplex B form poly(dGC) Minor groove Zc1 
Duplex B form poly(dGC) Intercalation gcit 
Duplex Z form 1 poly(dGC) Groove I zdl 
Duplex Z form I poly(dGC) Groove 2 zd2 
Duplex Z form poly(dGC) Intercalation zint 
Triplex DNA poly(dA)-[poly(dT)b Minor groove dal 
Triplex RNA poly(A)-[poly(U)b Minor groove ra2 
Triplex DNA poly(dA)-[poly(dT)h Intercalation dadtdtint 
Triplex RNA poly(A)-[poly(U)b Intercalation raruruint 
Imotif1 (AACCCC)4 Groove I iml 
Imotifl lAACCCC14 Groove 2 im2 
Quadruplex A3GGG(TTAGGG)3A2 Groove I lhl 
Quadruplex A3GGG(TTAGGG)3A2 Groove 2 Ih2 
Quadruplex A3GGG(TTAGGG)3A2 Groove 3 Ih3 
Quadruplex A3GGG(TTAGGG)3A2 Groove 4 Ih4 
Quadruplex A3GGG(TTAGGG)3A2 Groove 5 Ih5 
Quadruplex A3GGG(TTAGGG)3A2 Intercalation Site I lhintl 
Quadruplex A3GGG(TTAGGG)3A2 Intercalation Site 2 Ihint2 
Quadruplex A3GGG(TTAGGG)3A2 End Pasting Site I I hend I 
Quadruplex A3GGG(TTAGGG)3A2 End Pasting Site 2 Ihend2 
I: Due to the structural dIversIty of these DNA, both grooves were targeted 
90 
Figure 14. Some of the nucleic acid structures used for the molecular docking 
experiments: (A) poly(dGC) B Form DNA; (B) poly(dAdT) B Form DNA; (C) 
poly(dGC) Z Form DNA; (D) polyrA : polydT A Form RNA-DNA hybrid; (E) polyrA : 
polyrU A Form RNA; (F) poly(dA)-[poly(dT)h triplex DNA; (G) poly(A)-[poly(U)h 
triplex RNA; (H) I-Motif and (I) Hybrid-l Quadruplex DNA. The color scheme is red = 
Adenine, dark blue = Thymine, green = Guanine, yellow = Cytosine and light blue = 
Uracil. 
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Figure 14. Some of the nucleic acid structures used for the molecular docking 
experiments. 
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typical fonns for these structures in vivo [116]. Poly (dGC) was built in the Z-Fonn and 
brominated by atom replacement of 50% of the deoxycytosines with 5 -
bromodeoxycytosine at alternating positions. The DNA and RNA triplexes, poly(dA)-
[poly(dT)]z and poly(A)-[poly(U)]z, respectively, were constructed using B-type parallel 
triplex with and without an X-ray structural intercalation site backbone fragments [(PDB) 
entry Ip20.ent] and minimized holding the heavy atoms fixed. The I-Motif structure of 
the sequence (AACCCC)4 was downloaded from the PDB [(PDB) entry lybl.ent]. The 
Hybrid-l quadruplex consisting of the sequence A3GGG(TT AGGG)3A2 was downloaded 
from the PDB [(PDB) entry 2hy9.ent]. Intercalation sites and end-pasting sites for the 
Hybrid-l quadruplex were using methods that will be further described in Chapter V. 
Briefly, a ligand consisting of four connected purines (a "quaterpurine" ligand) was 
placed at the site of interest and the nucleic acid was energetically minimized using 
sequential steepest descent and Polak Ribier Conjugate Gradient Methods iterations, 
allowing the nucleotides adjacent to the ligand to remain flexible but the remaining 
structure to be rigid. For all structures, AMBER atom types were assigned using Sybyl 
8.1. 
Preparation of the In silico Compound Libraries. Three sets of small molecules were 
built for the in silico molecular docking studies; the "Positive Control" set, the 
"Validation" set and the "67 Compound Library" set. The Positive Control set consists 
of the four small molecules which bind to nucleic acids by either groove binding 
(distamycin and pentamidine) or intercalation (daunorubicin and ellipticine) and were 
initially used for validation of the molecular docking software Autodock and Surflex for 
targeting nucleic acid structures (Figure 15) [63, 79-80]. This Positive Control set will be 
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Figure 15. The Positive Control Set of Ligands used for the molecular docking 
experiments 
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Figure 15. The Positive Control Set of Ligands used for the molecular docking 
experiments 
Daunorubicin Distamycin 
Ellipticine Pentamidine 
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used to develop the preliminary virtual screening metrics for characterizing the binding 
mechanism and specificity of small molecules for nucleic acid targets. The second 
testing set is the Validation set and consists of three novel compounds that we initially 
discovered in silico and demonstrated in vitro to bind to either triplex or quadruplex 
nucleic acid structures. These compounds are referred to as triplex compounds I and 2 
and the quadruplex compound [64]. The in silico rules developed on the Positive Control 
set were tested on the Validation set to determine if the metrics are predictive of the 
known binding activity of the compounds in the Validation set. Finally, the third set is 
the 67 Compound library which were subdivided into 11 smaller sets grouped by 
chemical similarity (Table 4). These clustered sets possess a range of chemical diversity 
and contain small molecules that interact with nucleic acids by groove binding, 
intercalation and end-pasting mechanisms. The 67 Compound set were used for 
robustness testing of the metrics on an expanded set of small molecules with different 
binding mechanisms and sequence and structural selectivity. The 67 Compound set was 
the best data set because we have competition dialysis data on these compounds which 
will be used as a reference to assess the accuracy of the in silico rules for predicting small 
molecule binding to various sequences and structural nucleic acids. All compounds in 
these experiments were built using Sybyl 8.1. Charges of the AMI-BCC type were 
added using the antechamber suite from Amber 8. 
Docking of Small Molecule Sets to Nucleic Acid Targets. One of the greatest challenges 
of molecular docking is that no single program is superior in all facets of a virtual screen. 
We had previously identified Surflex-Dock 2.4 as superior software for molecular 
docking and appropriate for large scale virtual screening [63]. To add robustness to our 
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Table 4. The classification of compounds from the 67 Compound library set grouped by 
chemical similarity. 
97 
Table 4. The classification of compounds from the 67 Compound library set grouped by 
chemical similarity. 
Compound Compound Number of 
Class Number Classification Compounds 
1 Ethidium Bromide Derivatives 9 
2 Acridine Derivatives 6 
3 Aromatic Diamidine Derivatives 3 
4 Cyclic Aromatic Derivatives 6 
5 Dibenzop_henanthroline Derivatives 5 
6 Bis-quinoline Derivatives 8 
7 Amidoanthraquinones (aromatic side chains) 9 
8 Amidoanthraquinones (non-aromatic side chains) 4 
9 Naphthoflavones 2 
10 Amidofluorenone Derivatives 4 
11 Other Compounds 11 
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screen; however, we also pursued the development of in silico metrics using Autodock 
4.0. Autodock is a logical choice for several reasons. First, it is one of the few virtual 
screening programs with a force field (AMBER) that is parameterized for nucleic acids. 
We have also previously found Autodock to be comparable to Surflex-Dock at accurately 
reproducing both groove binding and intercalation crystal structures [63]. Autodock also 
adds versatility to the virtual screening platform as it is complementary to Surflex with 
respect to both docking and scoring functions [60]. Finally, Autodock is the most widely 
cited molecular docking program in the literature, making our findings relevant to the 
research that is on-going in many laboratories. Importantly, in our previous work, we 
optimized the docking parameters for these software for docking both minor groove 
binding and intercalating ligands to nucleic acids. Thus, the same docking parameters 
used for those experiments were used here. Specifically, for Surflex, the "Multi start 5" 
option was employed for each ligand and for Autodock, the "Number of Runs" was set to 
5 and the "Number of Energy Evaluations" was set to 20,000,000 (2E7). These docking 
parameters were described in detail in our previous report and were found to reproduce 
with a high degree of accuracy the crystal structures of a set of small molecule groove 
binders and intercalators in the Positive control set (Figure 15) [63]. 
The details of how Surflex and Autodock perform molecular docking have been 
described in detail in previously [60]. Briefly, Surflex uses protomols that characterize 
the chemical and spatial properties of the binding site and guides the docking of each 
small molecule to that site. Protomols were prepared using ligand-based methods against 
35 possible binding sites on the 10 nucleic acids, as previously described [63]. The 
various sites represent groove, intercalation or end-pasting sites that are all possible sites 
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of interaction for each of the docking small molecules. All files were saved in MOL2 
format using Sybyl 8.1 prior to molecular docking. Autodock precomputes energy grids 
around the nucleic acid to characterize the properties of the target [117]. Each ligand is 
docked and evaluated against the target using a Lamarkian Genetic Algorithm and the top 
pose was selected as the most energetically stable pose of the ligand with respect to the 
target. PERL scripts were written to center the Autodock docking energy grids on the 
center of the Surflex protomol for each site, to best compare the performance of the two 
programs. Targets were visualized in AutoDockTools to ensure the grid center was 
centered on the Surflex-Dock protomol. All files were saved in PDBQT format using 
AutoDockTools. The Autodock grid center and extent of the grid maps for each of the 
targets can be found in Table 5. For each docking compound, the score for the top 
ranked pose (the highest docking score) was used for subsequent data analysis. All 
preparation procedures and docking experiments were performed on a 440 computer IBM 
server with 2.66GHz Intel(R) Xeon(R) E5430 processors. 
Results and Discussion 
Initial Docking of the Positive Control Set to the In silico Nucleic Acid Targets. 
The initial objective in these studies was to dock the four ligands of the Positive Control 
set to the array of nucleic acids and determine if the scores would yield insights as to the 
preferential binding mode (groove binding versus intercalation) and the sequence 
selectivity of the small molecules. In order to perform docking to these structures, 
typically a site on the target must be specified to guide the docking. This required 
generalizing which specific site on each nucleic acid target are "relevant" for small 
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Table 5. Autodock Grid Properties used for Docking Experiments 
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--------------- ------ -------------- ------------------------------------
Table 5. Autodock Grid Properties used for Docking Experiments 
Autodock Target Gridcenter (X, Y ,Z) Number of Grid Points 
at1 1.463 -0.0503.149 40X40X40 
at2 -0.541 0.8954.139 40X40X40 
tal 4.842 2.005 0.299 40X40X40 
ta2 1.506 -0.1594.317 40X40X40 
zd1 2.467 -4.137 -1.358 40X40X40 
zd2 5.371 -3.340 -3.319 40X40X40 
cg1 1.100 -3.746 -1.423 40X40X40 
cg2 1.807 1.431 4.152 40X40X40 
gel -3.929 -3.230 1.876 40X40X40 
gc2 -2.5760.5704.061 40X40X40 
arl -1.827 -1.902 0.880 40X40X40 
ar2 -0.4120.4668.713 40X40X40 
au1 1.048 -0.070 -0.115 40X40X40 
au2 7.6292.534 1.076 40X40X40 
da1 -1.574 -1.340 6.844 40X40X40 
da2 9.3992.7365.313 40X40X40 
da3 5.451 5.0880.048 40X40X40 
ra1 6.2372.560 -1.739 40X40X40 
ra2 5.3142.801 -0.509 40X40X40 
ra3 -1.385 -1.390 11.110 40X40X40 
im1 5.814 1.4982.134 40X40X40 
im2 7.521 2.221 0.992 40X40X40 
1h1 5.9907.1520.890 40X40X40 
1h2 -2.6476.861 5.388 40X40X40 
1h3 5.9670.905 6.972 40 X 40 X 40 
1h4 3.016 -0.706 10.441 40X40 X40 
1h5 -8.534 -3.914 1.367 40 X 40 X 40 
gcit 0.339 -0.334 -2.261 40X40X40 
zint 0.4450.145 1.473 40 X 40 X 40 
dadtdtint 0.214 1.929 -0.129 40X40X40 
raruruint -0.165 1.302 0.030 40X40X40 
1hint1 0.4022.6980.144 40 X 40 X 40 
1hint2 1.928 -0.579 -0.217 40 X 40 X 40 
1 hend 1 -1.6446.950 -0.460 40 X 40 X 40 
1hend2 -0.491 5.057 -0.484 40X40X40 
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molecule interactions. For example, in the case of distamycin and pentamidine for the 
Positive Control set, we would expect the highest reported docking scores to be for the 
minor groove of AT rich B-DNA, as these compounds are known minor groove binders 
to this sequence [118-119]. 
Applying this rationale to the other nucleic acid targets, for the RNA and RNA-
DNA hybrid structures, the major groove was the target while for triplexes, the minor 
groove was the initial target. For the quadruplex structure, all grooves were targeted, as 
the most likely binding sites for compounds with the quadruplex are less clear. Finally, 
in order to select for molecules in the Positive Control Set that bind by intercalation 
(daunorubicin and ellipticine), we included multiple intercalation sites in duplex, triplex 
and quadruplex structures in the nucleic acid library. In total, each of the four 
compounds in the Positive Control set were docked using both Surflex and Autodock 
against a total of 25 groove, intercalation and end pasting sites on all 10 nucleic acids 
(Table 6-highlighted in green). The data were evaluated to determine if the ligands in 
the Positive Control set could be classified by binding mechanism and sequence 
specificity based solely on the in silico screening results. 
The initial docking results for the Positive Control Set are shown in Figures 16 
(groove site scores) and 17 (intercalation site scores). In both figures, more positive 
docking scores for Surflex and Autodock are generally indicative of better binding to the 
nucleic acid site of interest. Surprisingly, both docking programs appear to dock all of the 
Positive Control small molecules to all of the sites of interest, regardless of whether the 
targets are grooves or intercalation sites. Generally, Surflex appears to have higher 
groove binding scores for distamycin and pentamidine compared to the intercalators 
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Table 6. The nucleic acids targeted for docking experiments. The targets highlighted in 
green were used in the original molecular docking experiments while the targets 
highlighted in yellow were added later to augment the initial experimental design. 
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Table 6. The nucleic acids targeted for docking experiments. The targets highlighted in 
green were used in the original molecular docking experiments while the targets 
highlighted in yellow were added later to augment the initial experimental design. 
Nucleic Acid Sequence Targeted Site Nomenclature 
I: Due to the structural diversity of these DNA, both grooves were targeted 
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Figure 16. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, before application of the groove binding metrics. The results 
shown are for the groove binding sites in the nucleic acid library. 
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Figure 16. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, before application of the groove binding metrics. The results 
shown are for the groove binding sites in the nucleic acid library. 
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Figure 17. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, before application of the intercalation metrics. The results 
shown are for the intercalation sites in the nucleic acid library. 
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Figure 17. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, before application of the intercalation metrics. The results 
shown are for the intercalation sites in the nucleic acid library. 
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daunorubicin and ellipticine, which supports the known preferential groove binding 
mechanism of these small molecules. However, distamycin and pentamidine also obtain 
higher Surflex-Dock scores for the intercalation sites than the known intercalators 
daunorubicin and ellipticine (Figure 17). The trend is less clear with Autodock, and few 
definitive conclusions can be drawn from these data. Overall, the data as seen in Figures 
16 and 17 make it difficult to discern either the "real" binding mechanism or sequence 
selectivity of the Positive Control Set. This suggests that the initial experimental 
approach must be augmented and refined to try to elucidate this information from the 
docking experiments. 
Augmentation of the Initial Positive Control Docking Experiments. The initial docking 
data for the Positive Control set reveal an important consideration when performing in 
silica docking. The docking software appear to dock compounds to almost any site 
"successfully" and return some positive value, suggesting that the compound may have 
some interaction with that site. This suggests that our initial strategy of limiting the 
initial docking to just the most likely binding site (for example, the minor groove for 
distamycin) is an over-simplification of what actually occurs in vitro in competition 
dialysis. The positive scores observed at almost all sites suggest that metrics must be 
developed based on the docking scores to separate the true positive "real" binding data 
from the "false positives." We briefly revisit how competition dialysis is performed in the 
hopes of redesigning our strategy to more closely mimic in silica what is occurring in 
competition dialysis in vitro. 
In competition dialysis, each nucleic acid resides in the retentate of individual 
dialysis cassettes and is exposed to a ligand that exists in a common dialysate. The 
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ligand has the potential to interact with multiple sites on each nucleic acid in the assay, 
including both grooves and intercalation sites. The idea of the small molecule having 
access to multiple sites on a single target led us to hypothesize that multiple sites on a 
target may non-specifically bind a ligand, so the interaction of a ligand with all of the 
sites on a target must be taken into account when considering the overall binding of the 
ligand to the site of interest. Our initial experiments oversimplified this concept as we 
targeted only the most likely site of interaction of the ligand with the nucleic acid. An 
example is illustrative. In the case of the triplex DNA, poly(dA)-[poly(dT)h, we believe 
it is insufficient to target just an intercalation site to try to identify ligands that act by 
intercalation (Figure 18A). Instead, all possible binding sites on the triplex must be 
considered (Figure 18B), including the major grove, minor grove and minor-minor 
groove. "Non-specific" binding of small molecules to sites other than the one of interest 
must be accounted for by developing in silico metrics to subtract out non-specific 
interactions. With this in mind, the number of docking sites was expanded from the 
original 25 (highlighted in green in Table 6) to a total of 35 (including the targets 
highlighted in yellow in Table 6) to take into account other possible binding sites for 
ligands on the nucleic acids. 
Re-Docking and Metric Development for the Positive Control Set. The Positive Control 
Set was docked against the expanded library of nucleic acid targets and separate metrics 
were developed based on the resulting data to classify the compounds in the Positive 
Control set as either groove binders or intercalators. These groove binding and 
intercalation metrics will be described in detail below. 
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Figure 18. (A) The triplex DNA poly(dA)-[poly(dT)h with an intercalation site that is 
designated as the target site by the Surflex-Dock protomol. (B) The same DNA with a 
protomol covering all available binding sites including the intercalation site, major 
groove, minor groove and minor-minor groove. Yellow = Surflex protomol. Blue = 
Thymine. Red = Adenine. 
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Figure 18. (A) The triplex DNA poly(dA)-[poly(dT)h with an intercalation site that is 
designated as the target site by the Surflex-Dock protomol. (B) The same DNA with a 
protomol covering all available binding sites including the intercalation site, major 
groove, minor groove and minor-minor groove. Yellow = Surflex protomol. Blue = 
Thymine. Red = Adenine. 
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Groove Binding Metric Development. The metrics developed to determine which 
compounds bind by groove binding as opposed to intercalation were developed as 
follows. The metrics seek to take into account "non-specific" binding of a ligand to 
multiple possible grooves that may exist on a single target. The hypothesis is that 
intercalators will likely bind with similarly low scores to all grooves while groove 
binders should bind with much higher scores to their respective minor grooves compared 
to the other grooves. The difference in scores should allow for discrimination between 
intercalators and minor groove binders. We have created a Surflex or Autodock "metric 
score" that takes into account the "non-specific" binding to each nucleic acid target. For 
example, for duplex B-DNA where we target the minor groove, the raw score for the 
major groove is subtracted as a "non-specific" interaction, as the minor groove is the 
typical interaction site for small molecules. The metric for this would therefore be: 
Metric score = Scoreminorgroove - Scoremajorgroove - CF (Correction Factor) (3) 
In this example, the compound would be docked against both sites and the metric score 
would be computed from (3). Note that we still had to include a numerical correction 
factor (CF) (Surflex: 2.8 and Autodock: 3.0) to differentiate groove binders from 
intercalators, as we will show later. U sing a similar rationale, metrics could be 
determined for duplex RNA and RNA-DNA hybrids, except in this case, the major 
groove is where small molecules typically bind, so the smaller minor groove score is 
subtracted as follows [120]: 
Metric score = ScoremajOrgroove - Scoreminorgroove - CF (4) 
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For triplex nucleic acids and quadruplex structures, the situation is more complicated as 
multiple grooves are present, but a similar rationale applies. In this case, since the minor 
groove ofpoly(dA)-[poly(dT)]z is of interest, the maximum score from either of the other 
grooves (major or minor-minor) is subtracted as follows: 
Metric score = Scoreminorgroove - MAX (Scoremajorgroove, Scoreminor-minorgroove) - CF (5) 
The principal idea here is the metric corrects for the docking software's attempt to always 
find a suitable dock for a small molecule on a target. A complete listing of the groove 
binding metrics for all sites can be found in Table 7. 
Intercalation and End Pasting Metric Development. The metrics developed to 
discriminate intercalators from groove binders were developed as follows. One lesson 
learned from our initial docking experiments was that while intercalators had fairly high 
positive docking scores to in silico intercalation sites, unfortunately so did many groove 
binders. However, we did also find that the true positive groove binders possessed higher 
groove binding scores to the groove sites than the intercalator ligands. This led us to 
hypothesize that the true intercalators could be discriminated from the groove binders by 
subtracting the maximal groove binding score observed across the nucleic acid library 
from each individual intercalation site score. This would effectively "penalize" groove 
binders more than intercalators and leave the intercalators with a higher overall net 
positive score. As we performed with the groove binding metrics, we have created an 
intercalator metric score. For example, with the triplex DNA poly(dA)-[poly(dT)]z, the 
metric score for the intercalation site is determined by subtracting the maximal groove 
site score observed for that compound across all of the grooves (27 groove sites in total) 
from the intercalation site score. This formula is as follows: 
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Table 7. The following table describes the groove binding and intercalation metrics that 
were developed for Surflex and Autodock. 
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Table 7. The following table describes the groove binding and intercalation metrics that 
were developed for Surflex and Autodock. 
Nucleic Acid Targeted Site Metric Score (MS) Formulae' 
Seauence / Nomenclature 
polyrA : polydT I ar2 Maior groove MS = Scoremaor - SCOreminor - CF 
polyrA : polyrU I au2 Maior groove MS = Scoremaor - SCoreminor - CF 
polydA : polydT I tal Minor groove MS = SCOreminor - Scoremaor - CF 
poly( dAdT) I at2 Minor groove MS = SCOreminor - Scoremaor - CF 
polydG : polydC I cg2 Minor groove MS = SCOreminor - Scoremaor - CF 
poly(dGC) I gel Minor groove MS = SCOreminor - Scoremaor - CF 
poly( dGC) I gcit Intercalation MS = Scoreintercalation site- MAX (Scoreall grooves) - CF 
poly(dGC) I I zdl Groove 1 MS = ScoregrOovel- Scoregroove2 - CF 
poly(dGC)1 I zd2 Groove 2 MS = Scoregroove2- Scoregroovel - CF 
poly( dGC) I zint Intercalation MS = Scoreintercalation site- MAX (Scoreall ~ooves) - CF 
poly(dAHpoly(dT)12 /dal Minor groove MS = SCOreminor - MAX(Scoremaor , SCoreminor.minor)- CF 
polY(A)-[poly(U)h I ra2 Minor groove MS = Scoreminor - MAX(Scoremaor , SCOreminor.minor)- CF 
poly(dA)-[poly(dT)h I dadtdtint Intercalation MS = Scoreintercalation site- MAX (Scoreall ~ooves) - CF 
poly(A)-[poly(U)h I raruruint Intercalation MS = Scoreintercalation site- MAX (Scoreall .rooves) - CF 
(AACCCC)4' I iml Groove 1 MS = Scor~oovel- ScoreJ<foove2 - CF 
(AACCCC)4' I im2 Groove 2 MS = Scor~oover Scor~oovel - CF 
A3GGG(TTAGGGhA2 I Ihl Groove I MS = Scor~oovel - MA~Scor~ooves2 3 4 5) - CF 
A3GGG(TTAGGGhA2 I Ih2 Groove 2 MS = Scoregroove2 - MAXJScor~oovesl 345) - CF 
A3GGG(TTAGGGhA2 I Ih3 Groove 3 MS = Scoregroove3 - MAX(ScoregrOOveSI 245) - CF 
A3GGG(TTAGGGhA2 I Ih4 Groove 4 MS = ScoregrOOve4 - MAX(Scoregroovesl 235) - CF 
A3GGG(TTAGGGhA2 Ilh5 Groove 5 MS = Scoregroove5 - MAX(Scoregroovesl 234) - CF 
A3GGG(TTAGGGhA2 I Ihintl Intercalation Site I MS = Scoreintercalation site- MAX (Scoreall grooves) - CF 
A3GGG(TTAGGGhA2 I Ihint2 Intercalation Site 2 MS = Scoreintercalation site- MAX (Scoreall grooves) - CF 
A3GGG(TTAGGGhA2 I Ihendl End Pasting Site I MS = Scoreendoasting site- MAX (Scoreall grooves) - CF 
A3GGG(TTAGGGhA2 I Ihend2 End Pasting Site 2 MS = Scoreendoasting site- MAX (Scoreall grooves) - CF 
I: Due to the structural diverSity of these DNA, both grooves were targeted 
2: A correction factor (CF) of 2.8 and 3.0 was used for Surflex groove binding and intercalation/end -
pasting metrics, respectively. A CF of 3.0 and 0.0 was used for Autodock groove binding and 
intercalation/end-pasting, metrics, respectively. 
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Metric score = Scoreintercalation_site - MAX (Scoreall_nucleicacidJJrooves) - CF (6) 
This formula is applied to all intercalation and end-pasting sites in the nucleic acid library 
to yield a metric score for these sites. A correction factor of 2.8 was necessary for 
Surflex to discriminate between groove binders and intercalators, while no correction 
factor was necessary for Autodock. A detailed list of the metric score formulae can be 
found in Table 7. 
Classification of the Positive Control Library after Metric Application. After 
completing the re-docking experiments of the Positive Control ligand set to the 
augmented nucleic acid library containing 35 sites, the groove binder and intercalator 
metrics were applied to the resulting docking data. The development and application of 
these in silico metrics greatly enhances the trends in the data and makes it possible to 
classify ligands as groove binders or intercalators, based solely on the transformed in 
silico data. A comparison of the groove binding data prior to metric application (Figure 
16) and after application (Figure 19) and intercalation data prior to metric application 
(Figure 17) and after application (Figure 20) particularly emphasizes this point. It is 
readily apparent that Surflex has only positive scores for the groove binders pentamidine 
and distamycin with no scores seen for the intercalators daunorubicin and ellipticine, 
which is what is expected for the groove sites (Figure 19). A similar general trend is seen 
with Autodock. While the groove binding metrics can discern groove binders from 
intercalators, the data show that predicting sequence selectivity is less clear. Surflex 
appears to do an overall better job compared to Autodock in this area, as Surflex has 
more positive scores for both the "at" and "ta" sites (AT rich B-DNA) which pentamidine 
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Figure 19. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, after application of the groove binding metrics. The results 
shown are for the groove binding sites in the nucleic acid library. 
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Figure 19. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, after application of the groove binding metrics. The results 
shown are for the groove binding sites in the nucleic acid library. 
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and distamycin are known to bind (Figure 19) [118-119]. It is interesting to observe that 
the minor groove of triplex DNA and RNA appears to have high scores, even after metric 
application for both Surflex and Autodock. This suggests that more subtle differences in 
structure are perhaps difficult to discriminate with the software and groove binding 
metrics that have been developed here. With the success of the groove binding metrics at 
preferably identifying groove binders over intercalators, the next question is whether the 
intercalator metrics could select out the intercalating ligands, daunorubicin and 
ellipticine. The intercalator metrics were developed and applied to the Positive Control 
set and the results are shown in Figure 20. For both Surflex and Autodock, after 
application of these metrics, only positive scores are seen for the intercalation sites with 
the intercalators daunorubicin and ellipticine, while no scores are seen for the groove 
binding ligands, distamycin and pentamidine. Surflex appears to have more overall 
positive scores for different types of intercalation sites, suggesting that prediction of in 
silico sequence selectivity may be more problematic. Surprisingly, for Surflex, neither 
daunorubicin nor ellipticine were predicted to bind to the "gcit" duplex intercalation site 
after application of the metrics. This is significant as the "gcit" target represents a 
"typical" intercalation site consisting of duplex B-DNA with a GC flanking sequence. 
We believe that this could be in part due to the way Surflex scores docked poses which is 
predominately shape and contact based. With triplex and quadruplex intercalation sites, 
there is more surface area present which could artificially elevate the Surflex score and 
unfairly penalize smaller intercalation sites such as "gcit." Interestingly, Autodock 
appears to predict intercalation of the intercalator Daunorubicin to "gcit." (Figure 20). 
The fact that Autodock does appear more sequence selective may be because Autodock 
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Figure 20. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, after application of the intercalation metrics. The results 
shown are for the intercalation sites in the nucleic acid library. 
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Figure 20. Surflex-Dock (top) and Autodock (bottom) docking scores for the Positive 
Control set of compounds, after application of the intercalation metrics. The results 
shown are for the intercalation sites in the nucleic acid library. 
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operates usmg a semi-empirical Amber Force Field which has been appropriately 
parameterized for DNA and thus may be more appropriate for our uses here. 
In summary, the newly developed groove binding and intercalation metrics appear 
capable of generally predicting the binding mechanism of the Positive Control set of 
ligands. The question remains whether the metrics that were developed here would also 
be predictive for the binding mechanism of other small molecules that we have 
discovered as well as when larger and more diverse chemical compound sets are tested, 
such as the 67 compound set. Additionally, the question of whether the metrics can 
predict sequence selectivity will be further evaluated by looking at the 67 Compound 
Library. 
Application of Metrics to the Validation Set. The Validation Set consists of two triplex 
DNA and one G-quadruplex DNA binding compound that our lab discovered using in 
silica based methods, as we will describe in detail in the next two chapters (Figure 21) 
[64]. Using the same metrics developed on the Positive Control Set, we sought to 
determine how the metrics would classify the mechanism of binding (groove binding 
versus intercalation) of these compounds as well as the predicted sequence selectivity of 
the compounds. This test of the metrics was valuable as we have already biophysically 
characterized the binding behavior of these compounds and can compare the predicted in 
silica behavior with the known binding behavior in vitro. The triplex compounds were 
found to intercalate selectively into the triplex poly(dA)-[poly(dT)h by Induced Circular 
Dichroism (lCD) experiments [64]. As we will show in Chapter V, the quadruplex 
compound binds to the human telomeric quadruplex AG3(TTAGGG)3 by end pasting and 
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Figure 21. The Validation Set of Ligands used for the molecular docking experiments 
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Figure 21. The Validation Set of Ligands used for the molecular docking experiments 
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possibly intercalation as shown by ICD and a Thiazole Orange Fluorescent Intercalation 
Displacement Assay (TO-FID). 
The Surflex and Autodock results before application of the groove binder and 
intercalator metrics can be seen in Figures 22 and 23, respectively. As with the Positive 
Control ligands, the raw data make it difficult to determine whether the triplex and 
quadruplex compounds are groove binders or intercalators. After applying the groove 
binding metrics, there are very few positive scores observed for any of the groove 
interaction sites (Figure 24), particularly for Surflex, which is expected, as the 
compounds are known intercalators. The Autodock data is somewhat less clear, but 
generally there are few groove binding scores overall, suggesting that groove binding is 
not the primary mechanism of action (Figure 24). After application of the intercalator 
metrics, the Surflex data show prominent positive scores in multiple intercalation sites for 
the triplex and quadruplex compounds (Figure 25). This suggests that intercalation is the 
primary mechanism of action of these compounds, which is also consistent with the 
known binding properties of these compounds. Autodock also shows positive scores 
particularly in the triplex intercalation sites for the triplex and quadruplex compounds 
except for triplex compound 1, for which no scores are present. Additionally, Autodock 
predicts that the quadruplex binding ligand will preferably intercalate into the triplex 
structure, but this binding behavior has not been biophysically determined. Overall, 
however, the application of the metrics to the Validation set suggests that the metrics 
(particularly with Surflex) are able to generally classify known intercalators correctly, but 
it remains a challenge to also predict sequence selectivity of these ligands. The next 
127 
Figure 22. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, before application of the groove binding metrics. The results shown 
are for the groove binding sites in the nucleic acid library. 
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Figure 22. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, before application of the groove binding metrics. The results shown 
are for the groove binding sites in the nucleic acid library. 
129 
76 
'" ,< ~ 
8 
10 C/) 
.:.c 
8 0 
8 
~ 
<II 
" 'E :l
C/) 
Figure 23. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, before application of the intercalation metrics. The results shown are 
for the intercalation sites in the nucleic acid library. 
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Figure 23. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, before application of the intercalation metrics. The results shown are 
for the intercalation sites in the nucleic acid library. 
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Figure 24. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, after application of the groove binding metrics. The results shown are 
for the groove binding sites in the nucleic acid library. 
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Figure 24. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, after application of the groove binding metrics. The results shown are 
for the groove binding sites in the nucleic acid library. 
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Figure 25. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, after application of the intercalation metrics. The results shown are for 
the intercalation sites in the nucleic acid library. 
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Figure 25. Surflex-Dock (top) and Autodock (bottom) docking scores for the Validation 
set of compounds, after application of the intercalation metrics. The results shown are for 
the intercalation sites in the nucleic acid library. 
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question is whether these metrics can be applied to the 67 Compound set to correctly 
classify the mechanism of action of these ligands. Moreover, the 67 compound set is 
particularly valuable here to assess the sequence selectivity, as competition dialysis data 
exists for each compound against the array of nucleic acids that was used for the in silica 
studies. 
Application of Metrics to the 67 Compound Set. The 67 Compound Set of ligands 
consists of both groove binders and intercalators with unique nucleic acid sequence 
selectivity determined by competition dialysis. The ligands have varying length, 
aromaticity and chemical features that make this diverse set of compounds appropriate 
for testing the metrics that have been developed on the Positive Control set and tested on 
the Validation set. For ease of comparison, the compounds have been grouped into sets 
of chemically similar compounds as shown in Table 4. The structures of the compounds 
can be found in Figure 26. For each class of compounds, the known binding mechanism 
and sequence selectivity as reported in the literature and determined by competition 
dialysis will be briefly discussed below. The metrics that were developed will then be 
applied to each class of compounds to determine if the compounds act as groove binders 
or intercalators. Finally, the molecular docking data after application of the metrics will 
then be compared to the known sequence selectivity data determined by competition 
dialysis to assess the accuracy of the metrics for predicting sequence selectivity. 
Ethidium Bromide Derivatives. Ethidium Bromide is the quintessential DNA "classical" 
intercalating small molecule that binds non-specifically to many types of DNA and RNA 
[10, 112, 121-124]. It possesses the "typical" structure of the known nucleic acid 
intercalators; a flat, planar aromatic surface that can facilitate stacking between adjacent 
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Figure 26. The Subsets of the 67 Compound Set of Ligands used for the molecular 
docking experiments. 
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Figure 26. The Subsets of the 67 Compound Set of Ligands used for the molecular 
docking experiments. 
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base pairs. The ethidium bromide derivatives (Figure 26) may act by both intercalation 
and groove binding, as the primary aromatic system may intercalate and the substituents 
may subsequently interact with the grooves, but generally they act primarily by 
intercalation [122]. The competition dialysis data (Figure 27) demonstrates this type of 
promiscuous binding of ethidium bromide to almost all of the structures in the 
competition dialysis assay. 
The Surflex and Autodock in silica data, after application of the metrics, show 
very few positive scores for groove sites (Figure 28) while many positive scores for the 
intercalation sites (Figure 29). This suggests that the in silica screen classifies the 
ethidium bromide derivatives as predominantly intercalators, which is their known 
mechanism of action. The in silica results for sequence specificity are more variable. 
Surflex generally has higher scores for the compounds binding to the various quadruplex 
intercalation and end-pasting sites while Autodock has higher scores for the triplex DNA 
intercalation sites (Figure 29). This data is consistent with the competition dialysis data 
that shows many of these compounds binding to both of the triplex and quadruplex DNA 
forms (Figure 27). However, there is almost a complete absence of predicted binding to 
duplex DNA, which is in contrast to the binding data from competition dialysis. Overall, 
the metrics can generally successfully classify the ethidium bromide derivatives as 
intercalators and but it is generally more challenging to predict sequence preference. 
Acridine Derivatives. The acridine derivatives (Figure 26) are another group of classical 
DNA intercalating agents [124]. Compounds in this chemical family are of interest 
because of their potent anti-bacterial and anti-neoplastic activity [125-126]. The potent 
intercalation activity of the acridines has contributed to the development of "hybrid" 
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Figure 27. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the ethidium bromide derivative set from the 67 Compound Set 
[10]. 
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Figure 27. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the ethidium bromide derivative set from the 67 Compound Set 
[10). 
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Figure 28. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium 
bromide derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 28. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium 
bromide derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 29. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium 
bromide derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
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Figure 29. Surflex-Dock (top) and Autodock (bottom) docking scores for the ethidium 
bromide derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
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molecules or "threading intercalators", by attaching DNA minor groove binding agents 
(such as netropsin) to a molecule with an acridine core scaffold (such as amsacrine) to 
impart both intercalation and groove binding properties to a single molecule [106]. The 
goal of this approach is to create a high affinity ligand with sequence specificity and 
these efforts have been modestly successful [106]. Another member of this class is 
amsacrine (also known as m-amsa) which has been shown to bind to topoisomerase II 
[124, 127-128]. Another example is BRACO-19 (a 3,6,9 trisubstituted acridine), one of 
the most potent G-quadruplex binding ligands discovered to date, consists of an aromatic 
acridine scaffold that is thought to end-stack with the G-quadruplex, and three "arms" 
that may bind the grooves and provide quadruplex specificity [126, 129]. 
Application of the groove binding (Figure 30) and intercalation (Figure 31) 
metrics shows most of the positive in silico scores present in the intercalation sites, 
supporting the known intercalation of the acridines. Interestingly, Autodock also predicts 
some triplex groove binding for the aac and ac compounds, which is possible given that 
these two compounds possess an aromatic core that can intercalate as well as an extended 
substituent that may also occupy available grooves of the nucleic acid. The competition 
dialysis data shows the acridines binding predominately to AT and GC rich duplex and 
triplex DNA structures and sequences (Figure 32). Surflex predicts intercalation into 
duplex, triplex and quadruplex nucleic acids while Autodock predicts intercalation 
mostly into triplex DNA and some quadruplex DNA (Figure 31). For this class of 
compounds, the metrics generally successfully predict the mechanism of action with 
moderate success in predicting sequence selectivity. 
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Figure 30. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine 
derivatives from the 67 Compound Set, after application of the groove binding metrics. 
The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 30. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine 
derivatives from the 67 Compound Set, after application of the groove binding metrics. 
The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 31. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine 
derivatives from the 67 Compound Set, after application of the intercalation metrics. The 
results shown are for the intercalation sites in the nucleic acid library. 
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Figure 31. Surflex-Dock (top) and Autodock (bottom) docking scores for the acridine 
derivatives from the 67 Compound Set, after application of the intercalation metrics. The 
results shown are for the intercalation sites in the nucleic acid library. 
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Figure 32. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the acridine derivative set from the 67 Compound Set 
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Figure 32. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the acridine derivative set from the 67 Compound Set 
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Aromatic Diamidine Derivatives. Members of the aromatic diamidine family (Figure 26) 
of compounds have proven to be effective treatments for many infectious diseases such 
as malaria and trypanosomiasis [111, 113]. These compounds have generally been shown 
to bind to AT rich DNA sequences and prefer binding to the DNA triplex, poly( dA)-
[poly(dT)b, which is consistent with the competition dialysis data (Figure 33) [130]. The 
crescent shaped structure of many of the compounds initially suggests that the aromatic 
diamidines generally bind to the minor groove, and this is true for many molecules in this 
family [130]. The crescent shape assists with fitting the compound to the geometry of the 
minor groove and allows the aromatic diamidines to form hydrogen bonds at the base of 
the groove [113]. Interestingly, however, the position of the terminal imidazoline groups 
for all three of the compounds in our test data set (Figures 26) increases the planarity of 
the compounds and causes the preferred mode of binding to be intercalation into the 
triplex DNA structure [111, 130]. 
When the groove and intercalation metrics are applied to the aromatic diamidine 
derivative set, the scores show some positive scores for the grooves, but mostly positive 
scores for the intercalation sites (Figures 34 and 35). This is generally consistent with the 
intercalation mechanism of the aromatic diamidines described here. The observation that 
there are positive groove scores predicted by the in silico metrics is not entirely 
surprising. Subtle changes in the aromatic diamidines (for example the para-para to 
meta-meta switch of the terminal groups) can switch the main mode of binding from 
groove binding to intercalation, but the compounds still may possess secondary groove 
binding interactions. Thus, while the compounds listed here primarily intercalate, they 
could easily groove bind with only minimal structural changes. This emphasizes that the 
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Figure 33. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the aromatic diamidine derivative set from the 67 Compound 
Set. 
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Figure 33. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the aromatic diamidine derivative set from the 67 Compound 
Set. 
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Figure 34. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic 
diamidine derivatives from the 67 Compound Set, llft~Lapplication of the inter~illi'ltiQI} 
metrics. The results shown are for the i!l1~~1l1a!i9J! sites in the nucleic acid library. 
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Figure 34. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic 
diamidine derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
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Figure 35. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic 
diamidine derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 35. Surflex-Dock (top) and Autodock (bottom) docking scores for the aromatic 
diamidine derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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experiments here are testing the limits of these software, as subtle chemical changes can 
make a significant difference in predicting the mode of binding, using the established 
metrics. 
The competition dialysis data show that the aromatic diamidines generally bind 
triplex DNA and RNA with some binding to quadruplex DNA (Figure 33). The Surflex 
data predicts intercalation of these compounds mostly to quadruplex DNA and somewhat 
to the triplex DNA (Figure 34). Autodock predicts intercalation predominately into the 
triplex DNA, with minimal quadruplex intercalation (Figure 34). Much lower binding to 
the grooves is predicted, although the scores are most positive for AT duplex DNA and 
triplex RNA which is where groove binding of many aromatic diamidines occurs in vitro 
(Figure 35). The Autodock data in particular closely resembles the sequence specificity 
of the aromatic diamidines that was determined by competition dialysis. Overall, these 
data suggest that the metrics can generally elucidate the mode of binding of the aromatic 
diamidines as well as predict sequence specificity of these compounds. 
Cyclic Aromatic Derivatives. This group of compounds, along with the "Other 
Compounds" set represents a diverse group of chemical compounds including 
porphyrins, the threading intercalator PIPER, and compounds that possess large, fused, 
aromatic chemical groups (Figure 26). As such, it is expected that these compounds 
should interact primarily by an intercalative or end-stacking mechanism. The porphyrins 
(including tetrakisporphrine and mesotetrakisporphine) are perhaps the best known class 
of G-quadruplex binding ligands. These compounds, in particular the compound 
TmPyP4, have been investigated in detail as their structure suggests that the compounds 
may preferentially stack and interact with the guanine quartet of quadruplex structures 
168 
[10, 131]. However, the porphyrins have also been shown to interact with the grooves of 
the human telomeric quadruplex, AG3(TTAGGG)3, through an "outside" groove binding 
mechanism [132]. Porphyrins also appear to generally suffer from non-specific binding 
to many other forms of duplex and triplex DNA and RNA, as has been demonstrated by 
competition dialysis [10]. On the other hand, the small molecule NMM, has been shown 
to be highly selective for G-quadruplexes over duplex and triplex nucleic acids, although 
NMM binds with lower affinity than porphyrins such as TmPyP4 [10]. The aromatic 
system of the bis acridine molecule Bisa, also reflects its propensity to intercalate into 
DNA as well as possibly act as a threading intercalator in various nucleic acids [133-
134]. Finally, the last member of this family is PIPER which is reported to bind by end-
stacking to various G-quadruplex nucleic acids and also possibly interacting by a 
threading intercalator mechanism [135]. 
The in silica Surflex data classifies all of these compounds primarily as 
intercalators, as there are no positive groove binding scores (Figure 36), but positive 
scores for several intercalation sites (Figure 37). The Autodock results are more diverse 
as the metrics predict some of the compounds to be exclusively groove binders 
(tetrakisporphine and bisa) while the others to act predominately by intercalation or 
endpasting (hoa, mesotetrakisporphine, nmm, piper). While it is likely that the 
porphyrin tetrakisporphine can interact with grooves, gIVen its promIscuouS binding 
behavior, it is well known that porphyrins in general can intercalate and endpaste into 
nucleic acids. Overall, Surflex appears superior at predicting the mechanism of action of 
these compounds compared to Autodock. For structure and sequence specificity, this 
group of compounds generally appears to bind with preference to triplex and quadruplex 
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Figure 36. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic 
aromatic derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 36. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic 
aromatic derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
171 
10 
~ 
9 8 
8 en 
:£ 
Q) 
~ 
.;,:: 
o o a 
~ 
'E 
::J 
en 
Figure 37. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic 
aromatic derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
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Figure 37. Surflex-Dock (top) and Autodock (bottom) docking scores for the cyclic 
aromatic derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
10 
Q) 
9 ... 8 
8 en 
~ :£ 
Q) 
~ 
173 
DNA, as determined by competition dialysis (Figure 38). The intercalator metrics from 
Surflex predict that these are also the preferred binding structures of DNA for all of the 
compounds (Figure 37). For the predicted intercalators using the Autodock metrics (hoa, 
mesotetrakisporphine, nmm, piper), these compounds are generally predicted to bind to 
the triplex DNA, except for hoa that is also predicted to bind to quadruplex DNA (Figure 
37). In summary, for the cyclic aromatic set, Surflex appears superior to Autodock at 
predicting both the binding mechanism and sequence specificity of the compounds and 
the predicted data is in reasonable agreement with the data from competition dialysis. 
Dibenzophenanthroline Derivatives. The dibenzophenanthrolines (Figure 26) were 
designed as small molecules that would intercalate into the triplex DNA poly( dA)-
[poly(dT)h [136]. The crescent-shaped curvature of the compounds suggests that the 
compounds may also bind to the grooves of DNA. These compounds posses a 
pentacyclic ring and are either monosubstituted (mpq2 and mpq3) or bisubstituted 
(mmql, mmq3 and moql). The monosubstitited compounds have reported preferential 
triplex binding compared to duplex, while the bisubstituted derivates show promiscuous 
binding to both duplex and triplex DNA, which is generally consistent with the 
competition dialysis results reported here. There are also recent reports of 
dibenzophenanthrolines suggesting that these molecules bind G-quadruplexes, as the 
fused aromatic chemical features provide large It-orbital stacking with the guanine 
tetrads of the G-quadruplexes [123, 136-137]. 
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Figure 38. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the cyclic aromatic derivative set from the 67 Compound Set. 
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Figure 38. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the cyclic aromatic derivative set from the 67 Compound Set. 
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The Surflex in silica docking results appear to generally segregate the 
dibenzophenanthrolines on the basis of whether they are monosubstituted (mpq2 and 
mpq3) or bisubstituted (mmql, mmq3, moql) (Figures 39 and 40). The monosubstituted 
ligands have few positive groove binding scores and instead have mostly positive 
intercalation site scores, suggesting intercalation is the mechanism of action. On the 
other hand, the bisubstituted ligands appear to be classified largely as groove binders 
according to the groove binding rules developed with Surflex (Figure 39). This is 
consistent with the more crescent shaped curvature of the bisubstituted ligands which 
have substituent locations that would support groove binding. Surflex appears to be able 
to modestly elucidate the sequence specificity of the classified mono and bisubstituted 
compounds. The groove binding scores that are positive are generally for the duplex AT 
rich DNA which the bisubstituted ligands are known to bind, as determined by 
competition dialysis (Figure 41). The intercalation binding scores that are the most 
positive are typically for the triplex and quadruplex sites for the monosubstituted 
compounds. The Autodock data are less clear, as there are positive scores present for the 
grooves and intercalation sites in both the mono and bisubstituted ligands, suggesting that 
the Autodock metrics are less successful at classifying the compounds as primarily 
groove binders or intercalators (Figure 39 and 40). However, Autodock does appear to 
be able to identify the sequence preference for the general class of compounds, as the 
highest groove binding scores are found for AT rich duplex DNA and the triplex nucleic 
acids (Figure 39). Also, the highest Autodock intercalation scores are found for the 
triplex intercalation sites, which were the basis for the original design of these small 
molecules (Figure 40). In summary, the metrics have only moderate success at 
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Figure 39. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the 
groove binding metrics. The results shown are for the groove binding sites in the nucleic 
acid library. 
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Figure 39. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the 
groove binding metrics. The results shown are for the groove binding sites in the nucleic 
acid library. 
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Figure 40. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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Figure 40. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
dibenzophenanthroline derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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Figure 41. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the dibenzophenanthroline derivative set from the 67 
Compound Set. 
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Figure 41. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the dibenzophenanthroline derivative set from the 67 
Compound Set. 
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predicting the mechanism of action and sequence selectivity of the 
dibenzophenanthroline derivatives. This may be ascribed to the minor chemical changes 
among these compounds that can result in a change in the binding mode. 
Bis-quinoline Derivatives. There is interest in "bis" intercalators as these compounds 
can intercalate into two sites in nucleic acids which allows increased affinity and 
specificity of the small molecule for the nucleic acid [121]. Previous results have shown 
that some of these compounds preferentially intercalate into triplex and quadruplex DNA 
structures [123]. These compounds are unique as they have a long linking chain that 
connects the two quinoline derivatives (Figure 26). This chain is capable of binding to 
the groove of the nucleic acid and thus these compounds exhibit both intercalation and 
groove binding character that may challenge the metrics as described here. 
Application of the in silica Surflex metrics shows that positive scores are present 
in the groove sites and the intercalation sites, suggesting that these compounds have 
substantial groove binding and intercalation character (Figures 42 and 43). This is 
possible given that the planar, aromatic groups intercalate into DNA and the long linker 
likely binds in the groove. The most positive scores for the groove sites are with AT rich 
DNA, an observation that is generally consistent with the known competition dialysis 
data which shows binding to AT rich DNA (Figure 44). The most positive intercalation 
scores are for the quadruplex nucleic acids which these ligands are known to interact. 
Autodock classifies these ligands exclusively as groove binders as there are only positive 
groove binding scores present (Figure 42). This could be due to the particularly long 
linker chains between the quinoline groups, which can lie in the groove and dramatically 
impact Autodock scores. 
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Figure 42. Surflex-Dock (top) and Autodock (bottom) docking scores for the bis-
quinoline derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 42. Surflex-Dock (top) and Autodock (bottom) docking scores for the bis-
quinoline derivatives from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 43. Surflex-Dock (top) and Autodock (bottom) docking scores for the bis-
quinoline derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
187 
Figure 43. Surflex-Dock (top) and Autodock (bottom) docking scores for the bis-
quinoline derivatives from the 67 Compound Set, after application of the intercalation 
metrics. The results shown are for the intercalation sites in the nucleic acid library. 
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Figure 44. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the bis-quinoline derivative set from the 67 Compound Set. 
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Figure 44. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the bis-quinoline derivative set from the 67 Compound Set. 
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Interestingly, the Autodock results do appear to generally mimic the sequence specificity 
of the compounds, as positive groove scores are seen for the AT rich DNA, the RNA and 
the quadruplex structures. Overall, however, Surflex again appears best at predicting the 
mechanism of action and sequence specificity of the Bis-quinoline derivatives. It is 
worth noting for this class of compound that the size and extended length of these 
molecules make these one of the most challenging docking experiments of all of the 
compound sets tested. 
Amidoanthraquinones (aromatic side chains and non-aromatic side chains). The 
amidoanthraquinones (Figure 26) have been reported to bind to various nucleic acids 
depending on the location of the side chains that extend from the central fused aromatic 
ring system. The so-called l,4-disubstituted small molecules (tcj74 and tcj62) appear to 
bind duplex DNA while the 2,6-disubstituted small molecules (tcj78, telominhl and 
telominh5 and tcj69) and the 2,7-disubstituted small molecules (pjp57 and pjp66) prefer 
triplex over duplex DNA [123, 138-139]. Additionally, the amidoanthraquinones have 
been shown to bind G-quadruplex nucleic acids, as is confirmed by the competition 
dialysis data (Figure 45) [140-141]. These compounds have a primary reported 
intercalation mechanism of binding with additional "threading" behavior, where the fused 
aromatic system intercalates, but the substituents can occupy the grooves of the nucleic 
acids [123, 138, 140]. 
For the amidoanthraquinones with aromatic side chains, the in silico groove 
binding metrics for Surflex show positive scores with the AT rich duplex DNA (Figure 
46). However, the scores for the intercalation sites after applying the metrics are 
generally higher and suggest that intercalation is the primary mechanism of action, with 
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Figure 45. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidoanthraquinones (aromatic side chains) derivative set 
from the 67 Compound Set. 
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Figure 45. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidoanthraquinones (aromatic side chains) derivative set 
from the 67 Compound Set. 
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Figure 46. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after 
application of the groove binding metrics. The results shown are for the groove binding 
sites in the nucleic acid library. 
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Figure 46. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after 
application of the groove binding metrics. The results shown are for the groove binding 
sites in the nucleic acid library. 
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some additional groove binding interactions possible (Figure 47). This is consistent with 
the known binding mechanism of action of many of these compounds. Interestingly, the 
highest in silica scores are found typically for the triplex and quadruplex intercalation 
sites, suggesting that these structures are the preferred intercalation sites, which is 
generally consistent with their known structural preference. The Autodock groove 
binding metrics yield less clear information, as there appears to be positive scores for 
many ligands to a number of different grooves (Figure 46). Application of the 
intercalation metrics for Autodock shows that many of the amidoanthraquinones actually 
appear to prefer to intercalate into the triplex DNA (Figure 47). However, no positive 
scores are seen for quadruplex intercalation sites which is somewhat surprising given that 
these compounds are generally known to bind quadruplexes. Generally, the score 
distribution for the groove and intercalation sites for Autodock support intercalation as 
the primary mechanism of action, with some groove binding behavior evident. 
For the amidoanthraquinones with non-aromatic side chains, the Surflex metrics clearly 
predict intercalation as the preferred mechanism of action, with some groove binding 
possible (Figures 48 and 49). Similar to the results seen with the amidoanthraquinones 
with aromatic side chains, both the triplex and quadruplex intercalation sites have the 
highest scores, suggesting that these are the preferred structures, which is generally 
consistent with the competition dialysis data (Figure 50). Application of the Autodock 
metrics classifies these compounds as almost exclusively groove binding in nature, as 
almost all of the positive scores seen are in the groove binding sites as opposed to the 
intercalation sites (Figures 48 and 49). We believe this may be due to the nature of the 
side chain substituents. In this class of compounds, the side chains are non-aromatic 
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Figure 47. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after 
application of the intercalation metrics. The results shown are for the intercalation sites 
in the nucleic acid library. 
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Figure 47. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (aromatic side chains) derivatives from the 67 Compound Set, after 
application of the intercalation metrics. The results shown are for the intercalation sites 
in the nucleic acid library. 
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Figure 48. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set, 
after application of the groove binding metrics. The results shown are for the groove 
binding sites in the nucleic acid library. 
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Figure 48. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set, 
after application of the groove binding metrics. The results shown are for the groove 
binding sites in the nucleic acid library. 
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Figure 49. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set, 
after application of the intercalation metrics. The results shown are for the intercalation 
sites in the nucleic acid library. 
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Figure 49. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidoanthraquinones (non-aromatic side chains) derivatives from the 67 Compound Set, 
after application of the intercalation metrics. The results shown are for the intercalation 
sites in the nucleic acid library. 
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Figure 50. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidoanthraquinones (non-aromatic side chains) derivative 
set from the 67 Compound Set. 
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Figure 50. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidoanthraquinones (non-aromatic side chains) derivative 
set from the 67 Compound Set. 
204 
- ------- -----------------------------------------------------
carbon chains, which should actually have supenor groove binding properties as 
compared to the aromatic side chains. Thus, the Autodock metrics appear to score these 
compounds as having better groove binding character, which is likely consistent with 
their binding properties, but comes at the expense of classifying the compounds as 
predominately groove binders instead of intercalators. Overall, the results suggest that 
Surflex and Autodock are generally able to predict the binding mechanism of action of 
these compounds but prediction of sequence and structural specificity IS more 
challenging. 
Naphthoflavones. The flavonoids class of compounds have long been known to exhibit 
anti-inflammatory and antiviral properties (Figure 26) [142]. The alpha and beta 
naphthoflavone flavonoids included and tested here are known to intercalate into triplex 
DNA with high specificity, with little or no perceived binding to other nucleic acid 
structures [123, 142]. This binding behavior has also been seen in the competition 
dialysis data that was acquired on these compounds (Figure 51). 
The Surflex and Autodock metric data for this class of compounds is perhaps the 
best out of all of the classes of compounds that were tested in silico with respect to 
differentiating groove binders versus intercalators. There are no positive scores present 
for either Surflex or Autodock with respect to the groove binding sites (Figure 52). 
Surflex has the most positive scores in the quadruplex intercalation sites while Autodock 
has the most positive scores in the triplex intercalation sites (Figure 53). This is 
important in several respects. First, both software predict exclusive intercalation of these 
compounds, with no discemable groove binding. This is entirely consistent with the 
reported literature and is expected given the planar, aromatic structure of the 
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Figure 51. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the naphthoflavone derivative set from the 67 Compound Set. 
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Figure 51. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the naphthoflavone derivative set from the 67 Compound Set. 
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Figure 52. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
naphthoflavone derivatives from the 67 Compound Set, after application of the groove 
binding metrics. The results shown are for the groove binding sites in the nucleic acid 
library. 
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Figure 52. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
naphthoflavone derivatives from the 67 Compound Set, after application of the groove 
binding metrics. The results shown are for the groove binding sites in the nucleic acid 
library. 
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Figure 53. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
naphthoflavone derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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Figure 53 . Surflex-Dock (top) and Autodock (bottom) docking scores for the 
naphthoflavone derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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naphthoflavones. Second, this is an example of where Autodock appears superior to 
Surflex as Autodock predicts preferential binding to triplex DNA which is what occurs in 
vitro while Surflex predicts binding to quadruplex structures. The success in this class of 
compounds may also be due to their small size and few rotatable bonds. Smaller 
compounds with fewer rotatable bonds are typically much easier to dock compared to 
larger molecules because of the fewer degrees of freedom of the smaller compounds [63]. 
These results suggest that the metrics for both Surflex and Autodock have potential for 
successfully classifying ligands based on mechanism of action and structural preference. 
AmidoJluorenone Derivatives. The synthesis of the amidofluorenones (Figure 26) came 
largely out of the observed success of the anthraquinones at binding to G-quadruplexes 
and inhibiting the enzyme telomerase. The fluorenones were designed with the goal of 
achieving similar inhibitory potencies but with fewer cytotoxic side effect of the 
anthraquinones [143]. Modeling studies have suggested that these compounds can bind to 
nucleic acids by intercalation or end-stacking [143 -144]. The side chains also suggest 
some groove binding occurs, imparting a "threading" type of intercalation binding 
behavior to these compounds. 
Both the Surflex and Autodock metrics appear to have some positive scores 
particularly for the triplex nucleic acid grooves, suggesting that the amidofluorenones 
have groove binding character (Figure 54). However, the majority of the positive scores 
for Surflex are in the intercalation sites, supporting intercalation as the primary 
mechanism of action, with some groove binding behavior present (Figure 55). The in 
silico Surflex data generally predicts that intercalation to quadruplex structures is 
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Figure 54. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidofluorenone derivatives from the 67 Compound Set, after application of the groove 
binding metrics. The results shown are for the groove binding sites in the nucleic acid 
library. 
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Figure 54. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidofluorenone derivatives from the 67 Compound Set, after application of the groove 
binding metrics. The results shown are for the groove binding sites in the nucleic acid 
library. 
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Figure 55. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidofluorenone derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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Figure 55. Surflex-Dock (top) and Autodock (bottom) docking scores for the 
amidofluorenone derivatives from the 67 Compound Set, after application of the 
intercalation metrics. The results shown are for the intercalation sites in the nucleic acid 
library. 
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Figure 56. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidofluorenone derivative set from the 67 Compound Set. 
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Figure 56. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the amidofluorenone derivative set from the 67 Compound Set. 
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preferred over triplex, while the competition dialysis data generally shows comparable 
binding of these compounds to both triplex and quadruplex structures (Figure 56). In 
contrast, the Autodock data suggests that these compounds bind exclusively by groove 
binding, as there are only positive scores present for the groove sites (Figure 54) and no 
positive scores for the intercalation sites (Figure 55). The Autodock results are not 
overly surprising given that similar problems were observed with the structurally related 
amidoanthraquinones. For this class of compounds, Surflex appears superior to 
Autodock at predicting the mechanism of binding as well as structural specificity. 
Other Compounds. Compounds that did not fall into any other chemical group have 
been included in the "Other Compounds" category and possess a large amount of 
structural diversity and nucleic acid binding specificity (Figure 26). The known 
mechanism of binding and sequence selectivity of these compounds is described briefly 
here. The competition dialysis data suggests that many of these compounds appear to 
favor triplex DNA, as well as interactions with quadruplex DNA and AT B-DNA to a 
lesser extent (Figure 57). Berberine has been shown to bind to predominantly triplex and 
quadruplex nucleic acids by intercalation or end-stacking [112, 145-147]. A preference 
for AT base pairs is notable for berberine [147]. Ditercalinium acts as a bis-intercalator 
with the linker sequence binding in the major groove of duplex DNA [148-149]. The 
interactions with the major groove are noteworthy as most small molecules interact with 
the minor groove [149]. Additionally, there have been reports of ditercalinium favoring 
Guanine-Cytosine over Adenine-Thymine sequences [149]. DODC has been identified 
as preferentially binding AT rich triplex DNA and to a lesser extent, quadruplex DNA 
structures [10,39, 150]. The ligand appears to interact with different grooves of different 
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Figure 57. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the Other Compound set from the 67 Compound Set. 
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Figure 57. Competition Dialysis data showing the concentration of ligand bound to each 
nucleic acid structure for the Other Compound set from the 67 Compound Set. 
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quadruplexes [150]. Less significant interactions have been reported with minor groove 
interactions in duplex DNA [150]. Hycanthone is recognized as an intercalator that 
appears to prefer AT sequences over GC sequences [151]. This molecule is a particularly 
interesting "non-classical" intercalator, as it lacks a charge on the cyclic ring [151]. 
Methylene blue and Methyl green are unique compounds and have been included here as 
they may interact with the major groove of DNA. These compounds may be 
inappropriate for classification based on the metrics developed here as the developed 
metrics identify molecules that bind to the minor groove, as this is the prefereable site of 
interaction on nucleic acids for most small molecules. Methylene blue is also an 
intercalator, but is unique in that at different ionic conditions, it may also interact with the 
major groove of AT rich DNA [112, 122]. Methyl green has been shown to prefer AT 
rich sequences and bind to the major groove of many different sequences of DNA[l22, 
152]. The compound pjp407 is a 2-phenylnapthalene derivative that has structure 
supporting intercalation [153]. Compound pjp72 appears similar in structure to some of 
the amidofluorenones that were previously discussed which suggests it possesses an 
intercalation or threading intercalation binding mechanism. Pm008 has a structure 
suggesting either groove binding or intercalation [121]. Quinacrine has long been 
utilized as an anti-malarial drug and is thought to act predominantly by intercalation. 
Sampangine is another anti-malarial and anti-fungal drug and the fused ring structure 
suggests it binds by classical intercalation [154-155]. 
The Surflex metrics appear to classify many of the compounds as exclusively 
intercalators, as there are many positive scores observed for the intercalation sites with 
few positive scores for the groove binding sites (Figures 58 and 59). Interestingly, 
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Figure 58. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other 
Compound set from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 58. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other 
Compound set from the 67 Compound Set, after application of the groove binding 
metrics. The results shown are for the groove binding sites in the nucleic acid library. 
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Figure 59. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other 
Compound Set from the 67 Compound Set, after application of the intercalation metrics. 
The results shown are for the intercalation sites in the nucleic acid library. 
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Figure 59. Surflex-Dock (top) and Autodock (bottom) docking scores for the Other 
Compound Set from the 67 Compound Set, after application of the intercalation metrics. 
The results shown are for the intercalation sites in the nucleic acid library. 
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ditercalinium and methylgreen are predicted to have some positive groove scores, 
suggesting groove binding is also involved in their mode of binding which is consistent 
with known data. While Surflex successfully predicts many of these compounds to be 
intercalators, it does a marginal job of predicting structural preference, as many of the 
compounds bind triplex DNA, while duplex and quadruplex intercalation sites are the 
preferred in silico binding sites. Autodock shows many of the compounds having some 
groove binding character to different nucleic acids, which is not surprising given the 
structural diversity. However, almost all of the compounds also are predicted to 
intercalate into triplex nucleic acids (Figure 59). This finding is significant, as it is most 
consistent with the mechanism of action of many of these ligands as well as the structural 
specificity. In total, these results suggest that even for a heterogeneous group of ligands 
such as those shown here, Surflex and Autodock can generally successfully predict the 
binding mechanism and sometimes predict structural preference of the ligands. 
Comparison and Limitations of Surjlex and Autodock Performance and Metrics. The 
data presented here allow some comparisons to be made between Surflex and Autodock 
about the performance of these docking programs as well as limitations of the software. 
For both programs, the metrics that were developed were able to generally differentiate 
groove binding small molecules (Pentamidine and Distamycin) from intercalators 
(Daunorubicin and Ellipticine) in the Positive Control set. A similar finding was 
observed when performing robustness testing in the Validation and 67 Compound library 
sets (Table 8). Moreover, in some cases, even sequence and structural selectivity were 
successfully predicted in silico and generally mimic the actual in vitro competition 
dialysis data. Perhaps the best example of the success of the metrics are the triplex 
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Table 8. Comparison of Software for the Prediction of Compound Binding Mechanism 
After Application of the In Silico Metrics 
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selective naphthoflavones, whose behavior was generally accurately predicted by the in 
silica metrics. We generally found Surflex to outperform Autodock with respect to 
predicting the binding mechanism while both programs had modest success at predicting 
sequence selectivity of the compounds. The success with Surflex was somewhat 
surprising, as Surflex is not parameterized for DNA and operates largely by-shaped based 
complementarity. On the other hand, Autodock has been used previ6usly for targeting 
DNA and is specifically parameterized for nucleic acids [34]. This may explain the 
ability of Autodock in some cases to outperform Surflex when predicting sequence 
selectivity of some classes of compounds in the 67 compound library such as the 
Naphthoflavones. Our general findings, however, support the use of Surflex for further 
study as a molecular docking tool to use to target nucleic acid for small molecule 
discovery. 
Based on the results from this study, there were several limitations of these 
software that require further elaboration. In general, the docking programs appeared to 
have a more difficult time predicting sequence and structural selectivity rather than 
predicting the binding mechanism, based on the in silica metrics developed here. We 
suspect that this is likely because even small structural changes can dramatically impact 
sequence and structural selectivity of a small molecule for nucleic acids. The docking 
programs also appear to have the most difficult time predicting the binding mechanism of 
larger molecules that bind by both intercalation and groove binding mechanisms. An 
example are the bis-quinolines which possess aromatic core scaffolds that can intercalate 
as well as a linker chain that bind into the grooves of the nucleic acids. Additionally, 
some molecules such as methylene blue bind to atypical sites such as the major groove of 
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duplex DNA instead of the mmor groove. The metrics as developed here may be 
inappropriate for classification of these few compounds as the metrics focus on predicting 
molecules that bind to the minor groove which is typically where small molecules 
interact with DNA. Finally, we emphasize here that the array of nucleic acids is by no 
means all encompassing but was merely used as this is the same array used for the 
competition dialysis assay and facilitated the comparison of the 67 compound library in 
silica and in vitra results. The array as constructed here is just a starting point. In the 
future, structures can be added to the in silica array as they become available that will 
hopefully add more diversity and power to this in silica approach. 
Conclusions 
Predicting how small molecules can interact with nucleic acids is crucial to 
discovering new compounds that target biologically relevant nucleic acids. Bourdouxhe-
Housiaux et at. outline three criteria that can profoundly impact the biological activity of 
compounds that interact with DNA; (1) mechanism of ligand interaction with nucleic 
acids; (2) sequence specificity and (3) kinetics of association and dissociation [106]. We 
address points (1) and (2) here by inventing a novel approach to predict in silica how 
small molecules interact with nucleic acids. In silica rules were developed based on the 
docking of four small molecules (Daunorubicin, Distamycin, Ellipticine and 
Pentamidine) to an array of nucleic acids that allowed for the classification of these small 
molecules as either intercalators or groove binders. These metrics were tested for 
robustness on several compounds that our lab has discovered as well as a 67 compound 
library, for which extensive competition dialysis exists. The results of the testing with 
the 67 compound library confirmed that the Surflex and Autodock metrics are generally 
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more successful at predicting binding mechanisms rather than sequence selectivity. A 
logical extension of this work is to utilize the metrics for the discovery of novel 
compounds that bind by a known mechanism to a specific nucleic acid. We envision that 
this would be accomplished by large scale virtual screening of millions of compounds to 
a nucleic acid target of interest. Top hits could then be screened against the in silica 
array of nucleic acids to check for unwanted binding and the metrics could be applied to 
elucidate the binding mechanism. As Surflex is approximately 10 times faster than 
Autodock under the conditions tested here, we describe in the next chapter of this work 
the use of Surflex with integrated selectivity metrics for the purposes of discovering new 
small molecules that bind nucleic acids. 
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CHAPTER IV 
DISCOVERY OF NOVEL TRIPLE HELICAL DNA INTERCALATORS BY AN 
INTEGRATED VIRTUAL AND ACTUAL SCREENING PLATFORM 
This chapter describes the use of ligand-based and structure-based virtual 
screening approaches for the purposes of discovering new small molecules that can 
specifically bind to triplex DNA. Our previous results in Chapters II and III supported 
the use of the virtual screening software Surflex for predicting the mechanism of action 
of small molecules that interact with nucleic acids. In this chapter, we use metrics to 
virtual screen millions of compounds to discover small molecules that specifically 
interact with triplex DNA by the mechanism of intercalation. My contribution to this 
work was the virtual screening experimental design and execution. Patricia Ragazzon, 
Ph.D. was responsible for the biophysical characterization experiments. The results of 
this work were published by P.A. Holt et al [64]. 
Virtual screening is an increasingly attractive way to discover new small 
molecules with potential medicinal value. We introduce a novel strategy that integrates 
use of the molecular docking software Surflex with experimental validation by the 
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method of competition dialysis. This integrated approach was used to identify ligands 
that selectively bind to the triplex DNA poly(dA)-[poly(dT)h. A library containing 
approximately 2 million ligands was screened to identify compounds with chemical and 
structural similarity to a known triplex intercalator, the napthylquinoline MHQ-12. 
Further molecular docking studies using compounds with high structural similarity 
resulted in the discovery of two compounds that were then demonstrated by competition 
dialysis to have a superior affinity and selectivity for the triplex nucleic acid than MHQ-
12. One of the compounds has a different chemical backbone than MHQ-12, which 
demonstrates the ability of this strategy to "scaffold hop" and to identify small molecules 
with novel binding properties. Biophysical characterization of these compounds by 
circular dichroism and thermal denaturation studies confirmed their binding mode and 
selectivity. These studies provide a proof-of-principle for our integrated screening 
strategy, and suggest that this platform may be extended to discover new compounds that 
target therapeutically and physiologically relevant nucleic acid morphologies. 
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DISCOVERY OF NOVEL TRIPLE HELICAL DNA INTERCALATORS BY AN 
INTEGRA TED VIRTUAL AND ACTUAL SCREENING PLATFORM 
Patrick A. Holt, Patricia Ragazzon, Lucjan Strekowski, Jonathan B. Chaires and John O. 
Trent. Discovery of Novel Triplex Helical DNA Intercalators by an Integrated Virtual 
and Actual Screening Platform. Nucleic Acids Res. 2009 Mar; 37 (4):1280-7. Epub 2009 
Jan 9. 
Introduction 
Triple helical nucleic acid forming sequences have become a source of increasing 
interest as a way to interfere with DNA transcription and modulate gene expression [56-
57, 156]. Several approaches attempt to use triplex nucleic acids to interfere with the 
transcription of genes, through either inducing the formation of triplex or stabilizing 
existing triplex nucleic acids. The former approach is the so-called "anti-gene" approach 
and involves the administration of triplex forming oligonucleotides (TFOs), which are 
short sequences of nucleic acids that can bind to the major groove of duplex nucleic acids 
in genes and promote the formation of triplex structures [58, 157]. TFOs have already 
been successful in reducing transcription of the c-myc oncogene that is located in the 
promoter site of genes [58, 158]. However, there are currently significant challenges 
associated with the use of TFOs and triplex structures in general. First, TFOs have 
significantly lower activity in cell-based systems, compared to in vitro systems [159]. 
This has been ascribed to many factors including improper cellular localization, 
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degradation of the oligonucleotide, or lack of accessilibity to chromatin wrapped DNA 
[159-160]. A second limitation is the inherent low stability of many triplex structures 
[161-162]. The latter limitation is the focus of this work where we demonstrate the use 
of a novel virtual and actual screening platform for identifying several compounds that 
can selectively bind to and stabilize a triplex nucleic acid structure. These newly 
identified small molecules could be used to target triplex structures in several ways. 
First, the small molecule could stabilize pre-existing triplex structures in vivo. The small 
molecules could be used in an adjuvant setting with TFOs to increase stability, or 
alternatively the small molecules can be linked to TFOs to enhance the stability of newly 
formed triplex structures [160]. Either of these approaches could be used to control gene 
expression. These capabilities make these small molecules potentially clinically relevant 
for treating cancer and other diseases that are closely linked with abnormal gene 
expressIOn. 
Several small molecules are known to intercalate into and stabilize triplex nucleic 
acids including coralyne, benzo[ e ]pyridoindoles (BePI), benzo[g]pyridoindoles (BgPI), 
dibenzophenanthrolines, and anthraquinones [136, 162-165]. One of the most selective 
and extensively studied classes are the napthylquinolines, which have been shown to 
intercalate into the TAT DNA triplex, poly(dA)-[poly(dT)h [166-168]. Chaires et al. 
performed an extensive study that characterized the selectivity and affinity of 14 
napthylquinoline derivatives [44]. The ligand MHQ-12 emerged from that study as the 
compound with the highest affinity and greatest selectivity for the poly(dA)-[poly(dT)h 
triplex. While this approach for the discovery of triplex-selective ligands was successful, 
it is a laborious and time-consuming process. We propose a novel alternative approach 
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for finding ligands that target a particular structure in which virtual screening is used to 
identify promising ligand candidates followed by validation using competition dialysis. 
We demonstrate here that this approach can identify small molecules that intercalate into 
po1y(dA)-[po1y(dT)h with higher selectivity and affinity than MHQ-12. A significant 
result of this approach is that a small molecule with a substantially different molecular 
scaffold was identified that has superior affinity and selectivity for triplex DNA 
compared to MHQ-12. This strategy thus provides a new platform for identifying 
promising small molecule drugs against nucleic acid targets. 
Virtual screening using molecular similarity and docking methods is becoming an 
increasingly important and economical approach to identify small molecules drug 
candidates [24]. While there are numerous studies using such screening methods for 
targeting proteins, far fewer virtual screening efforts have been performed targeting 
nucleic acids. The few studies that have been performed targeting nucleic acids have 
produced promising results. They have shown that screening methods can accurately 
reproduce crystallographic structures of ligand-nucleic acid complexes using a variety of 
docking programs including DOCK, Autodock and Surflex [33-34, 63]. Our virtual 
screening approach uses both ligand and structure-based discovery principles to select 
ligands from a commercially available library that bind to po1y(dA)-[po1y(dT)h with 
higher affinity and selectivity than MHQ-12. Initial virtual screening is performed with 
Surflex-Sim, which is a ligand similarity-based software program that has superior 
performance compared to most traditiona12D similarity methods [169]. This program is 
an effective tool to rapidly prescreen large virtual compound libraries to enrich for 
structurally similar ligands [169]. Surflex-Sim maximizes 3D morphological similarity 
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and alignment of a test ligand to the control ligand, which in this work was MHQ-12 
[169-171]. The quantitative metric that is used for evaluating Surflex-Sim results is the 
Surflex-Sim score, which embodies an all atom comparison and alignment of the test 
ligand with the control ligand. The top ranked Surflex-Sim results were used for 
structure-based docking studies to dock the ligand to the intercalation site and the three 
grooves (major-major, major-minor and minor) of the triplex structure using the docking 
program Surflex-Dock [44]. Surflex-Dock performs docking of test ligands to a 
"protomol" or idealized representation of the binding site on the nucleic acid target. The 
ligands are docked to the target and the poses are ranked by a Surflex Raw Score (SRS) 
which consists of an affinity score of the ligand for the target [171]. This sequential 
combination of Surflex-Sim followed by Surflex-Dock produced several ligands that had 
hypothesized higher binding affinity and selectivity for the triplex intercalation site, 
compared to MHQ-12. 
A critically important step after virtual screening is validation by experimental 
testing of the top candidates. To accomplish this, competition dialysis was employed 
because of its extensive use to determine the selectivity and affinity of a small molecule 
for single stranded, duplex, triplex and quadruplex nucleic acid targets [7, 10, 130, 164, 
172-179]. The advantage of competition dialysis is that it is not limited to the target 
sequence, or a simple comparison with one other form of DNA, but with as many nucleic 
acid forms as are included in the assay. Competition dialysis involves dialyzing solutions 
of an array of nucleic acid sequences and structures against a common solution 
containing a test ligand [10]. The solution is allowed to reach equilibrium, and the 
amount of ligand that is bound to each nucleic acid is measured using either fluorescence 
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or absorbance [10]. Comparison of the total and relative amounts of ligand bound to each 
nucleic acid assesses the affinity and selectivity, respectively, of the ligand for any 
included nucleic acid. Competition dialysis testing is used here to validate the affinity 
and selectivity of the top virtual screening hits. Circular dichroism and thermal 
denaturation were used for further characterization of the triplex binding of the top virtual 
screening candidate hits. 
By using this integrated approach we have identified small molecules that have 
higher selectivity and affinity for triplex poly(dA)-[poly(dT)h than the original molecule, 
MHQ-12, and which are among the most selective and tightest triplex binding molecules 
reported to date. 
Materials and Methods 
Virtual Library Construction. The triplex-selective ligand MHQ-12 was constructed and 
hydrogen atoms were added using Macromodel (version 7.0). The ligand was 
energetically minimized using a sequential combination of 2000 iterations of a Steepest 
Descent algorithm followed by 2000 iterations of a Polak-Ribier Conjugate Gradient 
(PRCG) algorithm. AMBER ligand atom types were assigned using Sybyl (version 7.3). 
The program Antechamber in the software suite Amber (version 8) was used to calculate 
AMI-BCC charges for the ligand and to convert to a MOL2 file format. A virtual set of 
1.962 million ZINC compounds in MOL2 format were obtained from the ZINC 2007 
"all-purchasable" subset of ligands from the University of California San Francisco 
(UCSF) [180]. The triplex nucleic acid structure poly(dA)-[poly(dT)h with an 
intercalation site was constructed using B-type parallel triplex with X-ray structural 
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intercalation site backbone fragments [Protein Data Bank entry Ip20.ent] and minimized 
holding the heavy atoms fixed [181]. 
Surflex Methods. The program Surflex (version 2.11) containing both the Surflex-Sim 
molecular similarity and the Surflex-Dock molecular docking programs was run on 30 
AMD Opteron 246 processors (2.0 GHz) running the Linux Red Hat operating system for 
all virtual screening experiments. Surflex-Sim experiments were performed using the 
"align_list" function to compare the MHQ-12 triplex selective ligand against 1.962 
million compounds in the ZINC library. The top 350 ligands, ranked according to the 
highest Surflex-Sim score, were selected as candidates for Surflex-Dock studies and were 
extracted as individual MOL2 files from the library files using in house PERL scripts. 
For the Surflex-Dock experiments, four protomols were generated to cover the major-
major groove, major-minor groove, minor groove and intercalation sites of the triplex 
nucleic acid, using the same methods previously described [63]. The "proto_bloat" 
function was set to accommodate all reasonable interactions of the protomols with the 
triplex target sites. Docking of the ligands to the target was performed using a whole 
molecule approach, as described previously [60, 63, 171]. The Surflex-Dock 
experiments involved docking each of the ligands to all four protomols individually, in 
separate experiments. Surflex-Dock was operated with parameters "Multi start 5" and 
"Random 5," which we have previously shown returned accurate top ranked docked 
poses for a set of small molecules to their respective nucleic acid targets [63]. The 
Surflex-Dock poses were ranked according to the highest Surflex Raw Score [97]. 
Surflex-Sim and Surflex-Dock poses were visualized using AutoDockTools (version 
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1.4.6). The properties of compounds 1 and 2 used in the QSAR analysis were generated 
with QikProp [105]. 
Compounds for Biophysical Testing. The highest ranked candidates identified by virtual 
screening were the ligands with ZINC identification numbers 632255 and 4623551, 
which will be referred to hereafter as compound 1 and compound 2, respectively. 
Compound 1, is 4-( 4-methylpiperazino-2-(2-naphthyl)quinoline and was obtained from 
Sigma-Aldrich (Milwaukee, WI). Compound 2 is 1-phenyl-4-pyrrolidino-2,3-dihydro-
1/H/-pyrrolo[2,3-/b/]quinoline and was obtained from Chemical Block (N.D. Zelinsky 
Institute of Organic Chemistry, Moscow, Russia). As positive controls, the known triplex 
selective ligands MHQ-15 and OZ-85H were synthesized as previously described [44]. 
Competition Dialysis Method. Competition dialysis experiments were done as previously 
described [7, 44, 173, 182]. The array of oligonucleotides used is given in Table 9. The 
buffer used consisted of Na2HP04 (6 mM), NaH2P04 (2 mM), NaCI (185mM), EDTA 
(0.1 mM), pH 7. All nucleic acid samples were of identical concentration of 75 ~, 
expressed in terms of monomeric unit (base pairs for duplex DNA, triplets for triplex 
DNA and tetrads for quadruplex DNA). At the end of the dialysis equilibration period, 
ligand concentrations were determined by fluorescence. A volume of 180 III of each 
sample was carefully transferred into one well of a 96-well microtiter plate (Costar® cat# 
3915; Coming Inc., Coming, NY). To each sample, 20 III of a 10% (w/v) sodium 
dodecyl sulfate (SDS) stock solution was added to give a final concentration of 1 % (w/v) 
SDS, sufficient to dissociate the ligand from the DNA structure and ensure that there are 
no complexities arising from differences in the optical properties of free and bound 
.ligands. The total ligand concentration (el ) within each dialysis well was determined 
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Table 9. Oligonucleotide Array for Competition Dialysis. 
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Table 9. Oligonucleotide Array for Competition Dialysis 
Nucleic Monomeric 
Conformation acid Nomenclature A(nm) E (M-1cm-1) unit 
Single-stranded DNA poly (dA) dA 257 8600 Nucleotide 
Single-stranded DNA poly (dT) dT 264 8520 Nucleotide 
Double-stranded Clostridium C. perf. 260 12476 base pair 
natural DNA Perfiingens (GC 
31%) 
Double-stranded Calf thymus (GC C.T. 260 12824 base pair 
natural DNA 42%) 
Double-stranded Microccocus M.lys. 260 13846 base pair 
natural DNA Iysodeiktus (GC 
72%) 
Double-stranded DNA Z-DNA Z-DNA 254 16060 base pair 
Double-stranded DNA poly (dAdT) dAdT 260 12000 base pair 
Double-stranded DNA poly (dAdT)- dAT 262 13200 base pair 
(dAdT) 
Double-stranded DNA poly (dGdC)- dGC 254 16800 base pair 
(dGdC) 
Double-stranded RNA poly (rArU) rArU 260 14280 base pair 
DNA-RNA hybrid poly (rAdT) rAdT 260 12460 base pair 
Triplex DNA or RNA poly(dA)- dAdTdT 260 17200 Triplet 
[poly(dT)], 
Quadruplex DNA TG4T TG4T 260 12672 Quartet 
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using a fluorescence standard curve for each tested ligand. Appropriate corrections were 
made for the small dilution resulting from the addition of the SDS stock solution. The 
free ligand concentration (Cr) was determined from an aliquot of the dialysate solution, 
which typically did not vary significantly from the initial 1 IlM concentration. 
Fluorescence measurements were made using a Safire microplate reader (Tecan US, 
Durham, NC), with the following parameters: excitation and emission bandwidth, 10 nm, 
gain: 100. Compound OZ-85H: excitation/emission 260/494 nm, compound MHQ-15: 
excitation/emission 260/437 nm, compound 1 excitation/emission 260/490 nm, 
compound 2: excitation/emission 348/446 nm. The bound ligand concentration (Cb) was 
then determined by: 
(7) 
Binding constants, specificity sums (SS) and the ratio Cb/SS were calculated as follows 
[183]. Apparent binding constants for each structure or sequence, Kapp, may be 
calculated by: 
(8) 
where Cb is the amount of ligand bound, Cf is the free ligand concentration and Stota] is 
the total nucleic acid concentration. By virtue of the experimental design used in the 
competition dialysis experiment, Cf = 1 IlM and Stota] = 75 11M, expressed in terms of the 
monomeric unit of the nucleic acid. The specificity sum, SS, is the sum of the 
normalized amounts bound to each nucleic acid species, i: 
ss= I Cb,i 
i Cmax 
(9) 
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where Cb,i is the amount bound and Cmax is the maximum amount bound to any species. 
The index i ranges from 1 to 13 in the current assay, corresponding to the 13 different 
nucleic acids. A SS value of 1 indicates absolute selectivity for one structure whereas a 
value of 13 indicates lack of selectivity. Information about compound binding affinity is a 
function of Cmax. Thus, the ratio Cmax/SS represents affinity and selectivity. If SS = 1, 
the maximal value of Cmax/SS will be obtained and if SS = 13, the minimal value is the 
result. A high value of the Cmax/SS ratio is representative of compounds with high 
binding affinity and selectivity. 
CD Titration and Thermal Denaturation Methods. CD titrations were done as 
previously described, using a Jasco 810 spectropolarimeter. Instrument settings were: 
wavelength range (220-500 nm), scan rate (100 nm min-I), averaging time (0.125 s), 
bandwidth (1 nm), number of scans (2), temperature (20 DC) [184]. The effect of ligands 
on the thermal denaturation of triplex DNA was studied using the exact protocol 
described previously [183]. 
Results and Discussion 
Virtual Screening. The initial step in virtual screening was performing Surflex-Sim to 
determine which of the ligands in the library were most structurally similar to the known, 
triplex selective intercalator MHQ-12. Of the approximately 2 million ligands screened 
for similarity against MHQ-12, 350 ligands had a Surflex-Sim score of greater than 0.70 
(range: 0.875 - 0.704) and were selected for Surflex-Docking studies. A cutoff Surflex-
Sim score of 0.70 was selected based on previous studies which suggested that this is the 
lowest score where the ligand structure-function relationship is typically maintained [97]. 
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--------------------------------------------- ----------------
The next step in the virtual screening process involved perfonning Surflex-Dock studies 
with the top 350 ranked Surflex-Sim ligands using the intercalation site and the three 
grooves (major-major, major-minor and minor) of the triplex as individual docking 
targets. Interestingly, MHQ-12 has the top Surflex Raw Score out of all 350 ligands that 
were docked to the intercalation site, which directly supports the ability of Surflex-Dock 
to successfully dock and rank a known selective triplex intercalator. We propose a new 
metric to evaluate the Surflex-Dock results, the "Nonnalized Surflex Raw Score 
(NSRS)". The rationale behind the nonnalization of the Surflex Raw Score is that the 
score for a ligand binding to a single site on a target measures only the interaction with 
that one site. However, a ligand may have multiple interaction sites on a particular target. 
Therefore for selectivity for a particular mode of binding, it is crucial to detennine the 
binding of the ligand to the site of interest relative to the binding to other potential sites 
on the target. Since ligands interact with nucleic acids typically through either the 
groove-binding or intercalation, protomols were constructed at the three grooves and the 
intercalation site [75]. Binding of the ligand to the intercalation site relative to binding in 
the three grooves embodies the "nonnalized" affinity and specificity of the ligand for 
triplex intercalation. The following metric, which was first developed in Chapter III of 
this work, detennines the NSRS for the intercalation site for each of the top 350 Surflex-
Dock results: 
NSRSintercalate site = SRSintercalate site - Maximum SRSmajor-major site, major-minor site, minor site (10) 
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Ranking of the 350 intercalation site Surflex-Dock results by NSRS shows that only three 
ligands have a higher NSRS score than MHQ-12 (NSRS of 6.8) (Figure 60A). The 
ligands are LS-08 (Figure 60B), compound 1 (Figure 60E) and compound 2 (Figure 60F) 
and have NSRS values of 7.03, 7.34 and 7.39, respectively (Figure 60) [185]. 
Interestingly, LS-08 (Figure 60B) which was identified by our virtual screening 
methodology, was previously tested by Chaires et ai. and shown to be highly triplex 
selective, which adds validity to our virtual screening approach used to identify triplex 
selective ligands [44,183]. Based on the NSRS values, compounds 1 (Figure 60E) and 2 
(Figure 60F) were hypothesized to have superior affinity and selectivity for binding to the 
triplex nucleic acid, and were tested by competition dialysis. Two known triplex 
selective compounds, MHQ-15 (Figure 60C) and OZ-85H (Figure 60D) served as 
positive controls, as these compounds have been extensively studied and characterized 
[44]. Biophysical characterization was performed by circular dichroism and thermal 
denaturation to assess the ability of the compounds to intercalate into the DNA triplex. 
Competition Dialysis. The results of the competition dialysis experiments are shown in 
Figure 61. It is visually apparent that compounds 1 and 2 have a much higher affinity for 
the TAT triplex than the two positive control reference compounds, MHQ-15 and OZ-
85H. The competition dialysis results for MHQ-12 have previously been described in 
detail, and this compound has a SS of 1.32 and a Cmax/SS ratio of 8.93 [44]. 
Determination of the SS (Table 10) for compounds 1 and 2 demonstrates superior triplex 
selectivity compared to OZ-85H but slightly less selectivity than MHQ-12 and MHQ-15. 
However, the significantly higher binding affinities of compounds 1 and 2 translates to 
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Figure 60. Chemical structures of the ligands used in virtual screening and competition 
dialysis Experiments. (A) MHQ-12, (B) LS-08, (C) MHQ-15, (D) OZ-85H, (E) 
compound 1 and (F) compound 2. 
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Figure 60. Chemical structures of the ligands used in virtual screening and competition 
E 
F 
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Figure 61. Competition dialysis results for MHQ-15, OZ-85H, compound 1 and 
compound 2. The concentration of bound ligand to each nucleic acid structure in the 
array is shown. 
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Figure 61. Competition dialysis results for MHQ-15, OZ-85H, compound 1 and 
compound 2. 
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Table 10. Competition dialysis metric results for the positive controls, MHQ-15, OZ-
85H, and the virtual screening top results, compounds 1 and 2. 
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Table 10. Competition dialysis metric results. 
Test Ligand Cb Kapp/lO!l SS Cmax / SS 
(J.l.M) (M-
1
) (J.l.M) 
MHQ-15 10.7 1.7 1.66 6.44 
OZ-85H 17.6 3.1 3.69 4.77 
Compound 1 24.2 4.8 2.30 10.47 
Compound 2 30.0 6.7 1.92 15.63 
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much higher Cmax/SS values than MHQ-12, MHQ-15 or OZ-85H. The Cmax/SS ratio 
for compounds 1 and 2 is significant as it suggests that compounds 1 and 2 have a 
superior combination of binding affinity and selectivity compared to the reference 
compounds. These results validate the virtual screening approach, and show that the 
method can be used to identify compounds with high affinity and selectivity for a target 
nucleic acid, in this case the DNA TAT triplex. 
Circular Dichroism. The interaction of compounds 1 and 2 with DNA was studied by 
circular dichroism (Figure 62). Both compounds show pronounced induced circular 
dichroism (ICD) in the presence of triplex DNA. The ICD is in a spectral range where 
the compounds absorb light but the DNA does not. This ICD is unambiguous proof of 
the ligand binding to triplex DNA. For both compounds 1 and 2, the ICD is negative in 
sign, and relatively weak in magnitude. Such behavior is consistent with an intercalative 
binding mode, although the mode of binding can only be definitively established by high-
resolution experimental structural analysis [186]. 
Thermal denaturation studies. Figure 63 shows the effects of compounds 1 and 2 on the 
thermal denaturation of the TAT triplex. In the absence of added ligand, two transitions 
are seen, corresponding to the melting of the third strand (~ 30°C) and the duplex (~ 
70°C). Titration with both ligands results in a clear elevation of the first transition, 
indicating stabilization of the triplex. The effect is maximal at saturating concentrations 
of ligand (1: 1, ligand:triplet), where melting of the triplex coalesces with duplex melting. 
Melting of the triplex is stabilized by ~ 40°C indicating tight binding of both compounds. 
Neither compound I nor compound 2 alter the transition temperature of the duplex form 
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Figure 62. Induced Circular Dichroism results for (A) compound 1 and (B) compound 2. 
(A) Spectra are shown for a ligand concentration of 45 ~ in the presence of triplex 
DNA ranging from 5 11M to 450 11M triplets. (B) Spectra are shown for a ligand 
concentration of22.5 11M in the presence of triplex DNA ranging from 2.25 11M to 225 
11M triplets. 
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Figure 62. Induced Circular Dichroism results. 
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Figure 63. Thermal Melting results for (A) compound 1 and (B) compound 2. Derivative 
melting curves were obtained using 32 JlM triplex DNA and ligand concentrations 
ranging from 0 - 16 JlM (A) or 0 -32 JlM (B). The peak near 30°C is for the melting of 
the third stand, while that near 70°C is for melting of the duplex. 
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Figure 63. Thennal Melting results. 
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to any appreciable extent, an observation that is fully consistent with the weak binding to 
duplex seen in competition dialysis experiments (Figure 61). 
Validation ofQSAR. In the previous study of naphthyl quinoline binding to triplex DNA 
[44], a QSAR was derived from competition dialysis binding data. The best three-term 
QSAR to emerge was: 
logKcw =O.OO264(±OJXXl65)S4S4 -0.693(±O.125)E4 -0. 1 96(±O.02)HBa 
-t4.66(±O.44) 
N =14;R=0.959;RM5E=0.13O;F=49.84;P=0.OOOI 
(11) 
In this relationship, log Kapp is the logarithm of the apparent binding constant (Table 10), 
SASA is the total solvent accessible surface area in A2, EA is electron affinity in eV and 
HBa is the number of hydrogen bond acceptors. The physical meaning of this is as 
follows. As SA SA increases, log Kapp increases in magnitude, indicating higher affinity 
for triplex DNA. Increases in the magnitudes of EA and HBa result in decreasing binding 
affinity. Increasing the solvent accessible surface areas of naphthyl quinoline compounds 
results in higher affinity for the triplex. Greater electron affinity and more hydrogen 
bond acceptors reduce the affinity of naphthylquinolines for triplex DNA. 
Binding data obtained for compounds 1 and 2 in this study validate the published 
QSAR. The molecular descriptors SASA, EA and HBa were calculated using QikProp, 
and substituted into equation (11). For compound 1, log Ka = 5.07 was predicted, 
compared to a measured value of log Kobs = 5.68. For compound 2, log K values of5.18 
and 5.82 were calculated and observed, respectively. The differences in calculated and 
observed values correspond to a factor of about 4 in binding constants, an acceptable 
agreement for predictions from a QSAR. 
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Conclusion 
This work demonstrates a novel strategy for discovering small molecules that can 
selectively bind to the triplex nucleic acid, poly(dA)-[poly(dT)b- Through the 
combination of virtual screening by Surflex and experimental validation by competition 
dialysis, compounds 1 and 2 were discovered. These compounds have the highest overall 
affinities and selectivities reported for triplex binders as determined by competition 
dialysis. Further biophysical characterization by circular dichroism and thermal melting 
confirmed the mechanism of action of these new compounds and verified the predictive 
nature of the virtual screening methodologies. Several aspects of the virtual screening 
results are noteworthy. First, the combination of a ligand-based (Surflex-Sim) with a 
structure-based approach (Surflex-Dock) proved to be a powerful and highly 
computationally efficient way to identify triplex selective small molecules, as Surflex-
Sim is two orders of magnitude faster than Surflex-Dock. Second, our development of 
the NSRS metric, which can predict a particular mode of binding of triplex selective 
ligands with both similar and different (scaffold hopping) chemical scaffolds. This is 
significant as it has the potential to identify new classes of small molecules that may have 
much higher affinity and selectivity for a given nucleic acid target. Future work will 
focus on extending this integrated virtual and actual screening platform to target other 
nucleic acid structures that may hold medicinal value and physiological relevance. 
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CHAPTER V 
DISCOVERY OF A G-QUADRUPLEX NUCLEIC ACID BINDING SMALL 
MOLECULE BY IN SILleo SCREENING AND MOLECULAR MODELING 
This chapter describes the utilization of the validated software Surflex and Autodock for 
the purpose of discovering novel small molecules that can bind to G-quadruplex DNA 
structures. The targeting of G-quadruplex nucleic acids by virtual screening approaches 
remains vastly underexplored despite the potential anti-neoplastic use of small molecules 
that bind specifically to G-quadruplexes. We report here the development of a novel, 
structure-based virtual screening approach that uses the molecular docking software tools 
Surflex and Autodock to screen over 6.6 million compounds for their binding to a 
specific site within the human telomeric G-quadruplex AGGG(TT AGGGh A novel 
compound with a scaffold unlike any previously reported was discovered in silico. The 
compound was demonstrated by spectroscopic and fluorescent biophysical methods to 
interact with the G-quadruplex by the specific mechanism predicted by the in silico 
screen. Models of the newly discovered compound interacting at various end-pasting 
sites on the human telomeric quadruplex were constructed which provides insights to the 
important ligand-nucleic acid interactions necessary for targeting quadruplex structures. 
The virtual screening approach as presented here may be applied to any number of 
nucleic acid targets to discover new compounds that may have medicinal benefit. 
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DISCOVERY OF A G-QUADRUPLEX NUCLEIC ACID BINDING SMALL 
MOLECULE BY IN SILleo SCREENING AND MOLECULAR MODELING 
Patrick A. Holt, Robert Buscaglia, Jonathan B. Chaires, John o. Trent 
Introduction 
Discovering small molecules that bind to nucleic acids using high throughput in 
silico virtual screening continues to be a largely untapped area of computational research 
and drug discovery. Indeed, nucleic acid focused therapeutics currently represent only a 
few percent of marketed drugs, with the vast majority focused on protein targets [1]. 
This initial neglect of nucleic acids as viable targets appears partially due to the failure to 
appreciate the structural diversity and functional significance of nucleic acids. With 
advances in the understanding of the diverse structures of nucleic acids, there is now an 
increasing list of nucleic acid targets with physiological and in vivo relevance [8]. 
Among the most attractive nucleic acid targets are the G-quadruplexes, which are found 
in the human telomeric region of chromosomes and consist of the motif (TT AGGG)n. 
These G-quadruplex nucleic acid structures have a novel mechanism of potentially 
inhibiting cancer cells replication [39, 53, 187]. Over 85% of cancer cells overexpress 
telomerase which allows cancer cells to maintain the ends of human telomeres and is 
ultimately responsible for cancer cell immortality [54]. G-quadruplex structures have 
been shown to destabilize telomerase from the telomere, resulting in decreasing cancer 
cell life [55]. Thus, these quadruplexes have become a source of great interest for the 
identification of small molecules that may bind and stabilize the structures in vivo, and 
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inhibit telomerase activity. Efforts to discover quadruplex binding small molecules have 
so far been modestly fruitful, and highlighted by the movement of Quarfloxin (owned by 
Cylene Pharmaceuticals) into humans III planned clinical trials. 
In addition to G-quadruplex in the human telomeric region of chromosomes, G-
quadruplexes also exist with increased frequency in the promoter regions of many genes. 
It appears that oncogene promoter regions contain potential quadruplex-forming 
sequences at a statistically significant increased rate, such as c-myc, bcl-2 and VEGF 
[188-189]. The c-myc promoter in particular has gained attention as its overexpression is 
strongly associated with cancer development. There is increasing evidence suggesting 
that G-quadruplexes play a role in the regulation and modulation of oncogene 
transcription and the G-quadruplexes have increasingly been the focus of small molecule 
targeted approaches. In the case of c-myc, the small molecule TmPyP 4 has been shown to 
stabilize quadruplex structures located in the nuclease hypersensitivity element III 1 
(NHE) area of the promoter, which controls >80% of c-myc gene transcription [188]. 
Ultimately, TmPyP4 is able to effectively inhibit gene transcription by stabilizing the 
quadruplex [108, 189]. This emphasizes that G-quadruplexes in promoters as well as in 
the human telomeric region are attractive structures for small molecule targeting. 
In spite of the promise of small molecules that may bind to G-quadruplex targets, 
in particular the human telomeric G-quadruplexes, there are very few published reports of 
large scale in silico molecular docking approaches to discover new small molecules that 
can bind to these targets [34, 36-37]. The studies that have been performed appear to 
screen only limited numbers of compounds, typically on the order of thousands of 
compounds [190]. A significant number on the order of tens of millions of in silico small 
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molecules that are currently available that may bind to these targets have yet to be 
explored. The lack of computational structure-based small molecule discovery in this 
research area exists for several reasons. First, while the human telomeric sequence 
AGGG(TTAGGG)3 is of intense interest and has been studied in depth in vitro, there 
remains great controversy as to the actual structure that this sequence adopts under 
physiologically relevant solutions in K+. A number of structures and sequence variants 
have been reported which emphasizes the unique polymorphism of the human telomeric 
and other closely related sequences [191]. Published X -ray crystallographic structures 
suggest this sequence forms an all-parallel "propeller" shape [191-193]. However, an 
increasing body of evidence suggests that in fact, this structure may not represent the 
"correct" structure(s) under physiological conditions in solution [194-195]. 
Unfortunately, an NMR solution structure of the 22mer human telomeric sequence has 
not been published although a number of variant sequences containing this human 
telomeric sequence suggest that the human telomere adopts a so-called Hybrid or 
paralleVanti-parallel structure under physiological relevant conditions [193-194, 196-
197]. 
Another reason for the lack of in silico structure-based targeting of the human 
telomeric quadruplex is that molecular docking software in large part has been 
developed, parameterized and validated almost exclusively for protein targets, and may 
not appropriately consider the unique properties of nucleic acids. Also, previous 
computational studies have focused on rationalizing known data, which is an important 
but different type of experiment than using the software to discover new nucleic acid 
binding small molecules with novel scaffolds [34, 63]. Additionally, it remains to be 
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seen whether large scale virtual screening of millions of small molecules to nucleic acid 
targets in silica is computationally feasible and whether the small molecules that are 
discovered possess the binding activity that was predicted in vitro. A rigorous in vitro 
validation is necessary to validate the predictive nature of computational approaches. 
A final reason that in silica approaches have been ignored for targeting the human 
telomeric quadruplex appears to the focus of many research groups on "rational" drug 
discovery by derivatizing known quadruplex binding small molecules, such as TMPyP4 
and other small molecules, to enhance binding to the human telomeric quadruplex 
structure [198-200]. Unfortunately, attempts to discover new small molecules with truly 
novel scaffolds that interact with G-quadruplexes by in silica based approaches have been 
severely limited. As a result, the ability of computational approaches to explore the full 
chemical space for new small molecule discovery remains underappreciated and 
underutilized. While these are only some of the challenges associated with targeting of 
quadruplex structures, two in particular are the main foci of this chapter. First, is how to 
select a relevant or representative human telomeric G-quadruplex structure for structure-
based virtual screening. Second, is to determine if an integrated in silica molecular 
docking and in vitro testing platform can successfully discover and validate the binding 
of new small molecules to the human telomeric G-quadruplex structure. 
An important issue that arises when targeting the human telomeric G-quadruplex 
is the choice of a representative structure to use for structure-based virtual screening. 
While there are known small molecules that appear to bind to the human telomeric 
sequence, the solved crystal structure to which these small molecules are bound may not 
be the "relevant" solution structure of the human telomeric quadruplex. For example, 
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structures are available of small molecules bound to the "propeller" shaped all-parallel 
quadruplex even though the Hybrid type quadruplex structure is largely considered to be 
the "relevant" structure in solution [194-195, 201]. The lack of relevant solution 
structures with small molecules bound with this specific DNA structure has undoubtedly 
limited structure-based drug discovery approaches [202]. Small molecules are known to 
interact with the AGGG(TT AGGG)3 quadruplex in three ways: first by groove 
interactions, second by intercalation between consecutive guanine tetrads and third by 
end-pasting, where the ligand is bounded on one side by the guanine quartet and on the 
other side by the loops of the quadruplex (Figure 64A) [203]. The end-pasting 
mechanism is of intense interest, as it is thought to confer selectivity for quadruplexes 
over other nucleic acid structures by taking into account both guanine quartet and loop 
interactions. Small molecules that interact in this manner are thought to stabilize G-
quadruplexes, prevent replication by telomerase and result in decreased cancer cell 
proliferation [55]. We were interested in performing virtual screening experiments to 
discover small molecules that may end-paste on the AGGG(TTAGGG)3 structure. 
However, a difficulty is identifying an in silico G-quadruplex structure in the RSCB PDB 
with a "representative" end-pasting site for targeting in which a small molecule is bound. 
For our purposes, it is preferable to use a virtual structure in which ligands are complexed 
as the ligands can be easily removed by computational methods and docking experiments 
performed without perturbing the nucleic acid structure. As we will show, the nucleic 
acid structure that was identified possesses an end-pasting site with strikingly 
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Figure 64. (A) A G-quadruplex structure (PDB ID 2JPZ) that contains the human 
telomeric repeat and shows potential ligand interaction sites in the grooves, intercalation 
sites and end-pasting sites. (B) The G-quadruplex (PDB ID INZM) with the sequence 
(TTAGGT)4 with a Guanine-Adenine end-pasting site that was initially used for virtual 
screening with Autodock and Surflex. The RHPS4 ligand that is positioned in the 
end-pasting site is removed for clarity. Blue = Thymine, Red = Adenine, Green = 
Guanine and Purple = K+ cations. 
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Figure 64. (A) A G-quadruplex structure (PDB ID 2JPZ) that contains the human 
telomeric repeat. (B) The G-quadruplex (PDB ID INZM) with the sequence 
(TTAGGT)4 with a Guanine-Adenine end-pasting site that was initially used for virtual 
screening with Autodock and Surflex. 
A B 
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similar properties of the human telomeric end-pasting site and this end-pasting site served 
as the target for the virtual screening of millions of compounds. 
After selection of a G-quadruplex nucleic acid structure for structure-based virtual 
screening, the next challenge is how to perform the molecular docking experiments. The 
use of molecular docking software to target nucleic acids has generally been limited 
almost entirely to proteins. However, our recent evidence suggests that two virtual 
screening software in particular, Surflex and Autodock, have great potential for 
molecular docking small molecules to nucleic acid targets [34, 63, 204]. We previously 
reported that both of these software accurately reproduced the crystal structures of a set 
of small molecules that interact with nucleic acids by both groove binding and 
intercalation [63]. However, the question remains whether the software can be used for 
virtual screening of millions of compounds to discover new small molecules that bind to a 
desirable target. Our previous results suggested that the accuracy of both software at 
reproducing known structures is comparable (under conditions previously tested), but 
Surflex is approximately 10 fold faster than Autodock and requires less file preparation 
for virtual screening [63]. Because of the complementary docking and scoring 
algorithms of Surflex and Autodock, however, we also investigate combining the power 
of both of these software into a single platform that is capable of novel small molecule 
discovery through a virtual screening strategy that is detailed below. 
Even given these challenges, we report here the successful development of a high 
throughput in silica molecular docking platform that discovered a human telomeric 
quadruplex binding small molecule with a chemical scaffold unlike any reported to date 
in the literature. A quadruplex with the sequence (TT AGGGT)4 that is complexed with a 
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small molecule intercalated between a guanine-adenine tetrad was used as an in silico 
basis for the representative "end-pasting" site contained in the human telomeric 
quadruplex AGGG(TTAGGG)J. A new virtual screening strategy is described that was 
successful and computationally plausible for screening millions of small molecules 
against a nucleic acid target. The top nine hits gleaned from the virtual screening studies 
were tested using spectroscopic and fluorescence based assays to validate the predicted in 
silico activity by in vitro testing. Finally, we computationally generated all possible end-
pasting sites in two in silico RSCB PDB structures containing the human telomeric G-
quadruplex AGGG(TT AGGG)3 repeat and docked the newly discovered compound to the 
sites to assess nucleic-acid and small molecule interactions. The results show that the 
virtual screening platform, as described here, is predictive and capable of discovering 
new small molecules with a specific mechanism of interacting with G-quadruplex nucleic 
acids. 
Experimental and Computational Methods 
In silico Ligand Database and Nucleic Acid Target Preparation. A ZINC database 
consisting of approximately 6.6 million virtual small molecules was used for initial 
virtual screening studies against the nucleic acid (TTAGGGT)4. These small molecules 
were the "Reference" subset of the 2008 "Drug-Like" dataset and are freely available for 
download from the University of Cali fomi a, San Fransisco [180]. The ligands have been 
named "Drug-Like" because of their adherence to Lipinski's rule of 5 to increase the 
chances that any hits will have higher oral bioavailability [31]. The small molecules 
were downloaded and used without any further modification from the initial procedures 
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perfonned by UCSF which included protonation based on a pH 7 reference, 3D 
coordinate generation and partial charge assignment from AMSOL semi-empirical 
quantum calculations. The NMR detennined G-quadruplex (TTAGGGT)4 with PDB ID 
1NZM was downloaded from the RSCB Protein Data Bank in PDB file fonnat for use in 
the virtual screening in silica experiments. Sybyl v8.1 (Tripos, Inc.) was used to assign 
AMBER atom types and convert the file to MOL2 fonnat in preparation for initial 
Surflex-Dock screening. The RHPS4 complexed ligand was removed prior to molecular 
docking experiments using Sybyl. All in silica virtual screening studies were perfonned 
on our server of 440 computers consisting of 2.66GHz Intel(R) Xeon(R) E5430 
processors and required approximately 3 days to complete the Surflex-Dock experiments 
and 2 days to complete the Autodock experiments. 
SurJlex and Autodock Virtual Screening Methods. We have previously validated the 
use of Surflex-Dock and Autodock for targeting nucleic acids and these software are a 
logical choice for the discovery of new ligands against novel targets [63]. The end-
pasting site on the nucleic acid (TTAGGGT)4 was considered a model of the end-pasting 
site on the human telomeric quadruplex AGGG(TTAGGG)3 and was targeted for 
molecular docking using both Surflex-Dock v2.2 (Tripos, Inc.) and Autodock v4.0 
(Scripps). The end-pasting cavity was specified for Surflex-Dock v2.2 docking using a 
ligand-based approach. This involves using the existing RHPS4 ligand that was bound 
inside the (TTAGGGT)4 end-pasting site to generate a Surflex-Dock "protomol" which 
guides the molecular docking of the in silica ligand library to the end-pasting site. The 
"protomol" was constructed by altering the "proto_bloat" and "proto_thresh" functions 
and visualized in Sybyl to ensure reasonable interactions in the end-pasting site. The 
271 
significance of the protomol and the Surflex-Dock docking and scoring functions have 
been described in detail previously [60]. Briefly, the "protomol" consists of a series of 
small chemical fragments that model important forces in the nucleic acid pocket, 
including steric effects and hydrogen bond acceptor and donor groups. Each of the 
ligands in the in silica virtual library is fragmented, aligned against the protomol, and 
subsequently scored based on the interactions in the binding site. Surflex-Dock was 
performed using default options which in our previous experience is appropriate for 
rapidly screening databases of small molecules against nucleic acid targets. 
The utilization of Autodock to target nucleic acid structures has also been 
previously described [34, 63-64, 204]. Autodock works by precomputing energy grids 
for a target [205]. A genetic algorithm such as the Lamarkian Genetic Algorithm is used 
to assess the interactions of the ligand with the pre-calculated energy grids until typically 
a specific number of energy evaluations is reached. The final top "pose" returned by 
Autodock is the computed lowest energy docked structure of the ligand with respect to 
the target. The highest scoring pose of the top 1% of ranked Surflex-Dock hits 
(approximately 66,000 small molecules) were extracted in MOL2 format and converted 
to PDBQT file format using the Python scripts included with Autodock. The G-
quadruplex nucleic acid (TTAGGGT)4 was prepared for Autodock by using 
AutoDockTools to convert the MOL2 to PDBQT file format. The extent of the Autodock 
grid maps was 66,64,40 points (X,Y,Z) with grid spacing distance of0.375A, and the grid 
centered on the end-pasting site. Autodock docking was performed by setting the number 
of docking runs to 5 and energy evaluations to 20 million energy evaluations, as we 
previously found these parameters to be optimal for docking of small molecules to 
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nucleic acids [63]. After completion of Autodock docking, the Surflex and Autodock 
results were re-ranked using a Ranked Consensus Scoring (RCS) function as follows 
[206]: 
'C'l"t Rt 
ReS = ~t=1. 
N (12) 
The rank-by-rank strategy (RCS) is used to assign an average rank for each of the top 
66,000 compounds from the two available scoring functions in Autodock and Surflex. 
The following example illustrates how this scoring function works. If the small molecule 
ranks 1 by Autodock and 3 by Surflex, than the consensus ranking score is 2, using 
equation 12 above [207]. The RCS is performed for all 66,000 compounds to develop a 
consensus ranked list of compounds. 
Oligonucleotide and Small Molecule Preparation. The G-quadruplex oligonucleotide 
AGGG(AGGGTT)3, also referred to here as the "K+ 22mer," was obtained from 
Integrated DNA technologies (IDT, Coralsville, IA) and prepared for experiments by 
dialysis and annealing. Dialysis was performed against KPEK buffer, which is composed 
ofK2HP04 (6mM), KHZP04 (2mM), KCI (185mM), EDTA (O.lmM), pH 7, using Pierce 
(Rockford, IL, USA) 3500 Da molecular weight cutoff dialysis cassettes. The 
oligonucleotides were annealed by heating at 90 °C for 2 minutes, cooling to room 
temperature overnight and left at 4 °C for 48 hours prior to use, as previously described 
[10,64]. The oligonucleotide (with E = 228,500 LI(mole cm) for the single-strand form) 
was characterized structurally by Circular Dichroism (CD) spectroscopy and the resulting 
spectrum was consistent with previously reported results for this structure (Figure 65) 
[132, 208]. All oligonucleotides used for the quadruplex melting studies were also 
obtained, annealed and characterized using the methods described and 
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Figure 65. CD Spectrum (A) and CD Melt (B) of the K+ 22mer G-Quadruplex. Both 
spectra are consistent with published structural data for this nucleic acid. 
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Figure 65. CD Spectrum (A) and CD Melt (B) of the K+ 22mer G-Quadruplex. 
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previously [10, 64]. The top nine small molecules with the best ranked consensus scores 
were purchased for testing. The molecule described in detail here has ZINC 
identification number 8927810, was purchased from InterBioScreen (Moscow, Russia) 
under the catalog number STOCK1S-61623 and is described chemically as 1-methyl-4-
[5-( 1-methyl-4-quinolylidene )-3-phenyl-penta-1 ,3-dienyl]-quinoline. This small molecule 
will be hereafter described as "Compound 1." Compound 1 was weighed and a stock 
solution was created by dissolved the weighed compound in DMSO (Sigma, St. Louis, 
MO, USA) prior to testing. 
Biophysical Testing Methods. UV /Vis Absorption titration experiments were performed 
on a Tecan Safire 96 well microplate reader (Durham, NC, USA) in duplicate and 
measured five times at 1nm step intervals between 550nm and 950nm, consistent with 
previously described procedures [203]. The percent hypochromicity for the UV/Vis 
absorption titrations was determined from the shift in the absorbance at no added DNA 
(650nm) and maximal added DNA (659nm) by the formula: 
(13) 
Both the UVNis Absorbance and CD experiments were performed using procedures 
previously described [184, 203, 209]. All CD experiments were performed on a Jasco J-
810 spectropolarimeter (Easton, MD, USA). CD scanning experiments for the purposes 
of K+ 22 mer quadruplex DNA characterization were performed at a concentration of 
3.51lM (strand) from 320nm to 220nm with a data interval of 1nm, band width of 1nm, 
response of 1 second, scanning speed of 200 nrn/minute and a total of four accumulated 
scans. Induced CD experiments were performed from 900nm to 550nm with a data 
interval of lnm, band width of lnm, response of 2 seconds, scanning speed of 200 
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nrn/minute and a total of three accumulated scans. For induced CD experiments, the 
Compound I concentration was fixed at 11.6JlM and separate solutions were prepared 
with increasing ratios of K+ 22 mer quadruplex DNA. CD melting experiments with the 
K+ 22mer were performed at a DNA concentration of 3.5JlM from 20°C - 98 °C with a 
scanning speed of I °C/minute. 
The Thiazole Orange Fluorescent Intercalation Displacement Assay (TO-FID) 
was performed using procedures previously described [40]. Thiazole Orange was 
obtained from Anaspec, Inc (San Jose, CA, USA) and dissolved in DMSO. Using a K+ 
22mer quadruplex concentration ofO.25JlM (strand) and a Thiazole Orange concentration 
of 0.50JlM, increasing amounts of Compound 1 test ligand are added to the solution and 
the fluorescence of Thiazole Orange is monitored. All TO-FID fluorescence readings 
were performed in duplicate and measure 5 times on a Tecan Safire 96 well microplate 
reader with Excitation at 501nm, Emission from 52lnm to 750nm, Emission maximum 
at 535nm, lnm step size, Excitation and Emission Band Widths of 9nm and a Gain of 
130. All spectroscopic and TO-FID testing was performed in a buffer solution consisting 
of KPEK and 5% DMSO. The absorbance of Compound 1 is in the region of 550nm -
900nm and does not interfere with reading TO fluorescence at 535nm. 
The quadruplex melting studies were performed in a 96-well plate format on an 
Applied Biosystems StepOnePlus Real-Time PCR System (Carlsbad, CA, USA) adapted 
for use in thermal melting experiments. The K+ 22mer quadruplex was labeled with a 
F AM-TAMRA Fluorescence Resonance Energy Transfer (FRET) pair to selectively 
monitor the K+ 22 mer quadruplex melting in the presence of competing DNA solutions. 
F or the F AM -T AMRA labeled K+ 22mer quadruplex compound melting saturation 
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experiments, increasing concentrations of Compound I were added to a fixed solution 
containing 250 nM FAM-TAMRA labeled K+ 22mer quadruplex (Sigma, St. Louis, MO, 
USA) and melting experiments were performed. The temperature range for the melting 
range was 20°C - 98°C with data measurements taken every 0.2°c. The F AM-TAMRA 
labeled quadruplex was monitored using a fluorescence filter that quantifies emission at 
520 nm. Melting curves were fit in Mathematica v6.0.2.1 (Wolfram Research) and 
melting temperatures calculated as previously described [210-211]. For the DNA 
competition experiments, a stock solution of250 /-lM ofFAM-TAMRA labeled K+ 22mer 
quadruplex was made by weighing the quadruplex, dissolving in a solution of tetrabutyl 
ammonium phosphate and adjusting the pH to 7.0 with tetrabutyl ammonium hydroxide. 
The stock solution ofFAM-TAMRA labeled K+ 22mer quadruplex was diluted to a final 
concentration of 150 nM using KPEK buffer for all melting experiments. Competing 
DNA solutions were added to the wells containing the FAM-TAMRA labeled K+ 22mer 
quadruplex such that the final concentration of competing DNA was 20 fold higher (3 
/-lM) than the concentration of the FAM-TAMRA labeled K+ 22mer quadruplex (150 
nM). Finally, Compound 1 was added such that the concentration ratio of Compound 1 
to FAM-TAMRA labeled K+ 22mer quadruplex was 40/1 (final Compound 1 
concentration of 6 /-lM). All melting studies were performed in a buffer consisting of 
KPEK + 5% DMSO. Oligonucleotides concentrations were based on a monomeric unit 
(nucleotide for duplex DNA, triplet for triplex DNA and quartet for quadruplex DNA) as 
previously described [172-173]. 
Hybrid-l and Hybrid-2 Quadruplex Modeling and Docking Methods. The nucleic acids 
that are representative of the Hybrid-l (PDB ID: 2HY9) and Hybrid-2 (PDB ID: 2JPZ) 
278 
structures that are present in the K+ 22mer quadruplex sequence were downloaded from 
the Protein Data Bank in PDB file format and prepared for molecular docking 
experiments as described above. Both of these structures contain the human telomeric 
repeat sequence (TT AGGG)n with Hybrid-l consisting of the sequence 
AAAGGG(TTAGGG)3AA and Hybrid-2 consisting of the sequence (TTAGGG)4TT. 
There are four possible end-pasting sites in these two structures to which Compound I 
was docked using both Surflex and Autodock. In each of these two structures, end-
stacking sites are present at both the 3' and 5' ends and occupy the space between the 
terminal guanine tetrad and accompanying loop structures. Unfortunately, Surflex v2.2 
has yet to include and have receptor flexibility validated for use with targeting nucleic 
acids. Therefore, an alternative strategy was employed to "open up" the external G-
quartet and surrounding bases that comprise the end-pasting site to allow for molecular 
docking to proceed. To expose the end-pasting sites, we built a virtual ligand consisting 
of a quaterpurine, a largely planar, aromatic, small molecule that would stack well upon 
the terminal guanine quartet. This virtual ligand was appropriately named because it 
consists of four purines that are connected together in a cyclic arrangement (Figure 66). 
Using Macromodel, the quaterpurine was initially positioned between the terminal G-
tetrad and loop region for each of the possible four endpasting sites. The nucleic acid 
was initially energetically minimized holding the ligand fixed using a Steepest Descent 
algorithm for 1000 iterations. The nucleotides comprising the end-pasting site including 
the terminal G-quartet and loop nucleotides were designated as flexible while the 
remaining nucleic acid bases were held rigid and fixed. Further structural minimizations 
were performed by 500 iterations of the Polak Ribier Conjugate Gradient Method. This 
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Figure 66. The structure of the Quaterpurine small molecule used to "open-up" the 
Hybrid-l and Hybrid-2 End Pasting sites. 
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Figure 66. The structure of the Quaterpurine small molecule used to "open-up" the 
Hybrid-l and Hybrid-2 End Pasting sites. 
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approach successfully opened the end-pasting sites for Surflex and Autodock molecular 
docking experiments. The docking of Compound 1 to the two end pasting sites in 
Hybrid-l and the two end pasting sites in Hybrid-2 using Surflex and Autodock was 
performed based on our previously published results validating the use of these software 
to target small molecules that bind to nucleic acids [63]. For Surflex, the "Multi start 5" 
option was enabled and with Autodock, the number of dockings was set to 5 and the 
number of energy evaluations was set to 20 million (2E7) [63]. The "protomol" used by 
Surflex was generated using the position of the quaterpurine ligand occupied in the end 
pasting sites. The Autodock procedures for grid map preparation and grid parameters 
used for docking have been previously described (Table 11) [63]. These molecular 
modeling studies of Compound 1 with the human telomeric structures were performed on 
a single computer consisting of 2.66GHz Intel(R) Xeon(R) E5430 processor and required 
an average of approximately 2.2 minutes and 31.8 minutes to complete each of the four 
Surflex and Autodock experiments, respectively. 
Results and Discussion 
The (TTA GGTh Quadruplex has a Representative End-Pasting Site for Virtual 
Screening. The discovery of small molecules that are able to bind to the end-pasting 
region of the human telomeric sequence AGGG(TTAGGG)3 (K+ 22mer) are of great 
interest as they can potentially stabilize the quadruplex in vivo and may possess anti-
cancer activity [55]. A search of the online RSCB PDB database showed over 120 
quadruplex structures that had been deposited as of December 2009. Surprisingly, 
however, there are conflicting published reports about the "correct" structure of the K+ 
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Table 11. Autodock Docking Parameters used for In silico Targeting of the End-Pasting 
Sites in Hybrid-I and Hybrid-2. 
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Table 11. Autodock Docking Parameters used for In silica Targeting of the End-Pasting 
Sites in Hybrid-l and Hybrid-2. 
Autodock Target Dimensions of Grid Grid Center 
(X, Y, Z) 
Hybrid 1 End Paste 1 66 X 46 X 70 -0.034 X 7.176 X 0.032 
Hybrid 1 End Paste 2 70X64X66 -0.01 X 4.819 X 0.036 
Hybrid 2 End Paste 1 50 X 40 X 50 -0.099 X 7.303 X 0.059 
Hybrid 2 End Paste 2 68 X 38 X 56 0.089 X 3.91 X -0.018 
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22mer under physiologically relevant conditions, even though there are mUltiple small 
molecules that are thought to interact with the human telomeric quadruplex by end-
pasting binding [191, 202]. Increasing evidence is suggesting that the K+ 22mer exists as 
a "hybrid" structure, but there have yet to be any NMR structures published with small 
molecules bound to this structure [191,193-194]. This is unfortunate, as the ligand could 
be easily removed computationally and the nucleic acid used for structure-based virtual 
screening. Instead, however, structures that possess the human telomeric repeat must be 
computationally altered prior to molecular docking to allow docking to the end-pasting 
region of the quadruplex. 
An alternative approach that we propose is selection of a G-quadruplex structure 
(with a small molecule complexed) which we believe possesses similar properties of the 
K+ 22mer end-pasting including a terminal guanine quartet with flanking Adenine 
containing residues. Interestingly, the quadruplex (TTAGGGT)4 with PDB ID INMZ 
appears to possesses many properties that makes it a representative end-pasting site of the 
K+ 22mer G-quadruplex structure. While the small molecule that is found in the 
(TTAGGGT)4 quadruplex site lies in an end-pasting site with adenine and guanine 
quartets (Figure 64B), we believe that this arrangement of nucleotides is remarkably 
similar to an end-pasting site that is present in the K+ 22mer (Figure 64A) and thus makes 
(TTAGGGT)4 a suitable choice for virtual screening experiments. The small molecule 
RHPS4 that is found in the end-pasting site of (TTAGGGT)4 is easily removed 
computationally and allows the nucleic acid structure to be used with minimal alterations 
for virtual screening experiments. In this sense, the (TTAGGGT)4 structure represents 
the in silica structure that is perhaps singularly most representative of an end-pasting site 
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found in the K+ 22mer. We prefer this strategy over previously reported approaches 
which typically involve breaking bonds of the target nucleic acid structure to generate an 
artificial site for docking as our approach preserves the fidelity of the in silico structure 
without manipulation or perturbation [212]. Importantly, this also demonstrates an 
approach for circumventing structure-based in silico screening problems when the target 
site is not entirely available from the in silico structure. 
Virtual Screening Discovery of a Novel Quadruplex Binding Ligand. The 
(TTAGGGT)4 structure with the representative pseudo end-pasting site was the basis for 
the virtual screening efforts to discover new quadruplex binding small molecules. The 
next challenge is the selection of molecular docking programs that are suitable for 
screening millions of compounds against a nucleic acid target. Our recent validation of 
two popular protein molecular docking programs, Autodock and Surflex, for use with 
nucleic acids demonstrated that these software can accurately reproduce multiple small 
molecule crystal structures of small molecules that interact with DNA by several 
mechanisms [34, 63]. The docking results showed that while both docking programs 
were accurate at reproducing the crystal structures, Autodock required approximately 10 
fold greater time for docking experiments compared to Surflex, under conditions reported 
previously [63]. This difference in docking speed is particularly important when the in 
silico library screened here is greater than 6.6 million small molecules. The question 
remains whether these two structure-based docking software can be combined in an in 
silico platform to target the (TTAGGGT)4 pseudo end-pasting site. 
While one possibility for virtual screening was to perform experiments using only 
Surflex, this would neglect the validated use of Autodock, as well as the fact that 
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Autodock implements different scoring and docking algorithms than Surflex, which may 
complement the Surflex approach [60, 205]. An alternative strategy that we developed is 
to use Surflex to pre-screen the entire in silico library and subsequently perform 
Autodock docking on only the top 1 % of ranked Surflex hits (Figure 67). This approach 
balances both the computational efficiency and accuracy of Surflex with the power of 
Autodock in a single, integrated, virtual screening platform. The top ranked hits (66,000 
compounds) for both programs were subsequently re-ranked using a rank-by-rank 
consensus scoring function that is preferable over a single scoring function and has 
previously been shown to increase success with virtual screening experiments [206-207]. 
In this case, a consensus approach is preferred as there is yet to be developed a 
"universal" scoring function that is suitable for either nucleic acids or proteins. Because 
each scoring function has distinct advantages and disadvantages, the adoption of a 
consensus-based approach increases the probability of discovering novel small 
molecules, while minimizing false positives that commonly occur in virtual screening 
studies of large numbers of in silico compounds [207, 213]. The virtual screening 
approach outlined in Scheme 1 was used for the selection of nine small molecules with 
hypothesized K+ 22mer end-stacking binding. Unfortunately, eight of the nine 
compounds were excluded from biophysical testing in the assays described herein due to 
such problems as solubility limitations or lack of a suitable chromophore for testing. 
However, one small molecule in particular, Compound 1 (Figure 68), possessed suitable 
properties for biophysical experiments and was tested to determine if the hypothesized 
activity that was identified through the in silico screen could be demonstrated in vitro. 
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Figure 67. The virtual screening strategy used to dock the in silico library of compounds 
to the (TTAGGT)4 quadruplex and determine the best hits for biophysical testing. 
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Figure 67. The virtual screening strategy used to dock the in silica library of compounds 
to the (TT AGGT)4 quadruplex and determine the best hits for biophysical testing. 
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Figure 68. The newly discovered small molecule, Compound 1, from the in silico virtual 
screening experiments. 
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Figure 68. The newly discovered small molecule, Compound 1, from the in silica virtual 
screening experiments. 
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These experiments were crucial to determine if the virtual screening strategy developed 
in Scheme 1 can not only discover new compounds, but also predict the specific site of 
binding of the compound to the quadruplex. 
Biophysical Validation of the Predicted In silico Activity of Compound 1. While our in 
silico approach successfully discovered multiple ligands with hypothesized K+ 22 mer G-
quadruplex binding activity, the question remains whether the computational methods are 
truly predictive of small molecule nucleic acid interactions in vitro. To address this 
concern, we present biophysical testing that suggests that our molecular docking 
approach as outlined in Scheme 1 successfully identifies a small molecule that not only 
interacts with the K+ 22mer quadruplex as predicted in silico, but also binds by the 
hypothesized end-stacking mechanism to the external guanine quartet. 
UVlVis Absorbance Titrations and CD Spectroscopy. UV/Vis absorption titrations and 
Circular Dichroism (CD) are powerful techniques that for our purposes can be used to 
confirm our in silico predictions of the interaction of Compound 1 with the K+ 22mer. 
The UV/Vis absorption experiments involve adding an increasing amount of K+ 22mer 
DNA to a solution of fixed ligand concentration while monitoring the absorbance 
spectrum of the ligand. Because the absorption spectrum of the ligand (550 nm - 900 
nm) is unique from that of the DNA «300 nm), changes in the monitored ligand spectra 
are indicative of specific interactions with the DNA. These spectra data show 
unambiguously that Compound 1 binds to the K+ 22mer. In the case of Compound 1, as 
increasing concentrations of K+ 22mer DNA are added to the solution, there is marked 
hypochromicity that occurs at 650nm as well as an appearance of a new peak at 827nm 
(Figure 69). The amount ofhypochromicity and relative wavelength shift can be used as 
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Figure 69. UV/Vis Absorption Titrations at increasing Quadruplex/Compound 1 ratios 
demonstrating the G-quadruplex interaction of Compound 1 with the K+ 22mer 
quadruplex, AGGG(TTAGGG)3. 
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Figure 69. UVN is Absorption Titrations at increasing Quadruplex/Compound 1 ratios 
demonstrating the G-quadruplex interaction of Compound 1 with the K+ 22mer 
quadruplex, AGGG(TT AGGG)3. 
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indicators to determine the DNA binding mode [214]. The amount of hypochromicity 
observed here (>38.2%) is consistent with ligands such as TmPyP4 that can interact with 
the K+ 22mer by both end-stacking and intercalation [132]. However, intercalation of 
ligands such as TmPyP4 is typically characterized by a bathochromic, red shift of> 15 
nm, while reports for ligands that interact by end-stacking such as Berberine are in the 
range of 8 - 12 nm [132, 146, 203, 209, 215]. Additionally, it has been reported that 
intercalation is energetically less favorable than terminal end-stacking due to the 
challenge of quadruplexes accommodating ligands stacked between existing guanine 
quartets [209]. In the case of Compound 1, in addition to the observed hypochromicity at 
650 nm, an estimated 9 nm red shift occurs from 650 nm to approximately 659 nm, 
suggesting that Compound 1 may interact with the K+ 22mer quadruplex by end-stacking. 
A consideration here is that the amount of hypochromicity and red-shift appears to be 
somewhat ligand-and quadruplex dependent, and the amount to which the quadruplex 
loop interactions are involved can substantially impact these values [209]. Nonetheless, 
the UV/Vis absorption data support an interaction of Compound 1 with the K+ 22mer 
quadruplex and suggest an end-stacking interaction with the external G-tetrads of the K+ 
22mer quadruplex. 
Circular Dichroism was also employed to determine if Compound 1 interacts with the K+ 
22mer quadruplex by the in silica predicted end-stacking mode. Circular Dichroism is 
useful for studying small molecule-nucleic acid interactions as ligands typically lack a 
CD signal, but upon binding to DNA, an "induced" CD (lCD) effect may be observed. 
Importantly, the magnitude and sign of the ICD signal typically allows for the 
classification of the ligand binding mechanism as either groove binding (a positive 
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signal) or intercalation (a negative signal) [184]. The CD results are consistent with the 
other data presented thus far and clearly show an interaction of Compound 1 with the K+ 
22mer quadruplex. At low Quadruplex/Compound 1 ratios (0.1 - 0.25), Figure 70A 
shows the presence of both a positive peak in the region of 625nm and a negative peak in 
the region of 665nm. The spectroscopic signature, with the presence ofbisignate positive 
and negative peaks, is likely the so-called "exciton" effect. The exciton effect is 
significant as it may indicate the presence of multimers or aggregates of Compound 1 that 
impart this unique spectroscopic signal [184]. At higher Quadruplex/Compound 1 ratios 
(2 - 5), there is a progressive negative inducible CD that is observed as well as shift from 
approximately 675 nm - 700 nm. This behavior is generally consistent with Compound 
1 interacting with the quadruplex by intercalation or end-stacking (Figure 70B). The shift 
of the CD spectral minimum from 675 to 700 nm could exist for several reasons. First, 
there may exist multiple end-pasting sites with variable affinity for the ligand. This site-
dependent variable affinity binding behavior has been seen previously with other K+ 
22mer binding small molecules such as TmPyP4 [203]. Additionally, because the K+ 
22mer DNA sequence typically consists of a heterogeneous mixture of species, there may 
be interactions with multiple, unique G-quadruplex end-pasting sites [194]. It is also 
possible that the ligand may interact primarily by end-stacking and by intercalation, as 
this dual type of binding behavior has been previously reported with other G-quadruplex 
binding ligands [131]. In total, however, the appearance of an induced CD signal as seen 
here is consistent with other biophysical data and supports the end-stacking of Compound 
1 to the K+ 22mer quadruplex. 
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Figure 70. Induced CD Spectroscopy at increasing QuadruplexlCompound 1 ratios 
showing the G-quadruplex interaction of Compound I with the K+ 22mer quadruplex, 
AGGG(TTAGGG)J. (A) and (B) show the spectroscopic profile at lower and higher 
QuadruplexlCompound 1 ratios, respectively. 
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Figure 70. Induced CD Spectroscopy at increasing Quadruplex/Compound 1 ratios 
showing the G-quadruplex interaction of Compound 1 with the K+ 22mer quadruplex, 
AGGG(TT AGGGh (A) and (B) show the spectroscopic profile at lower and higher 
Quadruplex/Compound 1 ratios, respectively. 
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Thiazole Orange Fluorescence Intercalation Displacement (TO-FID). The TO-FID 
assay is a complementary assay to the UV Nis absorbance and CD spectroscopic studies 
and is another method to determine if Compound I interacts with the K+ 22mer 
quadruplex by end-stacking. One of the advantages of this assay is that only the 
fluorescence ofthiazole orange (TO) is monitored, so the tested ligand need not have any 
fluorescent or absorbance properties. The assay requires no specialized equipment and 
less training than other techniques that have been used to assess DNA-small molecule 
interactions such as ESI-MS and SPR [40]. Finally, the assay is amenable to a 96 well 
microplate format; a property that is desirable for high-throughput testing of ligands that 
may be discovered by virtual screening and other computational methods. Successful 
operation of the TO-FID assay relies on the known binding of TO to the end-pasting 
region of the human telomeric quadruplex K+ 22mer which has been previously well 
characterized [40, 216-217]. Thiazole Orange is unique as it typically has a reported 
several hundred to thousand fold increase in fluorescence when it is bound to DNA and 
an insignificant fluorescence when displaced from DNA and unbound in solution [217-
219]. The assay is performed by initially saturating the K+ 22mer DNA with TO and 
subsequently adding increasing amounts of the ligand to the solution. If the ligand binds 
to the quadruplex end-stacking region with sufficiently high affinity, TO will be 
displaced and the fluorescence will be quenched. This assay can thus confirm both 
binding of the ligand to the quadruplex and the probable site of binding. Indeed, the 
quenching of TO fluorescence upon addition of Compound 1 suggests that it dissociates 
TO from the end-pasting region of the K+ 22mer (Figure 71). The testing of Compound 1 
was successful and avoided the limitations of the assay, which are as follows. First, if the 
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Figure 71. TO-FID results showing the displacement of Thiazole Orange (TO) from the 
K+ 22mer quadruplex and subsequent TO fluorescence quenching at increasing 
concentrations of the ligand Compound 1. The inset shows the structure of TO. Black 
squares = TO + DNA + buffer. Red circles = TO + DNA + Compound 1. Green 
triangles = TO + Compound 1. Data plotted are the average of experiments in duplicate. 
Error bars represent ± one standard deviation. 
300 
Figure 7l. TO-FID results showing the displacement of Thiazole Orange (TO) from the 
K+ 22mer quadruplex and subsequent TO fluorescence quenching at increasing 
concentrations of the ligand Compound 1. Data plotted are the average of experiments in 
duplicate. Error bars represent ± one standard deviation. 
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ligand is of weak affinity (or has a binding constant lower than that of TO), it may not be 
sufficient to displace TO. Second, the ligand may bind the quadruplex at a different site, 
the grooves for example, instead of the end sites, and this binding would elude detection 
by the FID method as described here. Third, the ligand of interest may have overlapping 
spectroscopic behavior with Thiazole Orange which can confound the results of the 
assay. Compound 1 circumvents these limitations as it clearly displaces and lacks any 
spectral overlap with the TO probe, allowing an assessment of the binding properties of 
Compound 1. It is conceivable that Compound 1 may also interact with the K+ 22mer by 
additional mechanisms at distinct sites on the K+ 22mer that may complicate the observed 
fluorescent quenching curve. However, in total, the TO-FID data are consistent with the 
UV/Vis and CD data and support the initial in silico based hypothesis that Compound 1 
likely interacts with the end-pasting sites on the human telomeric K+ 22mer quadruplex. 
Selective Recognition and Thermal Stabilization of the JC 22mer Quadruplex. 
Melting experiments were performed to determine whether Compound 1 can thermally 
stabilize the K+ 22mer quadruplex in the absence and presence of competing DNA 
structures. Many of the most studied quadruplex binding ligands have been shown to 
increase the quadruplex melting temperature (Tm) [220]. It is worth mentioning that the 
melting temperature of the K + 22mer quadruplex (as tested here) occurs at approximately 
noc which is far above physiological temperature (37°C) and may not reflect what 
occurs under more biologically representative conditions [221]. However, the assay 
provides further unambiguous proof of binding of a compound to the quadruplex target. 
As Figure n shows, the addition of increasing amounts of ligand to the K+ 22mer results 
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Figure 72. Effect of Compound 1 on the Melting Temperature of the FAM-TAMRA 
labeled K+ 22mer G-Quadruplex. 
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Figure 72. Effect of Compound 1 on the Melting Temperature of the FAM-TAMRA 
labeled K+ 22mer G-Quadruplex. Data plotted are the average of experiments performed 
in triplicate. Error bars are ± one standard deviation. 
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in an increase in the T m of the quadruplex of approximately 10°C at the highest levels of 
Compound 1 tested. 
Competition experiments were performed to determine if Compound 1 prefers the 
K+ 22mer over other DNA structures. Under the conditions tested, Compound 1 
stabilizes the K+ 22mer from approximately 73°C (- cmpd 1) to 79.5°C (+ cmpd 1). The 
addition of 20 fold excess competitor quadruplex (T2G20T2, bcl-2, VEGF, Rb, C-myc) 
relative to the K+ 22mer can generally decrease the T m of the K+ 22mer which suggests 
that these structures are successfully competing for binding to Compound 1 (Figure 73). 
The VEGF quadruplex appears to be most successful at competing for Compound 1 as is 
evidenced by the greatest decrease in K+ 22mer T m. However, the addition of dAdT and 
dGdC does not effect the T m, which suggests that Compound 1 selectively prefers the K+ 
22mer quadruplex compared to these DNA structures. Taken in total, these results 
further validate the binding of Compound 1 to the K+ 22mer quadruplex and also suggest 
that Compound 1 offers some selectivity for quadruplex compared to duplex DNA 
structures. 
Molecular Docking of Compound 1 to Hybrid-l and Hybrid-2. With the initial 
discovery of Compound I and subsequent biophysical testing to demonstrate binding 
activity to the K+ 22mer G-quadruplex, the next goal was to develop possible models for 
how Compound 1 can interact with the external G-quartet that is present in the K+ 22mer 
quadruplex. These models could provide valuable insights into the possible interaction 
of Compound 1 with the terminal G-quartets and loop regions that are present in the 
human telomeric quadruplex structure. The K+ 22mer is polymorphic and is known to 
adopt several so-called Hybrid structures (Hybrid-l and Hybrid-2) in vitro [146]. 
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Figure 73: Effect of a 20 fold Excess of Competitor DNA on the Ability of Compound 1 
to Thermally Stabilize the F AM-TAMRA labeled K+ 22mer G-Quadruplex. Duplex, 
triplex and quadruplex nucleic acids were used as competitor DNA structures. 
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Figure 73: Effect of a 20 fold Excess of Competitor DNA on the Ability of Compound I 
to Thermally Stabalize the F AM -T AMRA labeled K+ 22mer G-Quadruplex. Duplex, 
triplex and quadruplex nucleic acids were used as competitor DNA structures. 
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Structures for the Hybrid-l (PDB ID 2HY9) and Hybrid-2 (PDB ID 2JPZ) quadruplexes 
are available in silico and were selected for modeling studies as they contain the human 
telomeric K+ 22mer repeat [196-197, 222], but have unique flanking sequences. These 
two structures each have two external G-quartet end-stacking sites for a total of four 
possible end-pasting sites. Interestingly, while the common conserved feature among 
these sites is the presence of the G-quartet, each of these sites has unique loop topologies 
that may confer ligand-binding specificity. Unfortunately, a limitation of these structures 
is that neither of these structures has a complexed ligand present in the end-pasting zone. 
An alternative approach is to computationally "open-up" the end-pasting site prior to 
docking of Compound 1. This was accomplished by constructing a planar, aromatic 
small molecule ligand, manually placing the ligand in the four possible end-pasting sites 
and energetically minimizing the nucleic acid structure around the ligand (Figure 66). 
This procedure was sufficient to open up the end-pasting site for molecular docking for 
the purposes of modeling the fit of Compound 1 in the putative end-pasting sites. 
Molecular docking of Compound 1 to all four end-pasting sites was successfully 
performed with Autodock and Surflex using a validated docking procedure previously 
described for nucleic acids [63]. The top poses of Compound 1 for these docking 
software are shown in Figure 74 with the resulting scores shown in Table 12. Based on 
our previous experience with these programs, the Autodock and Surflex scores for all 
docked complexes are comparable. Generally, Compound 1 appears to dock and fit well 
in all four of the end-pasting sites. A closer view of the top poses without the nucleic 
acid present (Figure 75) reveals that the top ranked poses for Surflex and Autodock 
appear to have a higher amount of overlap for the two Hybrid 1 end-pasting sites 
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Figure 74. The top ranked poses for Compound 1 docked using Surflex (Gold) and 
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l 
End Paste Site 1 (B) Hybrid- 1 End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D) 
Hybrid-2 End Paste Site 2. The nucleic acid structures are shown in white except for the 
small molecule interacting terminal guanine tetrads which are shown in green. 
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Figure 74. The top ranked poses for Compound I docked using Surflex (Gold) and 
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l 
End Paste Site 1 (B) Hybrid- 1 End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D) 
Hybrid-2 End Paste Site 2. 
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Table 12. The scores for the top-ranked pose from A~todock or Surflex for the four 
possible end-pasting sites in Hybrid-l and Hybrid-2. 
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Table 12. The scores for the top-ranked pose from Autodock or Surflex for the four 
possible end-pasting sites in Hybrid-l and Hybrid-2. 
Hybrid Structure / Surflex-Dock Score Autodock Score 
PDBID (-I02(K.J) ) (kcal/mol) 
Hybrid-l /2HY9 14.29 -11.45 
End Paste site 1 
Hybrid-l /2HY9 15.19 -11.77 
End Paste site 2 
Hybrid-2 /2JPZ 14.98 -12.71 
End Paste site 1 
Hybrid-2 /2JPZ 13.56 -12.57 
End Paste site 2 
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Figure 75. The top ranked poses for Compound 1 docked using Surflex (Gold) and 
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l 
End Paste Site 1 (B) Hybrid-l End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D) 
Hybrid-2 End Paste Site 2. The file format for the Autodock poses is PDBQT with 
merging of non-polar hydrogens. 
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Figure 75. The top ranked poses for Compound 1 docked using Surflex (Gold) and 
Autodock (Cyan) to the following G-quadruplex nucleic acid structures: (A) Hybrid-l 
End Paste Site 1 (B) Hybrid-l End Paste Site 2 (C) Hybrid-2 End Paste Site 1 and (D) 
Hybrid-2 End Paste Site 2. 
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compared to Surflex and Autodock top ranked poses for the end-pasting sites of Hybrid-
2. Visual inspection of the top ranked pose is necessary to evaluate ligand interactions 
with the guanine quartet and the loop regions. Indeed, in all four of the end-pasting 
models, Compound 1 appears to stack well on the guanine quartet. This type of binding 
behavior is in agreement and consistent with that of many largely aromatic compounds 
such as TMPyP4 that bind G-quadruplex structures by either end-pasting or intercalation 
[202]. What is typically more difficult to interpret, but albeit equally important, is the 
interaction of Compound 1 with the various terminal loop structures. In contrast to the 
Guanine tetrad, the loop arrangements appear much more flexible and conformationally 
heterogeneous. The models certainly suggest that Compound 1 can interact with the 
various loops to different extents, which could potentially modulate selective binding and 
stabilization of quadruple x structures. In fact, compounds that bind by end-stacking as 
well as preferentially to specific quadruplex loops and accompanying grooves are 
currently a source of great interest as this is thought to confer quadruplex discriminatory 
capability to small molecules. Of interest here is the modeling data suggesting both 
guanine quartet interactions as well as potential loop interactions with the four possible 
end-pasting sites of the Hybrid-l and Hybrid-2 quadruplex structures. These models also 
suggest that Compound 1 may serve as a lead compound for derivatization experiments 
to increase preferential loop and or groove binding to impart specific quadruplex 
discrimination. 
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Conclusions 
The discovery of novel G-quadruplex nucleic acid small molecules using in silico virtual 
screening was investigated. This work details the development of an in silico virtual 
screening approach using the end-pasting site from the quadruplex (TTAGGGT)4 as a 
representative pseudo end-pasting site for the K+ 22mer quadruplex. The software 
Surflex and Autodock were used to dock over 6.6 million small molecules to the pseudo 
end-pasting site and resulted in the discovery of a novel G-quadruplex binding small 
molecule with a completely novel scaffold. Biophysical testing by spectroscopic and 
fluorescence based assays validated our virtual screening approach and demonstrated that 
the strategy was predictive and capable of discovering small molecules that bind 
quadruplexes specifically by an end-pasting mechanism. Furthermore, four molecular 
models were developed demonstrating the interaction of the newly discovered compound 
with the guanine tetrad and loop regions of the end-pasting sites present in structures 
containing the K+ 22mer. These results suggest that the in silico platform presented here 
can be utilized to discover new small molecules that have G-quadruplex binding activity 
and may serve as lead compounds for further modification to optimize quadruplex 
binding and discriminatory properties. 
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CHAPTER VI 
CONCLUSIONS 
The use of molecular docking and virtual screening has gained widespread use for 
the discovery of novel small molecules for targeting proteins. However, these 
computational approaches have historically neglected the targeting of nucleic acid 
structures. With the increase in the understanding of nucleic acid structure and in vivo 
function, nucleic acids have garnered increased attention as relevant and good targets. 
This is particularly true of the G-quadruplex nucleic acids which can inhibit telomerase 
activity in vivo and decrease cancer cell proliferation. While small molecules have been 
discovered that bind to G-quadruplexes, many such as TmPyP4 suffer from poor 
selectivity and bind to many other nucleic acid structures. With the general landscape of 
"druggable" targets expanding to include nucleic acids such as the G-quadruplexes, there 
is a critical need to determine if computational resources can be utilized and customized 
for the discovery of new small molecules that interact with nucleic acid targets 
selectively and by a known binding mechanism. 
The initial goal of this research was determining if the docking software 
Autodock and Surflex can be used for targeting nucleic acids. We demonstrated 
conclusively in Chapter II that both software packages can accomplish this goal. The 
next focus was to determine if in silica rules can be developed to predict the mechanism 
of action and structural selectivity of small molecules that are known to 
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interact with nucleic acids. The answer was affirmative, and in silico rules for 
distinguishing intercalator from groove binders were obtained. This was largely based on 
the rationalization of known competition dialysis binding data of several sets of small 
molecules to an array of heterogeneous nucleic acid structures. Finally, the knowledge 
from this early work was utilized for the discovery of novel triplex and quadruplex 
binding compounds that may have in vivo significance. Importantly, the predicted in 
silico binding behavior of the newly discovered triplex and quadruplex binding 
compounds was rigorously validated using a combination of spectroscopic, calorimetric 
and thermodynamic assays. This demonstrates the practical application of the research 
that is described in this work. This work also provides, for perhaps the first time, an 
integrated, computational and experimental platform for drug discovery for nucleic acids. 
The first set of experiments involved the validation of the molecular docking 
software Autodock and Surflex for targeting nucleic acid structures. This was 
accomplished by selecting several minor groove binders (distamycin and pentamidine) 
and intercalators (daunorubicin and ellipticine) as these ligands have solved in silico 
nucleic acid - ligand structures. Using molecular docking techniques, the software were 
found to be able to successfully reproduce the in silico complexes to a high degree of 
accuracy. Surflex was discovered to be of comparable accuracy to Autodock but 
approximately an order of magnitude faster for the molecular docking experiments, 
which made this software particularly relevant for virtual screening applications. The 
"optimal" software parameters for virtual screening were determined which served as the 
basis for the use of these software for the remaining work in this dissertation. 
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After the establishment of the feasibility of using Autodock and Surflex to target 
nucleic acids, the next focus was on whether in silica rules could be developed to 
specifically predict the mechanism of action and nucleic acid sequence and structural 
selectivity of small molecules. Using the four small molecules from the initial validation 
study (daunorubicin, distamycin, ellipticine and pentamidine), molecular docking 
experiments were performed for each of the small molecules against an in silica array of 
nucleic acids. Based on these results, in silica metrics were developed for Autodock and 
Surflex to classify each of the small molecules on the basis of their binding mechanism 
(groove binder or intercalator) and nucleic acid structural and sequence preference. The 
in silica rules were further tested and validated on multiple triplex and quadruplex 
binding compounds that our lab has discovered as well as an extensive 67 compound 
library set of compounds for which detailed competition dialysis data exists using the 
identical array of nucleic acids used for the in silica molecular docking experiments. The 
results supported the use of the metrics for generally successfully predicting the 
mechanism of action of ligand. Prediction of sequence and structural selectivity of the 
small molecules generally appeared to be more challenging, especially for some of the 
larger molecules that were tested. 
The development of the in silica metrics set the stage for application of the 
metrics III large scale virtual screening experiments for the discovery of new small 
molecules that can target physiologically significant nucleic acid structures. A combined 
ligand and structure based virtual screening approach was utilized for the discovery of 
novel triplex binding small molecules. After screening several million small molecules 
and applying the in silica metrics, two small molecules were tested using a combination 
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of biophysical techniques and were demonstrated to bind selectively to the triplex 
structure, as predicted by the in silico screen. These findings were a critical validation of 
the use of the in silico metrics for the discovery of new scaffolds of ligands that may have 
therapeutic value. 
Finally, the last set of experiments describes the use of structure-based molecular 
docking approaches to identify new quadruplex binding small molecules. Over 6.6 
million small molecules were docked into a quadruplex end-pasting site that we 
hypothesized to be structurally representative of the end-pasting site of the human 
telomeric G-quadruplex AGGG(TTAGGGk A rank-by-rank consensus scoring function 
was used to re-rank the top hits from both Autodock and Surflex into a single top hit list. 
A single novel compound was discovered to bind to the human telomeric quadruplex by 
the in silico hypothesized end-pasting mechanism using a combination of biophysical 
techniques. This compound has a scaffold unlike any reported to date in the literature 
and represents a good lead for future derivatization experiments to further optimize the 
binding behavior of the compound. 
The work presented has laid the foundation for future research investigating how 
small molecules interact with nucleic acids. We envision several areas in which this 
research can be well utilized. While the initial focus of this research was on the 
prediction of binding behavior of "pure" groove binders or classical intercalators, we 
believe this research can be extended to the field of "non-classical" intercalators, which 
are typified structurally by unfused polyaromatic ring systems and consist of a mixed-
mode action with both groove binding and intercalation character. Compounds that bind 
by "non-classical intercalation" have garnered great interest recently because of their 
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prevalence in the phannaceutical industry. In fact, it was recently detennined that as 
many as 26 out of 50 currently marketed drugs demonstrated surprising clastogenicity 
and these compounds were surprisingly mutagenic. This may be partly ascribed to the 
majority of these ligands having atypical, non-standard intercalator structures [223]. 
While there is software including DEREK, TOPKAT and MeASE that is used to 
estimate the toxicity of phannaceutical compounds, these software have been largely 
unsuccessful at predicting the toxicity of non-classical intercalators [223]. It would be 
particularly valuable to extend the work perfonned here to the field of non-classical 
intercalators to detennine if this binding mechanism can also be predicted by in silico 
based approaches. 
The research here also has particular additional relevance in the field of 
quadruplex nucleic acids. A logical extension of our work is to develop metrics that can 
be used to discover small molecules that selectively discriminate between various 
quadruplex structures. Finding small molecules that can selectively bind to a specific G-
quadruplex morphology has largely been elusive in the literature. The development of 
targeted metrics for predicting this behavior could be immensely powerful as virtual 
screening could potentially be used to identify new scaffolds of ligands that bind to a 
quadruplex of interest. 
The research presented investigates the prediction of small molecule -nucleic acid 
interactions by in silico molecular docking and metric development. A unique facet of 
the work is the empirical validation of the in silico results using a number of 
spectroscopic, calorimetric and other techniques. This emphasizes that the work as 
described here has practical applications for the clinical discovery of new small 
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molecules with therapeutic indications. There continues to be an increasing need to find 
new drugs to treat many types of disease. The research as outlined here provides a novel 
approach to discover small molecules to meet this need. 
The combined approach of virtual screening and empirical validation of hits 
continues to identify many compounds with medicinal benefit. Our most recent work and 
our current focus is on investigating the potential anti-cancer properties of over 20 
compounds that we have recently identified. Preliminary testing of these compounds has 
demonstrated that all of these compounds bind to the K+ 22 mer human telomeric 
quadruplex and several compounds significantly stabilize the quadruplex, suggesting they 
may also inhibit telomerase and suppress tumor cell growth. The labs of Drs Trent and 
Chaires are now focused on rigorously testing these hits using a combination of 
spectroscopic, calorimetric and other biophysical techniques as well as multiple assays to 
measure cellular inhibition of telomerase (TRAP assay) and tumor cell proliferation 
(MTT assay). This is a practical application of our research and demonstrates that the 
integrated discovery and testing strategy we described here has led to the discovery of 
multiple novel small molecules with possible anti-cancer activity. 
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